Drug, bio-affecting and body treating compositions patents - Monitor Patents
FreshPatents.com Logo    FreshPatents.com icons
Monitor Keywords Patent Organizer File a Provisional Patent Browse Inventors Browse Industry Browse Agents



USPTO Class 514  |  Browse by Industry: Previous - Next | All     monitor keywords
11/2011 | Recent  |  14: Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | 13: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | 12: Dec | Nov | Oct | Sep | Aug | July | June | May | April | Mar | Feb | Jan | 11: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan | 10: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May | Apr | Mar | Feb | Jan |  | 09: Dec | Nov | Oct | Sep | Aug | Jl | Jn | May | Apr | Mar | Fb | Jn |  | 2008 | 2007 |

Drug, bio-affecting and body treating compositions November recently filed with US Patent Office 11/11

Below are recently published patent applications awaiting approval from the USPTO. Recent week's RSS XML file available below.
Listing for abstract view: USPTO application #, Title, Abstract excerpt,Patent Agent. Listing format for list view: USPTO National Class full category number, title of the patent application.
  
11/24/2011 > 182 patent applications in 138 patent subcategories. recently filed with US Patent Office

20110288001 - Biologically active proteins activatable by peptidase: The present invention provides biologically active proteins that are activatable by peptidase exposure, such as dipeptidase exposure. The biologically active protein may be a recombinant version of a protein factor that is processed from a native precursor molecule in vivo. Upon administration of the recombinant product to a patient in... Agent:

20110288002 - Novel bag proteins and nucleic acid molecules encoding them: The present invention provides a family of BAG-1 related proteins from humans (BAG-1L, BAG-1, BAG-2, BAG-3, BAG-4 and BAG-5), the invertebrate C. elegans (BAG-1, BAG-2) and the fission yeast S. pombe (BAG-1A, BAG-1B) and the nucleic acid molecules that encode them.... Agent: Sanford-burnham Medical Research Institute

20110288003 - Amide based glucagon and superfamily peptide prodrugs: Prodrug formulations of glucagon superfamily peptides are provided wherein the glucagon superfamily peptide has been modified by the linkage of a dipeptide to the glucagon superfamily through an amide bond linkage. The prodrugs disclosed herein have extended half lives and are converted to the active form at physiological conditions through... Agent: Indiana University Research And Technology Corporation

20110288004 - Viral sequences and uses thereof: The invention features polypeptide and polynucleotide sequences based on the 134R sequence. In some embodiments, these sequences include a heterologous signal sequence, such as the myxoma virus T7 signal sequence. The invention also features methods for treating immunological disorders and neoplasms (e.g., cancer) using the polypeptides and nucleotides described herein.... Agent: Robarts Research Institute

20110288005 - Alpha 1-antitrypsin compositions and methods of making and using same: The present invention relates to compositions comprising alpha 1-antitrypsin linked to extended recombinant polypeptide (XTEN), isolated nucleic acids encoding the compositions and vectors and host cells containing the same, and methods of making and using such compositions in the treatment of alpha 1-antitrypsin-related diseases, disorders, and conditions.... Agent: Amunix Operating Inc. A Delware Corporation

20110288006 - Peptides and methods for inducing cell death: The invention provide isolated peptides, protides and conjugates having novel peptide sequences which are able to induce antimicrobial, anti-cancer, anti-inflammatory, anti-proliferative or programmed cell death activity. The invention also provides a method of inducing programmed cell death in a cell by contacting the cell with an isolated peptide, protide or... Agent: Los Angeles Biomedical Research Institute At Harbor-ucla Medical Center

20110288007 - Biocidal fusion peptide comprising ll-37: The present invention relates to a biocidal fusion peptide comprising: a) a peptide LL-37 or an active fragment or active derivative thereof; b) and a further heterologous bioactive peptide or an active fragment thereof, wherein part or all of the amino acid sequence of the fusion peptide is predicted to... Agent: The Secreatary Of State For Defence

20110288008 - Antibacterial and plasmid elimination agents: Inhibitors of the tmRNA pathway have antibacterial activity with broad species specificity, including B. anthracis and other pathogens of military and civilian interest. Identified cyclic or linear peptides are further selected by in vivo selection methods, kill bacterial pathogens when added exogenously, and/or eliminate plasmids carrying antibiotic resistance or virulence... Agent: The Penn State Research Foundation

20110288009 - Leptin and leptin analog conjugates and uses thereof: The present invention features a compound having the formula A-X-B, where A is peptide vector capable of enhancing transport of the compound across the blood-brain barrier or into particular cell types, X is a linker, and B is a leptin, a leptin analog, or OB receptor agonist. The compounds of... Agent: Angiochem Inc.

20110288010 - Utilization of peptides as active ingredients for slimming: A method of using proteins of the SIRT family or of polypeptide or peptide fragments of SIRT proteins as an active ingredient for slimming, alone or in combination with at least one other active agent, in a cosmetic composition or for the preparation of a pharmaceutical and/or dermatological composition. The... Agent: Societe D'extraction Des Principes Actifs Sa (vincience)

20110288011 - Peptide therapeutic conjugates and uses thereof: The present invention features a compound having the formula A-X-B, where A is peptide vector capable of enhancing transport of the compound across the blood-brain barrier or into particular cell types, X is a linker, and B is a peptide therapeutic. The compounds of the invention can be used to... Agent:

20110288012 - Nutrition composition: The nutrition composition of the present invention m contains one or more kinds of free amino acids selected from the group consisting of valine, leucine, isoleucine and histidine, and a lipid comprising ω-3 fatty acid and ω-6 fatty acid at a weight ratio (ω-6 fatty acid to ω-3 fatty acid)... Agent: Ajinomoto Co., Inc.

20110288013 - Glycemic control for reduction of cardiovascular disease risk in diabetic patients expressing haptoglobin 2-2: This invention relates to methods of reducing risk of developing cardiovascular complications in diabetic patients. Specifically, the invention relates to the use of haptoglobin genotyping for determining the importance of maintaining tight glycemic control in diabetic subjects expressing Hp 2-2 allele.... Agent:

20110288014 - Methods and compositions for diabetes treatment and prevention: The present invention relates to methods and compositions for preventing or treating diabetes. The invention in particular discloses compounds according to formula (I) for use in the prevention and treatment of type II or I diabetes.... Agent: Tum Technische Universitat Munchen

20110288015 - Treatment of renal dysfunction and multiple myeloma using pacap compounds: The present invention relates to methods and compositions for the treatment, management, or prevention of multiple myeloma and/or renal dysfunction in mammals. The methods of the invention comprise the administration of an effective amount of one or more pituitary adenylate cyclase activating polypeptide (“PACAP”) compounds, which includes PACAP, vasoactive intestinal... Agent:

20110288016 - Preparation for use of aspartate and vitamin b12 or biotin for regulating ketone bodies: It has been found that high amounts of aspartate equivalents in combination with vitamin B12 and/or biotin, especially in relative absence of glutamate equivalents, improve the metabolism of ketobodies and/or lactate in a mammal's body, especially in diseased or traumatic conditions. As a result, levels of ketobodies and lactate can... Agent: N.v. Nutricia

20110288017 - Apo-lipoprotein propeptide: This invention relates generally to a peptide being a fragment of the mammalian apolipoprotein AI peptide, said peptide comprising the sequence RHFWQQ (human, macaque and pig), the sequence WEFWQQ (rat), and the sequence WHVWQQ (mouse), or suitable modifications thereof, or equivalent synthetic peptides. In contrast to the entire protein, these... Agent:

20110288018 - Beverage lowering serum cholesterol: A beverage including protein, plant sterol ester and/or plant stanol ester, a fruit and/or vegetable preparation, and a stabiliser.... Agent: Raisio Nutrition Ltd

20110288019 - Methods of increasing platelet and hematopoietic stem cell production: A method of increasing hematopoietic stem cell production is disclosed. The method includes administering a TPO mimetic compound to a subject. Pharmaceutical compositions including a TPO mimetic compound and a pharmaceutically acceptable carrier are also disclosed.... Agent: Janssen Pharmaceutica, N.v.

20110288020 - Use of vegf and homologues to treat neuron disorders: The present invention relates to neurological and physiological dysfunction associated with neuron disorders. In particular, the invention relates to the involvement of vascular endothelial growth factor (VEGF) and homologues in the aetiology of motor neuron disorders. The invention further concerns a novel, mutant transgenic mouse (VEGFm/m) with a homozygous deletion... Agent:

20110288021 - Administration of angiocidin for the treatment of cancer: Methods are presented for the therapeutic administration of angiocidin in the treatment of cancers such as glioma, breast cancer, and leukemia. Methods are also presented for inducing growth arrest and/or apoptosis of tumor cells, as well as inducing differentiation of tumor cells to inhibit tumorigenicity and to confer a non-tumor... Agent: Temple University Of The Commonwealth System Of Higher Education

20110288022 - Treatment of depressive disorders: The invention provides for the use of carbonic anhydrase activators; protein kinase C activators and FGF-18 to treat depressive disorders. The invention also relates to improved animal models and methods for screening and identifying compounds the treatment of depressive disorders.... Agent:

20110288023 - Cancer drug delivery using modified transferrin: The invention provides modified Transferrin (Tf) molecules and conjugates of the Tf molecules with a therapeutic agent. The invention also provides methods of treating cancer wherein the therapeutic agents are chemotherapeutic agents. The modified Tf molecules improve the delivery of the conjugated agent to a target tissue. In some embodiments,... Agent: University Of Vermont And State Agricultural College

20110288024 - Compositions and methods for treating arthritis and/or diseases involving cartilage degeneration: The invention provides pharmaceutical polypeptide compositions that promote proteoglycan synthesis, and promote the activity of chondrocyte cells, thereby treating arthritis. Methods of providing these compositions to treat arthritis are also provided.... Agent: Five Prime Therapeutics, Inc.

20110288025 - Biopolymer produced by fermenting the extract of soybean with folic acid and a composition containing thereof: Provided are a folyl extract of fermented soybean (EFS) produced by fermenting a culture including a folic acid and soybean extract by using a microorganism, and a composition including the folyl EFS. The folyl EFS has an anti-histamine effect, an anti-allergic effect, a calcium-absorption-promotion effect, a bone-growth-promotion effect, a cell... Agent: Damy Chemical Co., Ltd.

20110288026 - Electroprocessed collagen and tissue engineering: The invention is directed to formation and use of electroprocessed collagen, including use as an extracellular matrix and, together with cells, its use in forming engineered tissue. The engineered tissue can include the synthetic manufacture of specific organs or tissues which may be implanted into a recipient. The electroprocessed collagen... Agent:

20110288027 - Targets, methods, and reagents for diagnosis and treatment of schizophrenia: The present invention provides targets, methods, and reagents for the diagnosis and treatment of schizophrenia and related conditions. The invention provides methods for the diagnosis of schizophrenia and susceptibility to schizophrenia by detection of polymorphisms, mutations, variations, alterations in expression, etc., in calcineurin genes or calcineurin interacting genes, or polymorphisms... Agent: Massachusetts Institute Of Technology

20110288028 - Amylin and amylin agonists for treating psychiatric diseases and disorders: Methods and compositions for treating psychiatric diseases and disorders are disclosed. The methods provided generally involve the administration of an amylin or an amylin agonist to a subject in order to treat psychiatric diseases and disorders, and conditions associated with psychiatric diseases and disorders.... Agent: Amylin Pharmaceuticals, Inc.

20110288029 - Method for inhibiting neuronal cell death: This invention relates to a method of inhibiting neuronal cell death, including protecting neronal cells from cell death and the effects of stress, such as high or low pH, comprising administering to the cells an effective amount of Teneurin C Associate Peptide (TCAP). The invention provides the use of TCAP... Agent:

20110288030 - Paralytic peptide for use in neuromuscular therapy: The invention relates to a low molecular weight peptide (or suite of related peptides) isolated from the submaxiliary saliva glands of shrews of the species Blarina as a paralytic agent. This novel paralytic agent is useful as a neuromuscular blocker and analgesic or as an insecticide.... Agent: Soricimed Biopharma Inc.

20110288031 - Identification of a novel bhd gene: The present disclosure relates to Birt-Hogg-Dubé syndrome, nucleic acids encoding the BHD gene, and methods of using the nucleic acids and proteins encoded thereby. In particular, the present disclosure relates to methods of diagnosing BHD disease and related conditions, such as spontaneous pneumothorax and kidney cancer, and methods of treating... Agent: The Gov't Of The U.s.a. As Represented By The Secretary Of The Dep't Of Health And Human Service

20110288032 - Enzastaurin for the treatment of cancer: The present invention relates to HDAC2 as a biological marker for treating cancer in a patient using Enzastaurin as a single agent or in combination with a Class I selective HDAC inhibitor.... Agent: Eli Lilly And Company

20110288033 - Disulfide compounds for phototherapy: The invention relates generally to optical agents for biomedical applications, including phototherapy. Provided are disulfide compounds having an acyclic S—S bond with at least one aromatic and/or heterocyclic aromatic group providing phototherapeutic agents, including Type 1 phototherapeutic agents. Optical agents of the invention enable a versatile phototherapy platform for treatment... Agent: Mallinckrodt Inc.

20110288034 - Methods of identifying adipocyte specific genes, the genes identified, and their uses: Disclosed is a method of identifying genes that are over-expressed in adipose tissue as compared to pre-adipocyte tissue or other tissues comprising performing differential gene expression analysis between the white adipose tissue (WAT) or stromal vascular tissue (SVT) from any two different mice selected from the group consisting of wild-type,... Agent: Hmgene Inc.

20110288035 - Pimap39 modulates inflammatory response: The present invention relates to a novel peptide sequence named PIMAP39 (herein referred to as SEQ ID NO.: 1) and methods of use of the novel sequence and functional variants thereof. The present invention also relates to methods for reducing and/or modulating inflammatory responses by administration of the peptide of... Agent:

20110288036 - Methods for treating or preventing vascular graft failure: The described invention provides pharmaceutical compositions and methods for treating or preventing vascular graft failure in a subject in need of such treatment, the method comprising administering a therapeutically effective amount of a composition comprising a polypeptide of amino acid sequence YARAAARQARAKALARQLGVAA (SEQ ID NO: 1) or a functional equivalent... Agent:

20110288037 - Pharmaceutical composition for the treatment of pathologies caused by the general response of the immune system: The present invention relates to a pharmaceutical composition consisting of amides of mono- and di-carboxylic acids and hydroxystilbenes, and may be used for the treatment of pathologies caused, sustained and/or characterised by an abnormal general response of the immune system, in both humans and animals.... Agent:

20110288038 - Hesperidin-containing composition: This invention relates to a composition that stably contains hesperidin. The present invention provides a composition containing (A) hesperidin, (B) at least one dihydric alcohol selected from the group consisting of ethylene glycol, diethylene glycol, triethylene glycol, polyethylene glycol, propylene glycol, dipropylene glycol, 1,3-butylene glycol, and 3-methyl-1,3-butanediol, and (C) a... Agent:

20110288039 - Topical ectoparasiticide composition: A topical ectoparasiticide composition comprising an Insect Growth Regulator and at least one C6-C12 medium chain triglyceride wherein the composition comprises at least 60% (w/v) of the triglyceride based on the total composition.... Agent:

20110288040 - Aryl- or heteroaryl-sulfonyl compounds as acid secretion inhibitors: wherein ring A is a saturated or unsaturated 5- or 6-membered ring group optionally having, as a ring-constituting atom besides carbon atom, 1 to 4 hetero atoms selected from a nitrogen atom, an oxygen atom and a sulfur atom, ring-constituting atoms X1 and X2 are each a carbon atom or... Agent: Takeda Pharmaceutical Company Limited

20110288041 - Antibacterial aminoglycoside analogs: e

20110288042 - Stable highly pure azacitidine and preparation methods therefor: Disclosed herein are methods of obtaining highly pure 5-azacytidine, which contains minimal amounts of degradation impurities and methods of assessing the impurity profile of the degradation of cytidine analogues, such as 5-azacytidine... Agent: Chemagis Ltd.

20110288147 - Compositions and methods for the specific inhibition of gene expression by dsrna containing a tetraloop: The invention features compositions and methods that are useful for reducing the expression or activity of a specified gene in a eukaryotic cell.... Agent:

20110288149 - Method of protecting against heart failure: The present invention relates, in general, to heart failure, and, in particular to a method of reducing the risk of heart failure, particularly in patents with established cardiomyopathy.... Agent: Duke University

20110288158 - Methods and compositions for the specific inhibition of gene expression by double-stranded rna: The invention is directed to compositions and methods for selectively reducing the expression of a gene product from a desired target gene in a cell, as well as for treating diseases caused by the expression of the gene. More particularly, the invention is directed to compositions that contain double stranded... Agent: City Of Hope

20110288151 - Methods of characterizing breast cancer and identifying treatments for same: This application describes antibodies to P-Rex 1, and methods of detecting breast cancer, and methods of treatments for the same.... Agent: The Trustees Of The University Of Pennsylvania

20110288156 - Nucleic acids, polypetides, and methods for modulating apoptosis: The present invention relates to isolated and/or purified rat apoptosis-specific eucaryotic initiation Factor-5A (eIF-5A) and deoxyhypusine synthase (DHS) nucleic acids and polypeptides. The present invention also relates to methods of modulating apoptosis using apoptosis-specific eIF-5A and DHS, and antisense oligonucleotides and expression vectors of apoptosis-specific and DHS useful in such... Agent:

20110288150 - Oligonucleotides for suppressing cancer cell invasion and migration: Provided herein is a method for detection of migratory and invasive cancer cells based on a number of marker nucleic acids differentially expressed in migratory/invasive cancer cells relative to nonmigratory/noninvasive cancer cells. Also disclosed are antisense oligonucleotides of the marker nucleic acids and uses thereof for suppressing cancer cell migration... Agent: Industrial Technology Research Institute(itri)

20110288152 - Psma binding ligand-linker conjugates and methods for using: Described herein are prostate specific membrane antigen (PSMA) binding conjugates that are useful for targeting prostate cancer cells. Also described herein are compositions containing them and methods of using the conjugates and compositions. Also described are processes for manufacture of the conjugates and the compositions containing them.... Agent: Purdue Research Foundation

20110288154 - Rna interference mediated inhibition of epithelial sodium channel (enac) gene expression using short interfering nucleic acid (sina): The present invention relates to compounds, compositions, and methods for the study, diagnosis, and treatment of traits, diseases and conditions that respond to the modulation of ENaC gene expression and/or activity, and/or modulate a ENaC gene expression pathway. Specifically, the invention relates to double-stranded nucleic acid molecules including small nucleic... Agent: Merck & Co., Inc.

20110288157 - Rnai-mediated inhibition of spleen tyrosine kinase-related inflammatory conditions: RNA interference is provided for inhibition of spleen tyrosine kinase (Syk) mRNA expression, in particular, for treating patients having a Syk-related inflammatory condition or at risk of developing a Syk-related inflammatory condition such as allergic conjunctivitis, ocular inflammation, dermatitis, rhinitis, asthma, allergy, or mast-cell disease.... Agent: Alcon Research, Ltd.

20110288155 - Sirna compounds and methods of use thereof: The present application relates to double stranded oligonucleotide inhibitors of target genes, pharmaceutical compositions comprising same and the use of such molecules to treat, inter alia, neurodegenerative disorders including Alzheimer's disease and Amyotrophic Lateral Sclerosis, eye diseases including glaucoma and ION, acute renal failure, hearing loss, acute respiratory distress syndrome... Agent:

20110288153 - Translation factors as anti-aging drug targets: In certain embodiments this invention pertains to the discovery that inhibition of the expression and/or activity of eukaryotic initiation factor 4A (eIF4A) inhibits the aging process. Accordingly, in certain embodiments, methods are provided for inhibiting/slowing aging. The methods typically involve administering to a mammal an agent that inhibits the expression... Agent: The Regents Of The University Of California

20110288148 - Triggered covalent probes for imaging and silencing genetic expression: The present invention relates to the use of cross-linking probes to covalently bind probes to nucleic acid targets. In some embodiments, the probe comprises an initiator region that is able to bind to a first portion of a target nucleic acid, a probe region linked too the initiator region that... Agent:

20110288161 - Methods for treatment of thiol-containing compound deficient conditions: Certain embodiments in the present invention provide for methods for therapy of lung diseases and other conditions such as infection are provided. In certain embodiments, the methods comprise one or more agents capable of increasing thiol-containing compound transport via a transporter system (i.e., ABC transporters such as MDR-1 or MRP-2)... Agent:

20110288159 - Methods of expressing a polypeptide in the brain and nucleic acid constructs capable of same: A nucleic acid construct and construct system are disclosed. The nucleic acid construct and system comprise a regulatory sequence which regulates inducible expression of a polypeptide of interest, the regulatory sequence comprising a choroid plexus specific promoter, with the proviso that the choroid plexus specific promoter is not a transthyretin... Agent: Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science

20110288160 - Treatment of metabolic-related disorders using hypothalamic gene transfer of bdnf and compositions therefor: Described herein is a system which uses a gene therapy particle that includes at least one gene, cDNA, fragment or analogue of at least one neurotropin that binds to the trkB receptor or the trkB receptor itself. The gene therapy particle is capable of being delivered to a subject in... Agent: The Ohio State University Research Foundation

20110288043 - Maintenance of platelet inhibition during antiplatelet therapy: A method of treating or preventing a disease or condition in a subject that was previously treated with at least one thienopyhdine is described. The method includes administering to the subject an effective amount of at least one reversible, short-acting P2Yi2 inhibitor. The described method can be used for subjects... Agent:

20110288044 - Modulation of sodium channels by nicotinamide adenine dinucleotide: The present invention relates to the use of oxidized nicotinamide adenine dinucleotide (NAD+) or of its reduced form, NADH, as sodium channel modulators. The present invention also relates to the use of compositions containing NAD+ or NADH to treat conditions associated with sodium channel current, such as arrhythmia. NAD+ is... Agent: U.s. Department Of Veterans Affairs

20110288045 - Wet granulation of tenofovir, emtricitabine and efavirenz: The present invention describes a method and composition for a pharmaceutical product based on Tenofovir disoproxil hemifumarate, Emtricitabine and Efavirenz. The composition can be prepared by a process comprising a wet granulation step to produce a stable dosage form suitable for the treatment of HIV in essential absence of known... Agent: Ultimorphix Technologies B.v.

20110288046 - Analysis of sulfated polysacchrides: The invention relates to methods and products associated with analyzing and monitoring heterogeneous populations of sulfated polysaccharides. In particular therapeutic heparin products including low molecular weight heparin products and methods of analyzing and monitoring these products are described.... Agent: Momenta Pharmaceuticals, Inc.

20110288047 - Process for the purification of heparan sulfate and use thereof in cosmetological and dermatological preparations: The present invention relates to cosmetological and dermatological compositions comprising heparan sulfate. The invention further discloses a process for the purification of heparan sulfate for dermatological and cosmetological applications, which process comprises the following steps: solubilization of heparan sulfate in water, adsorption on an anion exchange resin, desorption from the... Agent: Laboratori Derivati Organici Spa

20110288048 - Promoter for hard tissue formation: The present invention provides an agent which induces acceleration of hard tissue formation, acceleration of cell differentiation and increase in cellular alkaline phosphatase activity, by directly acting on the cell. Specifically, it provides a hard tissue formation promoter, a cell differentiation inducer and a cellular alkaline phosphatase activity reinforcing agent... Agent: Seikagaku Corporation

20110288049 - Compositions, systems, and/or methods involving chlorine dioxide (\"clo2\"): Certain exemplary embodiments can provide a composition of matter comprising a solid form of chlorine dioxide complexed with a cyclodextrin. The concentration of chlorine dioxide in said solid form is greater than approximately 5.8 percent by weight. Certain exemplary embodiments can provide a method comprising forming a solid complex comprising... Agent:

20110288050 - Protein phosphatase inhibitor: Provided is a novel protein phosphatase inhibitor. The protein phosphatase inhibitor contains, as an active ingredient, a silicon compound represented by the following general formula (1) or a salt thereof, wherein R1, R2 and R3 are the same or different and represent a hydrocarbon group having 1 to 12 carbon... Agent: Lsip, LLC

20110288051 - Triazolopyridine 11-beta hydroxysteroid dehydrogenase type i inhibitors: o

20110288052 - Novel compounds, pharmaceutical compositions containing same, and methods of use for same: The class compounds of the present invention may be represented by Formula (I), wherein X may be O, S, or N. R1 and R2 are independently either H, C1-C20 alkyl, cycloalkyl, alkenyl, aryl, arylalkyl, or alkylaryl. R3 and R4 are independently either H, an aryl group, a heteroaryl group, and... Agent:

20110288053 - Antiviral phosphonate analogs: The invention is related to phosphorus substituted compounds with antiviral activity, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.... Agent: Gilead Sciences, Inc.

20110288054 - Compounds for the treatment of inflammatory disorders: This invention relates to compounds of the Formula (I) as described herein, or a pharmaceutically acceptable salt, solvate or ester thereof, which can be useful for the treatment of diseases or conditions mediated by MMPs, ADAMs, TACE, aggrecanase, TNF- or combinations thereof.... Agent: Schering Corporation

20110288055 - Mitoquinone derivatives used as mitochondrially targeted antioxidants: This invention relates to pharmaceutically acceptable amphiphilic antioxidant compounds, compositions and dosage forms comprising said compounds, and methods and uses reliant on said compounds. The exemplified compounds are all mitoquinone derivatives, being methoxyphenyl alkyl triphenylphosphonium or methoxy dioxocyclohexadiene alkyl triphenylphosphonium derivatives. The compounds, compositions, dosage forms, uses and methods are... Agent:

20110288056 - Once daily formulations of tetracyclines: Disclosed are once-daily formulations containing tetracyclines, especially doxycycline. Such formulations are useful, for instance, for the treatment of collagenase destructive enzyme-dependent diseases, such as periodontal disease and acne, and acute and chronic inflammatory disease states, such as rosacea and arthritis.... Agent: Supernus Pharmaceuticals, Inc.

20110288058 - Methods for preventing or reducing colon carcinogenesis: The present invention is directed in part to methods of preventing or reducing colon carcinogenesis comprising administering to a patient at risk of colorectal cancer, a pharmaceutical preparation comprising disclosed chemopreventive. In another aspect, the invention is directed to methods attenuation of oxygen free radicals comprising administrating to a patient... Agent:

20110288057 - Salicylic acid derivatives being farnesyl pyrophosphate synthase activity inhibitors: e

20110288059 - Neuroactive steroid compositions and methods of use therefor: Provided are methods for ameliorating a symptom of a neuropsychiatric disorder in a subject. Also provided are methods for ameliorating at least one physical symptom or at least one psychological symptom resulting from tobacco cessation in a subject, methods for ameliorating a symptom of Alzheimer's disease or other cognitive disorder... Agent:

20110288060 - apparatus and process for producing crystals: This invention provides an oscillating baffled reactor apparatus for preparing crystalline particles of at least one substance comprising: a reactor vessel; means for supplying a first flowing stream; means for oscillating fluid within the reactor vessel; a plurality of baffles; source of ultrasonic radiation; and means for collecting said particles.... Agent: Prosonix Limited

20110288061 - Triterpenoid derivatives, benzenoid derivatives and pharmaceutical compositions containing the same: i

20110288062 - Biodegradable polymer system: A polymer system useful for in vivo delivery of a therapeutic agent is provided. The polymer system comprises a biocompatible biodegradable polymeric backbone that is capable of a reversible stimuli-induced transition from liquid to gel.... Agent:

20110288063 - Novel fused bridged bicyclic heteroaryl substituted 6-alkylidene penems as potent beta-lactamase inhibitors: p

20110288065 - Aminopyrazine derivative and medicine:

20110288064 - Methods for treating disorders associated with hyperlipidemia in a mammal: The invention is directed to methods for treating hyperlipidemia in a mammal. The methods involve combination therapies using a microsomal triglyceride transfer protein (MTP) inhibitor (for example, BMS-201038 and implitade) and a cholesterol absorption inhibitor (CAI) (for example, ezetimibe). Co-administration of the MTP inhibitor with the CAI produces a therapeutic... Agent:

20110288067 - Pyrrolopyrazine kinase inhibitors: e

20110288068 - Aza spiro alkane derivatives as inhibitors of metalloproteases:

20110288066 - Phenoxy acetic acid derivatives: The present invention provides phenoxyacetic acid derivatives of Formula (I) for the treatment of CRTH2 related disorders and disease selected from asthma, atopic dermatitis and inflammatory dermatoses.... Agent: Merck Serono S.a.

20110288069 - Benzodiazepine and pyridodiazepine derivatives: e

20110288071 - Substituted pyrimidines for the treatment of diseases such as cancer: The present invention encompasses compounds of general formula (1) wherein A, B, X, R1 to R3 are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, and their use for preparing a medicament having the above-mentioned properties.... Agent: Boehringer Ingelheim International Gmbh

20110288070 - Methods for treating cognitive disorders using inhibitors of histone deacetylase: This disclosure relates to compounds for the inhibition of histone deacetylase and treatment of a cognitive disorder or deficit. More particularly, the disclosure provides for compounds of formula (I) wherein (I), Q, J, L and Z are as defined in the specification.... Agent:

20110288073 - Alpha-aminocyclolactam ligands for g-protein coupled receptors, and methods of using same: i

20110288072 - Use of ivabradine for obtaining medicaments intended for the treatment of endothelial dysfunction: Use of ivabradine, or 3-{3-[{[(7S)-3,4-dimethoxybicyclo [4.2.0]octa-1,3,5-trien-7-yl]-methyl }-(methyl)-amino]-propyl}-7,8-dimethoxy-1,3,4,5 -tetrahydro-2H-3-benzazepin-2-one, its addition salts with a pharmaceutically acceptable acid and their hydrates, for obtaining a medicament intended for the treatment of endothelial dysfunction.... Agent: Les Laboratoires Servier

20110288074 - New adenosine receptor ligands and uses thereof: The present invention provides new compounds with high affinity for adenosine A2A receptors. It also provides antagonists of adenosine A2A receptors and their use as medicaments for the treatment and/or prophylaxis of diseases and disorders where the partial or total inactivation of adenosine A2A receptors signalling pathways could be beneficial... Agent: Domain Therapeutics

20110288075 - Pyridazinone derivatives: The present invention is directed to novel pyridazinone derivatives that mediate enzymatic activity. In particular, the compounds may be effective in the treatment of diseases or disease states related to the activity of the histamine H3 receptor, including, for example, neurodegenerative disorders, sleep/wake disorders, attention deficit hyperactivity disorder and cognition/cognitive... Agent: Cephalon, Inc.

20110288076 - Sphingosine-1-phosphate receptor antagonists: This disclosure relates to sphingosine-1-phosphate (S1P) receptor antagonists, compositions comprising the S1P receptor antagonists and methods for using and processes for making the S1P receptor antagonists. In particularly, this disclosure relates to sphingosine-1-phosphate 1 (S1P1) receptor antagonists, compositions comprising the S1P1 receptor antagonist and methods for using the S1P1 receptor... Agent: Exelixis, Inc.

20110288077 - Compounds for the treatment of inflammatory diseases: This invention relates to compounds of the Formula (I)-(IX):, as defined herein, or a pharmaceutically acceptable salt, solvate or ester thereof, which can be useful for the treatment of diseases or conditions mediated by MMPs, ADAMs, TACE, aggrecanase, TNF-α combinations thereof.... Agent: Schering Corporation

20110288078 - Pyrazinopyrazines and derivatives as kinase inhibitors: This invention relates to compounds of the general formula: in which the variable groups are as defined herein, and to their preparation and use.... Agent: Ariad Pharmaceuticals, Inc.

20110288079 - Tannate compositions, methods of making and methods of use: Tannate compositions containing active pharmaceutical ingredients to be used for treating nausea, vomiting, pain, convulsions, and insomnia and manufacturing processes for preparing the tannate compositions.... Agent:

20110288080 - Nitrofuran compounds for the treatment of cancer and angiogenesis: The invention is directed to the synthesis and use of nitrofuran compounds, especially Nifurtimox, as medicaments to treat cancer, especially neuroblastoma, and to inhibit angiogenesis. The invention also provides compositions, unit dosage forms, and kits comprising the compounds.... Agent: Brown University

20110288081 - Pyrimidine compounds and uses thereof: e

20110288083 - Method of treating cancer by inhibition of protein kinase-like endoplasmic reticulum protein kinase: The present invention relates to a method of identifying compounds useful in inhibiting protein kinase-like endoplasmic reticulum protein kinase (PERK). The method comprises providing a first model comprising PERK active domains, where the said active domains are selected from the group consisting of the peptide spanning from amino acid residue... Agent: New York University

20110288082 - Methods and compositions for inhibition of the transitional endoplasmic reticulum atpase: Compounds of Formulas I-XLIII are identified as direct inhibitors of p97 ATPase or of the degradation of a p97-dependent ubiquitin-proteasome system (UPS) substrate. Methods and compositions are disclosed for inhibiting p97 ATPase and the degradation of a p97-dependent UPS substrate, and for identifying inhibitors thereof... Agent:

20110288084 - [4-( 1-amino-ethyl) - cyclohexyl ] - methyl - amines as antibacterials: The present invention relates to compounds of Formula (I) and pharmaceutically acceptable salts thereof, to their use in the treatment of bacterial infections, and to their methods of preparation.... Agent: Astrazeneca Ab

20110288087 - Fused ring compound and use thereof: Wherein each symbol is as defined in the specification, or a salt thereof, which has an angiotensin II receptor antagonistic activity and a peroxisome proliferator-activated receptor γ agonistic activity, and is useful as an agent for the prophylaxis or treatment of circulatory diseases such as hypertension and the like and/or... Agent: Takeda Pharmaceutical Company Limited

20110288085 - Imidazopyridine and imidazopyrazine compounds useful as kinase inhibitors: A compound of Formula (I) or Formula (II) and enantiomers, diastereomers and pharmaceutically-acceptable salts thereof. Also disclosed are pharmaceutical compositions containing compounds of Formula (I) or Formula (II), and methods of treating conditions associated with the activity of p38 kinase.... Agent: Bristol-myers Squibb Company

20110288086 - Polycyclic quinazolines, preparation thereof, and use thereof: c

20110288090 - Inhibitors of akt activity: The instant invention provides for compounds that inhibit Akt activity. In particular, the compounds disclosed selectively inhibit one or two of the Akt isoforms. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting Akt activity by administering the compound to a patient in need of... Agent:

20110288089 - Insecticidal compounds: A compound of Formula (I): wherein A1, A2, A3, A4, A5, G1, R1, R2, R3 and R4 are as defined in claim 1; or a salt or N-oxide thereof. Furthermore, the present invention relates to processes and intermediates for preparing compounds of formula (I), to insecticidal, acaricidal, nematicidal and molluscicidal... Agent: Syngenta Crop Protection LLC

20110288088 - Substituted pyrrolo-pyrazole derivatives active as kinase inhibitors: Substituted pyrrolo-pyrazole derivatives of formula (I) and pharmaceutically acceptable salts thereof, as defined in the specification, process for their preparation and pharmaceutical compositions comprising them are disclosed; the compounds of the invention may be useful in therapy in the treatment of diseases associated with dysregulated protein kinase activity, like cancer.... Agent: Nerviano Medical Sciences S.r.i.

20110288091 - Soluble mtor complexes and modulators thereof: The present invention relates to small molecule modulators of mTORC1 and mTORC2, syntheses thereof, and intermediates thereto. Such small molecule modulators are useful in the treatment of proliferative diseases (e.g., benign neoplasms, cancers, inflammatory diseases, autoimmune diseases, diabetic retinopathy) and metabolic diseases. Novel small molecules are provided that inhibit one... Agent: Dana-farber Cancer Institute, Inc.

20110288092 - Heterocyclic inhibitors of mek and methods of use thereof: e

20110288093 - Compounds, compositions, and methods comprising pyridazine sulfonamide derivatives: The present invention relates to methods for treating a disease in an animal, which disease is responsive to blocking of chloride channel by administering to a mammal in need thereof an effective amount of a compound defined herein (including those compounds set forth in Tables 1-3 or encompassed by formula... Agent: Institute For Oneworld Health

20110288094 - 1-aryl-1-hydroxy-2,3-diamino-propyl amines, 1-heteroaryl-1-hydroxy-2,3-diamino-propyl amines and related compounds having analgesic and/or immuno stimulant activity: e

20110288099 - Compositions with reduced hepatotoxicity: Pharmaceutical compositions of hepatotoxic compounds are provided in which the hepatotoxicity of the compounds is mitigated by including quantities of nicotinamide and methionine in the composition. Folic acid also can be included to further mitigate the hepatotoxic effects. The hepatotoxic compounds can include acetaminophen, methotrexate, atorvastatin, simvastatin, niacin, flucanozole, divalproex... Agent:

20110288096 - Methods and compositions for treating or preventing erythema: Methods and products for treating or preventing erythema or a symptom associated with erythema in a subject are described. The methods involve topically applying to an affected skin area a topical aqueous gel composition comprising about 0.01% to about 10% by weight of at least one α-adrenergic receptor agonist and... Agent: Galderma Laboratories Inc.

20110288098 - Novel compounds: This invention relates to imidazopyrazine substituted piperidine derivatives and their use as pharmaceuticals.... Agent: Glaxo Group Limited

20110288097 - Pyrrolopyrazine kinase inhibitors: i

20110288095 - Thiophene-carboxamides useful as inhibitors of protein kinases: The present invention relates to compounds useful as inhibitors of protein kinase. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders. The invention also provides processes for preparing compounds of the inventions.... Agent: Vertex Pharmaceuticals Incorporated

20110288100 - Therapeutic agents useful for treating pain: where Ar1, Ar2, X, Z1, Z2, R3, and m are as disclosed herein or a pharmaceutically acceptable salt thereof (a “Pyridylene Compound”); compositions comprising an effective amount of a Pyridylene Compound; and methods for treating or preventing pain or other conditions in an animal comprising administering to an animal in... Agent: Purdue Pharma L.p.

20110288101 - Surgical compositions containing sigma-receptor agonists: One aspect of the present invention relates to aqueous surgical compositions comprising a sigma-1 receptor agonist. Another aspect of the present invention relates to methods of irrigating ocular tissues during an ophthalmic surgical procedure such as cataract surgery. Such methods comprise bathing the ocular tissues with a composition comprising a... Agent: Alcon Research, Ltd.

20110288102 - Il-8 biomarker for monitoring cancer treatment: The present application includes methods for using IL-8 as a biomarker for, e.g., tumor size, for example, during course of treatment with an anti-cancer agent such as an ERK inhibitor.... Agent: Schering Corporation

20110288103 - Compounds, compositions, and methods comprising 1,3,4-oxadiazole derivatives: The present invention relates to methods for treating a disease in an animal, which disease is responsive to blocking of calcium activated chloride echannel (CaCC) by administering to a mammal in need thereof an effective amount of a compound defined herein (including those compounds set forth in Tables 1-2 or... Agent: Institute For Oneworld Health

20110288104 - Beta-3 receptor ligands and their use in therapy: The present invention relates to new compounds, ligands of the beta-3 adrenergic receptor, their preparation and their use in therapy or as research tools for said receptor; the invention also relates to a process for the preparation of the compounds of the invention and the use of inverse agonists of... Agent: Universita' Degli Studi Di Bari

20110288105 - Eltoprazine for the treatment of l-dopa-induced dyskinesia: The present invention relates to the treatment of an individual afflicted with L-DOPA-induced dyskinesia, which condition may arise as a consequence of long-term treatment with L-DOPA therapy in Parkinson's patients, the instant treatment comprising administering to the individual an effective amount of eltoprazine or a pharmaceutically acceptable salt thereof.... Agent: Merz Pharma Gmbh & Co. Kgaa

20110288106 - Adenine receptor ligands: The invention relates to adenine receptor ligands useful for treating, alleviating and/or preventing diseases and disorders related to adenine receptor function as well as pharmaceutical compositions comprising such compounds and methods for preparing such compounds. The invention is further directed to the use of these compounds, alone or in combination... Agent: Rheinische Friedrich-wilhelms-universitaet Bonn Regina-pacis-weg 3

20110288107 - Topical formulation for a jak inhibitor: This invention relates to pharmaceutical formulations for topical skin application comprising (R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile, or a pharmaceutically acceptable salt thereof, and use in the treatment of skin disorders.... Agent:

20110288108 - Tricyclic compounds having antimitotic and/or antitumor activity and methods of use thereof: The present invention provides tricyclic compounds, pharmaceutically acceptable salts, prodrugs, solvates, or hydrates thereof, having antimitotic activity, anti-multidrug resistance activity, for example P-glycoprotein inhibition, and antitumor activity, and which inhibit paclitaxel sensitive and resistant tumor cells. Also provided are methods of utilizing these compounds for treating tumor cells and inhibiting... Agent:

20110288109 - New compounds: The present invention includes compounds of general Formula (1), wherein A, X, R1 and R2 are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, and their use for preparing a medicament having the above-mentioned properties.... Agent: Boehringer Ingelheim International Gmbh

20110288110 - Methods for treating disorders associated with hyperlipidemia in a mammal: The invention is directed to methods for treating hyperlipidemia in a mammal. The methods involve combination therapies using a microsomal triglyceride transfer protein (MTP) inhibitor (for example, BMS-201038 and implitapide) and a HMG-CoA reductase inhibitor (for example simvastatin or atorvastatin). Co-administration of the MTP inhibitor with the HMG-CoA reductase inhibitor... Agent:

20110288111 - Inhibition of influenza m2 proton channel: Provided are compounds that are capable of modulating the activity of the influenza A virus via interaction with the M2 transmembrane protein. Also provided are methods for treating an influenza A-affected disease state or infection comprising administering a composition comprising one or more compounds that have been identified as being... Agent: The Trustees Of The University Of Pennsylvania

20110288112 - Method of providing sustained analgesia with buprenorphine: A method of effectively treating pain in humans is achieved by administering buprenorphine in accordance with first order kinetics over an initial three-day dosing interval, such that a maximum plasma concentration from about 20 pg/ml to about 1052 pg/ml is attained, and thereafter maintaining the administration of buprenorphine for at... Agent:

20110288113 - Method to reduce or elminate the use by a patient of a tolerance-inducing pharamacological agent: A multiple total daily dose regimen is developed in order to decrease the use by a patient of a tolerance-inducing pharmacological agent. In one example, the method reduces or phases out altogether a patient's chronic use of opioid drugs by use of a successive reduction of the total daily dose... Agent:

20110288114 - Compositions for the treatment of fibrotic diseases or conditions: A method of treating a fibrotic disease or condition in a patient comprising administering noscapine and a pharmaceutical carrier to said patient.... Agent: Kinemed, Inc.

20110288115 - Treatment of vagally-mediated spectrum disorders: The present invention provides a method of treatment of a vagally-mediated spectrum disorder, comprising administering an effective amount of a 5-HT3 receptor antagonist to a patient in need thereof.... Agent: Avmedis LLC

20110288116 - Iap inhibitors: The present invention describes compounds of the following formula: processes for their preparation, pharmaceutical compositions containing them, and their use in therapy. The compounds of the present invention inhibit IAPs (inhibitors of apoptosis proteins) and thus are useful in the treatment of cancer, autoimmune diseases and other disorders where a... Agent: Tetralogic Pharmaceuitcal Corporation

20110288117 - Substituted hydroxamic acids and uses thereof: wherein R1a, R1, R2a, and R2b have values as described in the specification, useful as inhibitors of HDAC6. The invention also provides pharmaceutical compositions comprising the compounds of the invention and methods of using the compositions in the treatment of proliferative, inflammatory, infectious, neurological or cardiovascular diseases or disorders.... Agent: Millennium Pharmaceuticals, Inc.

20110288119 - Low dose - prov (alpha 7-evp): (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide has been found to have procognitive effects in humans at unexpectedly low doses. Thus, (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide and pharmaceutically acceptable salts thereof can be used at unexpectedly low doses improve cognition.... Agent:

20110288118 - Pharmaceutical composition comprising solifenacin: Disclosed is a pharmaceutical composition comprising a complex between solifenacin or a pharmaceutically acceptable salt thereof and an ion exchange resin, and an acrylic based polymer.... Agent: Astellas Pharma Inc.

20110288120 - Isoquinolinone derivatives as nk3 antagonists: Isoquinolone derivatives of the general formula (I) are NK3 antagonists.... Agent: H. Lundbeck A/s

20110288123 - Formulations for the treatment of acute herpes zoster pain: The present invention provides compositions and methods that are useful for treatment of pain associated with acute herpes zoster. The aqueous compositions are non-stinging and non-irritating.... Agent: Nuvo Research Inc.

20110288122 - Pharmaceutical compositions and administrations thereof: The present invention relates to the use of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide, solids forms, and pharmaceutical compositions thereof for the treatment of CFTR mediated diseases, particularly cystic fibrosis, in patients possessing specific genetic mutations.... Agent: Vertex Pharmaceuticals Incorporated

20110288121 - Processes for producing modulators of cystic fibrosis transmembrane conductance regulator: The present invention relates to the process for producing modulators of cystic fibrosis transmembrane conductance regulator (CFTR).... Agent: Vertex Pharmaceuticals Incorporated

20110288124 - Compositions and method for treatment of attention deficit disorder and attention deficit/hyperactivity disorder with methylphenidate: The invention relates to a method of treating Attention Deficit Disorder (ADD) and Attention Deficit/Hyperactivity Disorder (ADHD) and compositions for topical application of methylphenidate comprising methylphenidate in a flexible, finite system wherein said composition comprises about 10 to 30 wt % methylphenidate, about 30 to 50 wt % acrylic adhesive,... Agent: Noven Pharmaceuticals, Inc.

20110288125 - Novel use of piperine: The present invention is related to novel use of piperine, and more specifically, it is related to a pharmaceutical or food composition for preventing and treating obesity comprising piperine or a salt thereof as an active ingredient. The present invention is related to novel use of piperine, and it provides... Agent: Industry-academic Cooperation Foundation, Yonsei University

20110288127 - Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione: Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione are disclosed. Compositions comprising the polymorphic forms, methods of making the polymorphic forms and methods of their use are also disclosed.... Agent: Celgene Corporation

20110288126 - Substituted dioxopiperidinyl phthalimide derivatives: This invention relates to novel substituted dioxopiperidinyl phthalimide derivatives and pharmaceutically acceptable acid addition salts thereof. The invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions beneficially treated by an immunomodulatory agent.... Agent: Concert Pharmaceuticals, Inc.

20110288128 - Oral transmucosal administration of sufentanil: Compositions and methods for administration of sufentanil-containing drug formulations to the oral mucosa of a subject are disclosed.... Agent: Acelrx Pharmaceuticals, Inc.

20110288129 - Amide derivatives as trpv1 antagonists: m

20110288130 - Bacterial thioredoxin reductase inhibitors and methods for use thereof: The mechanism of action of Ebselen differentiates between bacterial and mammalian thioredoxin reductase (TrxR). It displays fast oxidation of mammalian Trx and via the NADPH-TrxR catalyzed turnover of ebselen selenol with hydrogen peroxide, and therefore are mammalian antioxidants. Ebselen, and its diselenide, are strong competitive inhibitors of E. coli TrxR... Agent: Thioredoxin Systems Ab

20110288131 - Insecticidal compounds: A compound of formula (I) wherein A1, A2, A3, A4, G1, G2, R1, R2, R3 and R4 are as defined in claim 1; or a salt or oxide thereof. Furthermore, the present invention relates to processes and intermediates for preparing compounds of formula (I), to insecticidal, acaricidal, nematicidal and molluscicidal... Agent: Syngenta Crop Protection LLC

20110288132 - Nicotine and cocoa powder compositions: The present invention relates to a nicotine-containing pharmaceutical composition and methods of using the composition in therapies, such as nicotine replacement therapy.... Agent:

20110288134 - Composition and method for treating fibrosis: The present invention relates, in general, to fibroproliferative disorders, and, in particular, to a method of treating, preventing or reducing fibroproliferative disorders by administering to a mammal in need a composition comprising pharmacologically effective doses of a cytokine modifier, such as tranilast or pirfenidone, and an anti-oxidant which is a... Agent: Pacific Therapeutics Ltd.

20110288133 - Histone deacetylase inhibitors: This invention relates to novel Histone deacetylases inhibitors. Also disclosed is a method for treating mucositis or cancer with these inhibitors.... Agent: Taipei Medical University

20110288135 - Fast dissolving tablet: The present invention relates to processes for the preparation of tablets which dissolve rapidly in the mouth and provide an excellent mouthfeel. The tablets of the invention comprise a compound which melts at about 37° C. or lower, have a low hardness, high stability and generally comprise few insoluble disintegrants... Agent: Wyeth LLC

20110288136 - Flavivirus inhibition by sultams and related compounds: Disclosed herein are compounds, compositions and methods for treating or ameliorating flavivirus infections. This is particularly important because the present disclosure provides methods for treating flavivirus infections for which there is no effective vaccine.... Agent: Oregon Health & Science University

20110288137 - Sydnonimines-specific dopamine reuptake inhibitors ad their use in treating dopamine related disorders: Derivatives of Sydnonimine and its analogues, which bind selectively to dopamine transporter (DAT) proteins are useful for treating and delaying the progression of disorders and illnesses that are alleviated by inhibiting dopamine reuptake.... Agent:

20110288138 - Orally disintegrating tablets of zolmitriptan and process for preparing the same: Silicon dioxide free orally disintegrating tablet formulations of zolmitriptan or a pharmaceutically acceptable salt thereof having magnesium carbonate heavy and sodium stearyl fumarate with one or more pharmaceutically acceptable excipients and a process for preparing such a formulation and its use in the treatment of migraines.... Agent: Sanovel Llac Sanayi Ve Ticaret Anonim Sirketi

20110288139 - Substituted amino-benzimidazoles, medicaments comprimising said compound, their use and their method of manufacture: The present invention relates to substituted amino-benzimidazoles of general formula (1) wherein the groups R1 to R14 and A, are defined as in the specification and claims and the use thereof for the treatment of Alzheimer's disease (AD) and similar diseases.... Agent: Boehringer Ingelheim International Gmbh

20110288140 - Treating inflammation and inflammatory pain in mucosa using mucosal prolonged release bioadhesive therapeutic carriers: The present invention concerns a pharmaceutical composition comprising an alpha-2 adrenergic receptor agonist for preventing or treating inflammatory pain and diseases in mucosa of oral cavity, pharynx and larynx. Inanother aspect the present invention provides mucosal bioadhesive slow release carriers for the extended and controlled release of alpha-2 adrenergic receptor... Agent: Bioalliance Pharma ,s.a.

20110288141 - Local topical administration formulations containing fipronil: The present invention provides formulations and methods useful in eradicating ectoparasites on a domestic animal, decreasing the number of ectoparasites on a domestic animal, and/or preventing ectoparasite infestation on a domestic animal, using a local topical formulation comprising fiproniland a veterinarily acceptable carrier.... Agent: Intervet Inc. And Intervet International B.v.

20110288142 - Crystalline n--5-chloro-4-(4-chloro-1-methyl-1h-pyrazol-5-yl)-2-thiophenecarboxamide hydrochloride: An improved AKT inhibiting compound, crystalline N-{(1S)-2-amino-1-[(3-fluorophenyl)methyl]ethyl}-5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)-2-thiophenecarboxamide hydrochloride.... Agent:

20110288143 - Bladder cancer treatment and methods: Therapeutic compositions comprising an indoloquinone compound and various bladder cancer treatments and methods are disclosed. More specifically, the compositions comprise an indoloquinone compound and a formulation vehicle. The formulation vehicle improves the solubility and stability of the indoloquinone compound. Additionally, the coating compositions can include coating agents that provide better... Agent:

20110288144 - Use of hdac inhibitors for the treatment of melanoma: The invention relates to the use of an HDAC inhibitor, more specifically or a pharmaceutically acceptable salt thereof for the manufacture of pharmaceutical compositions for the treatment of melanoma; the use of an HDAC inhibitor or a pharmaceutically acceptable salt thereof in the treatment of melanoma; a method of treating... Agent: Novartis Ag

20110288145 - Novel formulation for l-tryptophane comprising carbidopa/benserazide: The present invention relates to the use of L-tryptophan and a peripheral degradation inhibitor of L-tryptophan for the manufacture of a medicament for prevention or therapy of pain, depressions, sleeping disorders and other serotonin dependent diseases of the CNS, wherein L-tryptophan is present in a retarded and the peripheral degradation... Agent:

20110288146 - Directly compressible granular microcrystalline cellulose based, excipient, manufacturing process and use thereof: An improved excipient comprising substantially homogeneous particles of a compressible, high functionality granular microcrystalline cellulose based excipient is provided. The improved excipient comprises microcrystalline cellulose and a binder, and optionally a disintegrant, and is formed by spraying a homogeneous slurry of the components. The excipient provides enhanced flowability/good flow properties,... Agent:

20110288162 - Transition metal complexes of a bis[thio-hydrazide amide] compounds: The present invention is directed to a compound comprising a bis[thiohydrazide amide] or a deprotonated form thereof, complexed to a transition metal cation, wherein the bis[thio-hydrazide amide] is represented by Structural Formula (I): or a prodrug, isomer, ester, salt, hydrate, solvate, polymorph or a deprotonated form thereof. The present invention... Agent: Synta Pharmaceutical Corp

20110288163 - Methods of using macrocyclic modulators of the ghrelin receptor: The present invention provides novel conformationally-defined macrocyclic compounds that have been demonstrated to be selective modulators of the ghrelin receptor (growth hormone secretagogue receptor, GHS-R1a and subtypes, isoforms and variants thereof). Methods of synthesizing the novel compounds are also described herein. These compounds are useful as agonists of the ghrelin... Agent:

20110288164 - Agent for inhibiting production of hepatitis c virus and its use: e

20110288165 - Novel lipid composition for the treatment of skin problems in companion animals: The present invention provides lipid compositions comprising linolenic acid (LA), alpha-linolenic acid (ALA), stearidonic acid (SDA) and gamma linolenic acid (GLA), said LA and ALA in a ratio of about less than 2:1 LA:ALA. The compositions find use in for improving, treating, or preventing a condition selected from the group... Agent: Olini Ltd

20110288166 - Triptolide c-ring derivatives as anticancer agents and immune modulators: Disclosed are compounds based on C- and D-ring modifications of triptolide and hydroxylated triptolide, for use in therapy, such as antiproliferative, anticancer, and immunosuppressive therapy.... Agent: Pharmagenesis, Inc.

20110288167 - Butylphthalide intravenous emulsion and application thereof: The present invention discloses a butylphthalide intravenous emulsion for intravenous injection or infusion, containing butylphthalide or derivatives thereof as an active ingredient in an amount of 0.01˜50 wt % and an excipient in an amount of 50˜99.99 wt %, based on the total weight of the emulsion.... Agent:

20110288168 - Histone deacetylase inhibitors: Histone deacetylase is a metallo-enzyme with zinc at the active site. Compounds having a zinc-binding moiety, such as, for example, a hydroxamic acid group or a carboxylic acid group, can inhibit histone deacetylase. Histone deacetylase inhibition can repress gene expression, including expression of genes related to tumor suppression. Accordingly, inhibition... Agent: Errant Gene Therapeutics, LLC

20110288169 - Triterpenoid compounds and methods of use thereof: The present invention provides therapeutically active compounds and compositions as receptor antagonists and methods of use thereof. In one aspect, the compounds are useful in modulating pain, inflammation and acute phase reactions by inhibiting the PGE2 receptors including PGE2 EP1, EP2 and EP4 receptors.... Agent: Biotechnology Research Corporation

20110288170 - Retinal derivatives and methods for the use thereof for the treatment of visual disorders: Compositions of and methods for using synthetic retinal derivatives as retinoid replacements and opsin agonists are provided.... Agent: University Of Washington

20110288171 - Methods of treating hypertriglyceridemia: In various embodiments, the present invention provides methods of treating and/or preventing cardiovascular-related disease and, in particular, a method of blood lipid therapy comprising administering to a subject in need thereof a pharmaceutical composition comprising eicosapentaenoic acid or a derivative thereof.... Agent: Amarin Pharma, Inc.

20110288172 - Dermatological compositions and methods: Dermatological compositions (methods of making and using) that include one or more anesthetic agents and/or one or more anti-inflammatory agents and/or a combination of ammonium, sodium, and potassium salts, preferably of an alpha-hydroxy acid.... Agent: Upsher-smith Laboratories, Inc.

20110288173 - Use of neboglamine in the treatment of toxicodependency: Use of neboglamine, (S)-4-amino-N(4,4-dimethyl-cyclohexyl)glutamic acid (CR 2249) (CAS Registry Number 163000-63-3), the racemic mixture thereof or a pharmaceutically acceptable salt thereof, for the preparation of a medicament for use in the treatment of toxicodependency induced by drugs such as CNS sedatives such as opiates, barbiturates, benzodiazepines, alcohol, stimulants such as... Agent: Rottapharm S.p.a.

20110288174 - Monohydrate of 4-(phenyl)ethyl]-amino}methyl)benzoic acid: The invention relates to novel forms of 4-({(4-carboxybutyl) [2-(2-{[4-(2-phenylethyl)benzyl]oxy}phenyl)ethyl]amino}methyl)benzoic acid, in particular to the monohydrate in form A, to processes for their preparation, to medicaments comprising them and to their use for fighting diseases.... Agent: Bayer Schering Pharma Aktiengesellschaft

20110288175 - 1-phenylalkanecarboxylic acid derivatives for the treatment of neurodegenerative diseases: 1-Phenylalkanecarboxylic acid derivatives, the processes for the preparation thereof and the use thereof in the treatment and/or prevention of neurodegenerative diseases such as Alzheimer's disease.... Agent: Chiesi Farmaceutici S.p.a.

20110288176 - Ethacrynic acid-containing composition for prevention or treatment of transglutaminase-related diseases and method for prevention or treatment of transglutaminase-related diseases using the same: The present invention relates to ethacrynic acid and a transglutaminase inhibitor comprising a pharmaceutically acceptable salt of ethacrynic acid; more particularly, to ethacrynic acid for inhibiting the activity of transglutaminase involved in the pathogenesis of diseases in cases of altered expression, a transglutaminase inhibitor comprising a pharmaceutically acceptable salt of... Agent:

20110288177 - Methods for preventing or reducing colon carcinogenesis: The present invention is directed in part to methods of preventing or reducing colon carcinogenesis comprising administering to a patient at risk of colorectal cancer, a pharmaceutical preparation comprising a chemopreventive agent disclosed herein.... Agent:

20110288178 - Radioprotective agents: Provided herein are methods, for reducing, preventing, mitigating and treating damage caused by radiation. The methods comprise delivering a compound, as described herein, to a patient in an amount and dosage regimen effective to prevent, mitigate or treat damage caused by radiation or to mitigate apoptosis. The compounds comprise glyburide... Agent:

20110288179 - Bimatoprost crystalline form i: The invention provides a novel polymorphic form I of crystalline bimatoprost, method for preparation thereof and new crystalline intermediates in the preparation. This form I of crystalline bimatoprost is used in purification of crude bimatoprost and in storage of bimatoprost as active pharmaceutical intermediate. Use of the physical form of... Agent:

20110288180 - Dietary purgatives: Described are kits, food compositions and methods for cleaning the bowel, e.g., in preparation for a medical procedure, e.g., a diagnostic or treatment procedure, such as an endoscopic or surgical procedure, or radiologic imaging such as CT colography.... Agent:

20110288181 - Preparations of biologically active substances with enlarged surface based on amphiphilic copolymers: Preparations with enlarged surface comprising an active ingredient and an amphiphilc copolymer, wherein the copolymer comprises at least one polyether-containing graft polymer. The preparations are partially or completely foamed. Processes for producing the preparations are also described, including processes comprising extrusion of a melt impregnated with a physiologically acceptable volatile... Agent: Basf Se

20110288182 - Health characteristic dulce de leche confection compositions and flavored milk: The present invention provides for Dulce de Leche confection compositions and Dulce de Leche based flavored milk that has an improved, healthier fat structure, unique antioxidant taste profile, lower sugar content, fiber component, and a 0% or greater supplement component that can add additional dietary benefits. Cholesterol reduction can be... Agent:

  
11/17/2011 > 172 patent applications in 126 patent subcategories. recently filed with US Patent Office

20110281786 - Stem cell expansion enhancing factor and method of use: The present invention relates to a stem cell expansion factor, and to a method for enhancing hematopoietic stem cell expansion by direct delivery of a protein in the cell and which protein is able to cross cell membrane. The method comprises directly delivering in a HSC an amino acid sequence... Agent:

20110281787 - Pharmaceutical compositions comprising antisense oligonucleotides and methods of using same: The invention provides compositions and associated methods for the antisense treatment of genetic disorders, infections and various other medical conditions. In particular, embodiments of the present invention are directed to pharmaceutical compositions comprising a combination of an antisense oligonucleotide compound conjugated with a positively charged polymer (“ON-PCP”) and a negatively... Agent: The Charlotte-mecklenburg Hospital Authority D/b/a Carolinas Medical Center

20110281788 - Anti fungal therapy: The present invention relates to the treatment of fungal infections and provides compounds, compositions, methods and for treating the same.... Agent:

20110281789 - Ulbp antibodies: The invention is directed to purified and isolated novel ULBP polypeptides, the nucleic acids encoding such polypeptides, processes for production of recombinant forms of such polypeptides, antibodies generated against these polypeptides, fragmented peptides derived from these polypeptides, and the uses of the above. ULBP polypeptide can be found on the... Agent: Immunex Corporation

20110281792 - Binding-site modified lectins and uses thereof: In one aspect, the disclosure provides cross-linked materials that include multivalent lectins with at least two binding sites for glucose, wherein the lectins include at least one covalently linked affinity ligand which is capable of competing with glucose for binding with at least one of said binding sites; and conjugates... Agent:

20110281791 - Crystalline insulin-conjugates: The present disclosure provides crystalline insulin-conjugates. The present disclosure also provides formulations, methods of treatment, methods of administering, and methods of making that encompass these crystalline insulin-conjugates.... Agent:

20110281790 - Insulin with a stable basal release profile: A basal insulin formulation composed of insulin, preferably insulin glargine, injectable zinc and injectable iron compounds as precipitating and/or stabilizing agents has been developed for subcutaneous, intradermal or intramuscular administration. The formulation is designed to form a precipitate of insulin following injection, creating a slow releasing “basal insulin” over a... Agent: Biodel, Inc.

20110281793 - Method for reducing cardiovascular morbidity and mortality in prediabetic patients and patients with type 2 diabetes: This invention relates to a method of reducing cardiovascular morbidity and mortality in a prediabetic or Type 2 Diabetes patient population. The method comprises administering an effective dosage of a long acting insulin, preferably insulin glargine, to a prediabetic or Type 2 Diabetes patient.... Agent: Aventis Pharmaceuticals Inc.

20110281794 - composition comprising nor-adrenaline and amphetamine for administering to a brain-dead, heart-beating potential organ donor: A composition, an infusion solution, a method for treatment, and a kit for intravascular administration for treatment of a brain-dead, heart-beating, respirated, potential organ donor. The composition includes a non-adrenaline and amphetamine or an amphetamine-like substance. The composition may in addition include adrenaline, hydrocortisone, thyroxin, insulin, triiodotyronine, dopamine, a vasopressor... Agent: Vivoline Medical Ab

20110281795 - Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use: Glucagon receptor antagonist compounds are disclosed. The compounds are useful for treating type 2 diabetes and related conditions. Pharmaceutical compositions and methods of treatment are also included.... Agent:

20110281796 - Novel activin receptor and uses thereof: The present invention provides novel activin IIB5 receptor polypeptides capable of binding and inhibiting the activities of activin A, myostatin, or GDF-11. The present invention also provides polynucleotides, vectors and host cells capable of producing the receptor polypeptides. Compositions and methods for treating muscle-wasting, metabolic and other disorders are also... Agent: Amgen Inc.

20110281798 - Methods for lowering plasma glucagon with exendins and exendin agonist analogs: Novel formulations containing exendins, exendin agonists and/or exendin analogs are provided.... Agent: Amylin Pharmaceuticals, Inc.

20110281797 - Site-specific monoconjugated insulinotropic glp-1 peptides: The present invention is related to glucagon-like peptide-1 (GLP-1) and analogues insulinotropic peptides, monoconjugated to biocompatible polymeric molecules by enzymatic direct and site-specific transglutamination reaction as well as their pharmaceutical formulations and delivery systems for therapeutical application in dismetabolic pathologies such as type 2 diabetes.... Agent: Bio-ker Srl

20110281799 - Vascular endothelial growth factor d (vegf-d) antibodies and vectors, and methods of uses: VEGF-D, a new member of the PDGF family of growth factors, which among other things stimulates endothelial cell proliferation and angiogenesis and increases vascular permeability, as well as nucleotide sequences encoding it, methods for producing it, antibodies and other antagonists to it, transfected or transformed host cells for expressing it,... Agent:

20110281800 - Recombinant fusion proteins to growth hormone and serum albumin: The invention describes albumin fusion proteins comprising growth hormone and serum albumin. The invention also describes nucleic acid molecules encoding the albumin fusion proteins of the invention, as well as vectors containing these nucleic acid molecules, host cells transformed with these vectors, and methods of making the albumin fusion proteins... Agent: Human Genome Sciences, Inc.

20110281801 - Prediction and prevention of preeclampsia: The present disclosure relates to methods for detecting an increased risk of preeclampsia, determining the presence of preeclampsia, reducing the likelihood that preeclampsia will develop and treating preeclampsia. It also provides methods of measuring relaxin levels in a biological sample of a pregnant woman.... Agent: University Of Pittsburgh-of The Comonwealth System

20110281802 - Composition for treatment and prevention of hair loss and premature graying of hair: Composition for treatment and prevention of human hair loss and/or hair greying, comprising an effective amount of thymic peptides of the family thymulin, thymosin alpha-1 and thymosin beta-4 and pharmaceutical excipient, diluent or carrier. Method and pharmaceutical composition for treatment and prevention of balding, hair loss, and alopecia.... Agent: Immudiagnostik Ag

20110281803 - Sulfatase enzymes: An isolated polypeptide inhibitor of SuIfIa having a sequence which is a variant of Sulf1a, and which lacks sulfatase activity and lacks the ability to bind to the surface of a cell. The polypeptide inhibitor of SuIf1a may be the alternatively spliced isoform SuIf1b. An isolated polypeptide inhibitor of Sulf2a... Agent:

20110281804 - Peptidic and peptidomimetic compounds for regulating autophagy: The present invention relates to peptides, peptidomimetic compounds and pharmaceutical uses thereof for the treatment of neurodegenerative diseases or tumourigenesis and more specifically diseases deriving from the dysregulation of the signalling system of Ambra-1-mediated autophagy.... Agent: Fondazione Santa Lucia

20110281805 - Use of an ang-(1-7) receptor agonist in acute lung injury: The present invention refers to a peptidic or non-peptidic angiotensin-(1-7) (Ang-(1-7)) receptor agonist, preferably a Mas receptor agonist, for the prevention and/or treatment of acute lung injury, preferably acute respiratory distress syndrome.... Agent:

20110281806 - Peptides for preventing or treating liver damage: The application of a peptide having sequence of formula I or its derivant in preparing the medicine for preventing or treating liver damage, especially liver damage and hepatitis C is disclosed, Xaa1-Gln-Xaa2-Xaa3-Thr-Ser-Gly-Xaa4 (formula I) wherein, Xaa1 is deletion, Ala, Gly, Val, Leu or Ile, Xaa2 is Thr or Ser, Xaa3... Agent:

20110281807 - Plant disease control agent comprising d-tagatose as active ingredient, and plant disease control method: A plant disease control agent comprising D-tagatose as an active ingredient; and a plant disease control agent comprising at least one member selected from the group consisting of saccharides and substances each having a bactericidal and/or fungicidal activity. The plant disease control agents are effective for the control of cucumber,... Agent: Mitsui Chemicals Agro, Inc

20110281808 - Composition and method for increasing pre workout thermogenics: The present invention provides a composition for causing a simultaneous and synergistic increase in central nervous system activity and thermogenesis in a mammal, comprising Yerba Mate as a source of caffeine, hordenine and naringin. The present invention further provides a composition for causing a simultaneous and synergistic increase in central... Agent: Allmax Nutrition Inc.

20110281809 - Methods and compositions for rapid treatment of otitis externa: Methods for treating and preventing otitis externa with a course of treatment consisting of as little as a single dose are provided. The methods are practiced by topical administration of compositions having a lipid carrier, such as liposomes and non-vesicular lipids, to the outer ear canal. Such compositions lack viscocity-enhancing... Agent: Triad Specialty Products LLC

20110281810 - Composition: The present invention relates to the use of a solubilizer for enhancing the solubility of an active pharmaceutical ingredient in water. The present invention further relates to a composition comprising a solubilizer and at least one active pharmaceutical ingredient. In both cases the solubilizer is an alkoxylated monoalcohol or a... Agent: CognisIPManagement Gmbh

20110281812 - Compounds: or salts thereof, useful in the treatment of neutrophil dominated inflammatory diseases, especially in the treatment of neutrophil dominated inflammatory diseases resulting from neutrophilic infiltration and/or diseases associated with altered cellular functionality of neutrophils, to methods for their preparation, to their use as therapeutic agents, and to salts thereof.... Agent:

20110281811 - Use of leukotriene inhibitors for treating lung diseases in prematurely born infants: The invention relates to the use of at least one leukotriene inhibitor for preparing a pharmaceutical composition for the prophylaxis and/or treatment of lung diseases, more particularly of bronchopulmonary dysplasia, in prematurely born infants. The invention further relates to a pharmaceutical composition for the prophylaxis and/or treatment of lung diseases,... Agent:

20110281813 - Method of treating c-kit positive relapsed acute myeloid leukemia: The present invention relates to a method of treating c-kit positive relapsed acute myeloid leukemia (AML) in a human patient population using a combination comprising a c-kit inhibitor, daunorubicin and cytarabine.... Agent: Cleveland Clinic

20110281814 - Methods and compositions for treating breast cancer: The invention relates to methods and compositions for treating a subject afflicted with breast cancer using a CX-CR4 antagonist and optionally in combination with a chemotherapeutic agent.... Agent: Genzyme Corporation

20110281935 - Combination therapy based on src and aurora kinase inhibition for the treatment of cancer: Compositions which act synergistically to inhibit the growth of cancer cells and methods of use thereof are disclosed.... Agent:

20110281933 - Methods and compositions for the management of cardiovascular disease with oligonucleotides: Disclosed are compositions and methods for treating cardiovascular disease and reducing the adverse effects induced by the administration of statins. In particular, disclosed is the use of antisense compounds to augment the expression of mirR-33 and associated genetic elements. In particular methods of the treatment of cardiovascular disease and the... Agent: Saint Louis University

20110281936 - Methods of treating cognitive disorders by inhibition of gpr12: The present invention provides methods for screening a pharmaceutical agent for its ability to modulate long term memory formation, performance of a hippocampal-dependent cognitive task or Gpr12 function. The present invention also provides methods for modulating long term memory formation or performance of a hippocampal-dependent cognitive task by modulating Gpr12-dependent... Agent:

20110281932 - Methods to enhance t-cell mediated immune response: The present invention provides methods for restoring or enhancing T cell mediated immune response in individuals of middle and advanced age.... Agent: The Board Of Trustees Of The Leland Stanford Junior University

20110281934 - Micelles of hydrophilically shielded membrane-destabilizing copolymers: Provided herein are micelles comprising a plurality of copolymers. In certain instances, micelles provided herein are pH sensitive particles.... Agent: University Of Washington

20110281931 - Rna sequence-specific mediators of rna interference: The present invention relates to a Drosophila in vitro system which was used to demonstrate that dsRNA is processed to RNA segments 21-23 nucleotides (nt) in length. Furthermore, when these 21-23 nt fragments are purified and added back to Drosophila extracts, they mediate RNA interference in the absence of long... Agent:

20110281938 - Aptamers to tissue factor pathway inhibitor and their use as bleeding disorder therapeutics: The invention relates generally to the field of nucleic acids and more particularly to aptamers that bind to TFPI, which are useful as therapeutics in and diagnostics of bleeding disorders and/or other diseases or disorders in which TFPI has been implicated. In addition, the TFPI aptamers may be used before,... Agent: Baxter International Inc.

20110281937 - Methods and compositions for treating neuropathic and neurodegenerative conditions: Disclosed herein are engineered zinc finger proteins which modulate transcription of the gene encoding vascular endothelial growth factor-A (VEGF-A) and other genes encoding products with neurotrophic activities. Also disclosed are methods for the use of these engineered zinc finger proteins in the treatment of neuropathy (including diabetic neuropathy), and other... Agent:

20110281939 - Polynucleotide aptamer-based cross-linked materials and uses thereof: In one aspect, the disclosure provides cross-linked materials that include multivalent polynucleotide aptamers that bind a target molecule; and conjugates that include two or more separate affinity ligands bound to a conjugate framework, wherein the two or more affinity ligands compete with the target molecule for binding with the aptamers... Agent:

20110281815 - Parental formulations of gemcitabine derivatives: The present invention relates to parenteral formulations for certain long chain saturated and monounsaturated fatty acid derivatives of 2′,2′-difluorodeoxycytidine (Gemcitabine). In particular, the present invention relates to a parenteral pharmaceutical composition and a method of the preparation thereof, in order to accommodate therapeutically effective doses of the said derivatives ameliorating... Agent: Clavis Pharma As

20110281816 - Fungicidally active compound combinations: e

20110281818 - High fructan cereal plants: The invention provides cereal plants having a high level of fructan useful for the production of a range of food, beverage, nutraceutical and pharmaceutical products. The invention provides methods of producing high-fructan products from plants modified to comprise a reduced level of an endogenous polypeptide with starch synthase activity, and... Agent:

20110281819 - Low-molecular polysulfated hyaluronic acid derivative and medicine containing same: e

20110281817 - Production of hyaluronic acid: Methods for producing hyaluronic acid are described, including altering the activity in Streptococcus cells of one or more enzymes and/or altering the amount of available substrates or substrate precursors.... Agent: The University Of Queensland

20110281820 - Glycosaminoglycans derived from k5 polysaccharide having high anticoagulant and antithrombotic activities and process for their preparation: Glycosaminoglycans derived from K5 polysaccharide having high anticoagulant and antithrombotic activity and useful for the control of coagulation and as antithrombotic agents are obtained starting from an optionally purified K5 polysaccharide by a process comprising the steps of N-deacetylation/N-sulfation, C5 epimerization, O-oversulfation, selective O-desulfation, 6-O-sulfation, N-sulfation, and optional depolymerization, in... Agent:

20110281821 - Modulators of mitotic kinases: The invention relates to compounds of Formula (I), a polymorph, an enantiomer, a stereoisomer, a solvate, an N-oxide derivative, or a pharmaceutically acceptable salt thereof: Formula (I), which have inhibitory effect on one or more protein kinases that are involved in cell mitosis.... Agent: Biogen Idec Ma Inc.

20110281822 - Aromatic compounds having sphingosine-1-phosphonate (s1p) receptor activity: Novel aromatic compounds which are useful as sphingosine-1-phosphate modulators and useful for treating a wide variety of disorders associated with modulation of sphingosine-1-phosphate receptors.... Agent: Allergan, Inc.

20110281823 - Pharmaceutical preparation containing an angiotensin ii receptor antagonist, a calcium channel blocker and polyvinyl alcohol: A pharmaceutical preparation including a pharmacologically effective amount of a combination of active ingredients containing an angiotensin II receptor antagonist, a calcium channel blocker and polyvinyl alcohol, wherein the polyvinyl alcohol is in an amount of 5 to 85% by weight of the total weight of the pharmaceutical preparation. A... Agent: Daiichi Sankyo Company, Limited

20110281824 - Benzofuran derived hiv protease inhibitors: Resistance-repellent and multidrug resistant retroviral protease inhibitors are provided. Pharmaceutical composition comprising such compounds, and methods of using such compounds to treat HIV infections in mammals, are also provided.... Agent: Sequoia Pharmaceuticals, Inc.

20110281825 - Inositol pyrophosphates, and methods of use thereof: The present invention comprises compounds, compositions thereof, and methods capable of delivering modified inositol hexaphosphate (IHP) comprising an internal pyrophosphate ring to the cytoplasm of mammalian cells. In certain embodiments, the present invention relates to compounds, compositions thereof, and methods that enhance the ability of mammalian red blood cells to... Agent: Normoxys

20110281826 - Stilbene derivatives for adp-ribosyl cyclase inhibitors: The present disclosure relates to bisphenyl compounds that are useful for inhibiting the ADP-ribosyl cyclase (ADPR-cyclase). More particularly, the disclosed compounds can be used for treatment and prevention of hypertension, hypertensive cardiac hypertrophy, diabetes, and diabetic nephropathy, in which pathogenesis ADPR-cyclase is involved. The compounds and compositions of the invention... Agent:

20110281827 - Stilbene derivatives for adp-ribosyl cyclase inhibitors: The present disclosure relates generally to compositions for cosmetic or pharmaceutical application. The compositions include a carrier and rheology modulators.... Agent: Foamix Ltd.

20110281828 - Substituted oxazolidinone derivatives: This invention relates to novel compounds that are substituted oxazolidinones derivatives and pharmaceutically acceptable salts thereof. More specifically, this invention relates to novel oxazolidinones compounds that are derivatives of rivaroxaban. The invention also provides pyrogen-free compositions comprising one or more compounds of the invention and a carrier, and the use... Agent: Concert Pharmaceuticals Inc.

20110281829 - Novel composition: This disclosure relates to a pharmaceutical composition that includes a first agent selected from the group consisting of an oxidative phosphorylation inhibitor, an ionophore, and an adenosine 5′-monophosphate-activated protein kinase (AMPK) activator; a second agent that possesses anti-inflammatory activity; and a third agent that is a serotonin metabolite.... Agent: Ipintl, LLC

20110281830 - Novel dermaceutical cream made using sodium fusidate and steroids: The invention discloses a dermaceutical cream containing steroids and an antibacterial agent in the form of Fusidic acid, which Fusidic acid is formed in situ from Sodium Fusidate as the starting raw material, wherein Sodium Fusidate is converted into Fusidic acid under oxygen-free environment. The cream of the present invention... Agent: Apex Laboratories Private Limited

20110281831 - Novel dermaceutical cream made using sodium fusidate, antifungals and steroids: The invention discloses a dermaceutical cream containing antifungal agents, steroids and an antibacterial agent in the form of Fusidic acid, which Fusidic acid is formed in situ from Sodium Fusidate as the starting raw material, wherein Sodium Fusidate is converted into Fusidic acid under oxygen-free environment. The cream of the... Agent: Apex Laboratories Private Limited

20110281833 - Composition for the treatment of ear infections and method: A composition for treating ear infections in animals includes an antifungal agent, an antibiotic agent, a steroidal anti-inflammatory agent, and an acid dissolved to form a liquid. The acid aids in keeping the steroidal anti-inflammatory agent in solution, and enhances the bactericidal effect of the composition. The method of preparing... Agent:

20110281832 - Organic compounds: Optionally substituted (5- or 7-amino)-3,4-dihydro-(optionally 4-oxo, 4-thioxo or 4-imino)-1H-pyrrolo[3,4-d]pyrimidin-2(6H)-ones, Compounds of Formula I, processes for their production, their use as pharmaceuticals and pharmaceutical compositions comprising them.... Agent:

20110281834 - Pharmaceutical formulations for iontophoretic delivery of a corticosteroid: The present invention provides pharmaceutical formulations suitable for iontophoresis that provide enhanced iontophoretic delivery of a corticosteroid to the skin.... Agent:

20110281835 - Novel 3-phenyl-azetidine derivatives useful as modulators of cortical catecholaminergic neurotransmission: The present invention relates to novel 3-phenyl-azetidine derivatives, useful for modulating extracellular levels of catecholamines, dopamine and norepinephrine, in cerebral cortical areas of the mammalian brain, and more specifically for the treatment of central nervous system disorders. In other aspects the invention relates to pharmaceutical compositions comprising the 3-phenyl-azetidine derivatives... Agent: Nsab, Filial Af Neurosearch Sweden Ab, Sverige

20110281839 - Combination therapy for the treatment of bacterial infections: The present invention is directed to co-therapy and methods for the treatment of bacterial infections due to A. baumannii, such as pneumonia, blood stream infections, wound infections, urinary tract infection and intra-abdominal infections.... Agent:

20110281840 - N-substituted saturated heterocyclic sulfone compounds with cb2 receptor agonistic activity: This invention relates to compounds of formula (I) or a pharmaceutically acceptable salt thereof, wherein X, R1, R2, R3, R4, R5, R6, R7, k, m, n, p, q, r and s are each as described herein, and compositions containing such compounds, and the use of such compounds in the treatment... Agent:

20110281837 - 3-substituted-6-aryl pyridines: wherein R1, R2, R3, R8, R9, A and Ar are defined herein. Such compounds are ligands of C5a receptors. Preferred compounds of Formula I bind to C5a receptors with high affinity and exhibit neutral antagonist or inverse agonist activity at C5a receptors. The present invention also relates to pharmaceutical compositions... Agent:

20110281838 - 5-alkynyl-pyrimidines: The present invention encompasses compounds of general Formula (1) wherein R1 to R4 are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, and the use thereof for preparing a medicament having the above-mentioned properties.... Agent: Boehringer Ingelheim International Gmbh

20110281836 - Silent desensitizers of neuronal nachr and methods of use thereof: One aspect of the present invention relates to heterocyclic compounds that are ligands for nicotinic acetylcholine receptors. A second aspect of the invention relates to the use of a compound of the invention for modulation of a mammalian nicotinic acetylcholine receptor.... Agent: Psychogenics, Inc.

20110281841 - Kinase inhibitors: The present invention provides a new group of protein kinase inhibitors, pyrropyrimidine and pyrazolopyrimidine derivatives, and pharmaceutically acceptable salts and prodrugs thereof that are useful for treating cell proliferative disease and disorder such as cancer, autoimmune diseases, infection, cardiovascular disease and neurodegenerative disease and disorder. The present invention provides methods... Agent: Genosco

20110281842 - Pyrrolopyridine and pyrrolopyrimidine inhibitors of kinases: e

20110281843 - Substituted indazole derivatives active as kinase inhibitors: Substituted indazole derivatives of formula (I) and pharmaceutically acceptable salts thereof, as defined in the specification, process for their preparation and pharmaceutical compositions comprising them are disclosed; the compounds of the invention may be useful in therapy in the treatment of diseases associated with a deregulated protein kinase activity, like... Agent: Nerviano Medical Sciences S.r.l.

20110281844 - Non-imidazole alkylamines as histamine h3-receptor ligands and their therapeutic applications: W is a residue which imparts antagonistic and/or agonistic activity at histamine H3-receptors when attached to an imidazole ring in 4(5) position; R1 and R2 may be identical or different and represent each independently a lower alkyl or cycloalkyl, or taken together with the nitrogen atom to which they are... Agent:

20110281845 - Organic compounds: The present disclosure relates to XIAP inhibitor compounds of the formula I.... Agent: Novartis Ag

20110281846 - Bridged bicyclic aryl and bridged bicyclic heteroaryl substituted triazoles useful as axl inhibitors: Bridged bicyclic aryl or heteroaryl substituted triazoles and pharmaceutical compositions containing the compounds are disclosed as being useful in inhibiting the activity of the receptor protein tyrosine kinase Axl. Methods of using the compounds in treating diseases or conditions associated with Axl activity are also disclosed.... Agent: Rigel Pharmaceuticals, Inc.

20110281847 - Selective estrogen receptor modulators for the treatment of vasomotor symptoms: The present invention relates to a selective estrogen receptor modulator of formula I or Ia: (I) (Ia); or a pharmaceutical acid addition salt thereof; useful for treating vasomotor symptoms, in particular hot flashes, night sweats and other symptoms that affect women around menopause.... Agent: Eli Lilly And Company

20110281848 - Imidazole compounds having pharmaceutical activity towards the sigma receptor: e

20110281849 - Aryl indolyl sulfonamide compounds and their use as 5-ht6 ligands: The present invention relates to novel aryl indolyl sulfonamide compounds of the formula (I), their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates described herein and pharmaceutically acceptable compositions containing them.... Agent: Suven Life Sciences Limited

20110281851 - Biphenyl compounds useful as muscarinic receptor antagonists: wherein a, b, c, m, s, t, W, Z, Ar, R1, R2, R3, R6, and R7 are as defined in the specification. The compounds of formula I are muscarinic receptor antagonists. The invention also provides pharmaceutical compositions containing such compounds, processes and intermediates for preparing such compounds and methods of... Agent: Theravance, Inc.

20110281850 - Intracellular kinase inhibitors: Intracellular kinase inhibitors and their therapeutic uses for patients with T cell malignancies, B cell malignancies, autoimmune disorders, and transplanted organs.... Agent: Mannkind Corporation

20110281853 - Compositions and methods for treating or preventing atrial fibrillation: The present invention provides compositions and methods for treating or preventing atrial fibrillation (AF). In particular, the present invention provides administration of muscarinic receptor antagonists (e.g., M2-selective muscarinic receptor blockers), administered alone or in combination with other therapeutic agents (e.g., beta-adrenergic receptor blockers) to treat and/or prevent atrial fibrillation.... Agent:

20110281852 - Pharmaceutical compositions containing berberine for treatment or prevention of weight gain and obesity associated with anti-psychotic drugs: The compositions and methods disclosed herein are of use for the treatment and prevention of weight gain and obesity. In particular, the compositions and methods include treatment of weight gain and obesity with berberine and/or berberine analogs alone or in combination thereof to cause a reduction in an individual's weight... Agent:

20110281854 - Morpholine compounds: Mineralocorticoid receptor antagonists (MRa), pharmaceutical compositions containing such inhibitors and the use of such inhibitors to treat, for example, diabetic nephropathy and hypertension in mammals, including humans.... Agent: Pfizer Inc

20110281855 - Novel and potent tapentadol dosage forms: The present invention provides a dosage form comprising at least one form of tapentadol, with or without a second analgesic, and at least one opioid antagonist, wherein tapentadol is present in an optimal or suboptimal amount and the said antagonist is present in an amount effective to improve the efficacy... Agent: Gruenenthal Gmbh

20110281856 - Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates and methods of making said conjugates: The present invention discloses a method for targeting maytansinoids to a selected cell population, the method comprising contacting a cell population or tissue suspected of containing the selected cell population with a cell-binding agent maytansinoid conjugate, wherein one or more maytansinoids is covalently linked to the cell-binding agent via a... Agent: Immunogen Inc.

20110281858 - Aerosol formulation for the inhalation of beta agonists: The present invention relates to a propellant-free aerosol formulation which [contains] one or more compounds of general formula (1) wherein the groups R1, R2, R3 and X− may have the meanings given in the claims and in the description, for inhalation.... Agent: Boehringer Ingelheim International Gmbh

20110281859 - Novel heterocyclic compounds as metap-2 inhibitors: Compounds of the formula I, in which D, X, Y, Z, R and R1 have the meanings indicated in Claim 1, are inhibitors of methionine aminopeptidase and can be employed for the treatment of tumours.... Agent: Merck Patent Gesellschaft Mit Beschrankter Haftung

20110281857 - Pi3k/mtor kinase inhibitors: 6-morpholin-4-yl-pyrazolo[3,4-d]pyrimidine and 2-morpholin-4-yl-7H-pyrrolo[2,3-d]pyrimidine derivatives have unexpected drug properties as inhibitors of PI3 and/or mTOR kinases and are useful in treating disorders related to abnormal PI3K/mTOR activities such as cancer, immune disorders, cardiovascular disease, viral infection, inflammation, metabolism/endocrine disorders and neurological disorders.... Agent: Xcovery Holding Company, LLC

20110281860 - Use of quinazoline derivatives for the treatment of viral diseases: The present invention relates to the use of quinazoline derivatives, which show EGFR inhibitory activity, for the prevention and/or treatment of virus-induced diseases, preferably virus induced respiratory diseases and exacerbation in chronic airway diseases such as COPD or asthma.... Agent: Boehringer Ingelheim International Gmbh

20110281861 - Thiazopyrimidinones and uses thereof: The present invention provides a compound of formula (I) or a pharmaceutically acceptable derivative, salt or prodrug thereof. The present invention further provides a method of treatment or prophylaxis of a viral infection in a subject comprising administering to said subject an effective amount of a compound of formula (I)... Agent:

20110281862 - Alfa-carboline inhibitors of npm-alk, ret, and bcr-abl: wherein R1, R2 and R3 are as defined in the description, to their pharmaceutical compositions and use thereof for the treatment of cancer expressing oncogenic ALK protein, particularly anaplastic large cell lymphoma (ALCL), diffuse large B cell lymphoma (DLBCL), inflammatory myofibroblastic tumours (IMT) and non-small cell lung cancer (NSCLC).... Agent: Universite' De Geneve

20110281863 - Imidazo[1,2-b]pyridazine and pyrazolo[1,5-a]pyrimidine derivatives and their use as protein kinase inhibitors: e

20110281866 - Heterocyclic kinase inhibitors: The present invention provides heterocyclic compounds for use as kinase inhibitors and in other applications. Also provided are pharmaceutical compositions and methods of treatments of diseases and conditions associated with P13 kinase activity.... Agent: Intellikine, Inc.

20110281865 - Novel 3,5-disubstituted-3h-imidazo[4,5-b]pyridine and 3,5- disubstituted -3h-[1,2,3]triazolo[4,5-b] pyridine compounds as modulators of protein kinases: The present invention provides, inter alia, compounds of formula I as protein kinase modulators, methods of preparing them, pharmaceutical compositions containing them and methods of treatment, prevention and/or amelioration of kinase mediated diseases or disorders with them.... Agent: Incozen Therapeutics Pvt. Ltd.

20110281864 - Pyrido[3,2-d]pyridazine-2(1h)-one compounds as p38 modulators and methods of use thereof: wherein R1, R2, R3, R4, R5, W and X are defined herein. The invention also comprises pharmaceutical compositions including one or more compounds of Formula I, uses of such compounds and compositions for treatment of p38 map kinase mediated diseases including rheumatoid arthritis, psoriasis, chronic obstructive pulmonary disease, pain and... Agent: Amgen Inc.

20110281867 - Compositions and methods of use for tyrosine kinase inhibitors to treat pathogenic infection: Compositions and methods are provided for using tyrosine kinase inhibitors to treat pathogenic infection. In particular, methods for using Abl-family tyrosine kinase inhibitors to treat pathogenic infection are provided. Infections to be treated according to the present invention include, particularly, those caused by microbial pathogens such as bacteria and viruses.... Agent:

20110281868 - Indazole inhibitors of kinase: m

20110281870 - Novel substituted octahydrocyclopenta[c]pyrrol-4-amines as calcium channel blockers:

20110281869 - Tetrahydroisoquinolines as antimalarial agents: The invention relates to novel tetrahydroisoquinoline derivatives and their use as active ingredients in the preparation of pharmaceutical compositions. The invention also concerns related aspects including pharmaceutical compositions containing one or more of those compounds and their use as medicaments for the treatment or prevention of protozoal infections, such as... Agent:

20110281871 - Taar1 ligands: e

20110281872 - Compositions and methods for the prevention and treatment of cancer: The invention relates to compositions and methods for the treatment and prevention of cancer and other cell proliferative disorders.... Agent: Kinex Pharmaceuticals, LLC

20110281873 - Pyrimidine compounds and methods of making and using same: Disclosed herein are pyrimidinyl compounds that are contemplated to be modulators of cystic fibrosis transmembrane regulators (CFTR), and methods of making and using same. Also provided are pharmaceutical compositions and methods of treating disorders associated with cystic fibrosis transmembrane regulators, such as airway inflammation, cystic fibrosis, and the like.... Agent:

20110281874 - 2-aminopyridine analogs as glucokinase activators: Provided are compounds that are useful in the treatment and/or prevention of diseases mediated by deficient levels of glucokinase activity, such as diabetes mellitus. Also provided are methods of treating or preventing diseases and disorders characterized by underactivity of glucokinase or which can be treated by activating glucokinase.... Agent: Array Biopharma Inc.

20110281875 - Inhibitors of iap: Novel compounds that inhibit the binding of the Smac protein to Inhibitor of Apoptosis Proteins (IAPs) of the formula (I).... Agent:

20110281876 - Therapeutic agents useful for treating pain: where Ar1, Ar2, X, R3, and m are as disclosed herein or a pharmaceutically acceptable salt thereof (a “Phenylene Compound”); compositions comprising an effective amount of a Phenylene Compound; and methods for treating or preventing pain and other conditions in an animal comprising administering to an animal in need thereof... Agent: Purdue Pharma L.p.

20110281877 - Dithiinopyridazinone derivatives: The present invention relates to new dithiinopyridazinedione derivatives, to processes for preparing them, to their use for controlling unwanted microorganisms, more particularly phytopathogenic fungi, in crop protection, in the household and hygiene sector and in the protection of materials, and also to crop protection compositions comprising these dithiinopyridazinedione derivatives.... Agent: Bayer Cropscience Ag

20110281878 - Inhibitors of p38: The present invention relates to inhibitors of p38, a mammalian protein kinase involved cell proliferation, cell death and response to extracellular stimuli. The invention also relates to methods for producing these inhibitors. The invention also provides pharmaceutical compositions comprising the inhibitors of the invention and methods of utilizing those compositions... Agent: Vertex Pharmaceuticals Incorporated

20110281882 - Compositions and methods for treating, controlling, reducing, or ameliorating inflammatory pain: A composition for treating, controlling, reducing, or ameliorating inflammatory pain comprises a dissociated glucocorticoid receptor agonist (“DIGRA”), a prodrug thereof, a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable ester thereof. The composition can comprise an additional anti-inflammatory agent and can be formulated for topical application, injection, or implantation. It... Agent:

20110281880 - Methods of administering tetrahydrobiopterin, associated compositions, and methods of measuring: The present invention is directed to treatment methods of administering tetrahydrobiopterin, including in oral dosage forms, in intravenous formulations, and with food. Also disclosed herein are biopterin assays for measuring the amount of biopterin and metabolites of biopterin in a sample.... Agent: Biomarin Pharmaceutical Inc.

20110281881 - Novel substituted bicyclic heterocyclic compounds as gamma secretase modulators: wherein Het1, Het2, A1, A2, A3 and A4 have the meaning defined in the claims. The compounds according to the present invention are useful as gamma secretase modulators. The invention further relates to processes for preparing such novel compounds, pharmaceutical compositions comprising said compounds as an active ingredient as well... Agent:

20110281879 - Sulfonyl containing compounds as cysteine protease inhibitors: The present invention is directed to compounds that are inhibitors of cysteine proteases, in particular, cathepsins B, K, L, F, and S and are therefore useful in treating diseases mediated by these proteases. The present invention is directed to pharmaceutical compositions comprising these compounds and processes for preparing them.... Agent: Virobay, Inc.

20110281883 - 4-phenyl-pyrane-3,5-diones, 4-phenyl-thiopyrane-3,5-diones and cyclohexanetriones and their use as insecticides, acaricides and/or fungicides: The present invention relates to the use of compounds of Formula (I) wherein R1, R2, R3, R4, R5, R6, R7, r, Y and G have the meanings given above as insecticides and/or acaricides and/or fungicides.... Agent: Bayer Cropscience Ag

20110281884 - Fused derivatives as pi3kdelta inhibitors: The present invention provides fused derivatives that modulate the activity of phosphoinositide 3-kinases (PI3Ks) and are useful in the treatment of diseases related to the activity of PI3Ks including, for example, inflammatory disorders, immune-based disorders, cancer, and other diseases.... Agent:

20110281885 - Therapeutic agents useful for treating pain: wherein A, Ar, R3, R6, and m are disclosed herein, or a pharmaceutically acceptable salt thereof (a “Cyanoiminopiperazine Compound”), compositions comprising an effective amount of a Cyanoiminopiperazine Compound, and methods for treating or preventing pain, urinary incontinence, an ulcer, inflammatory-bowel disease, irritable-bowel syndrome, an addictive disorder, Parkinson's disease, parkinsonism, anxiety,... Agent: Purdue Pharma L.p.

20110281886 - Pharmaceutical compositions with attenuated release of phenolic opioids: Pharmaceutical compositions and their methods of use are provided, where the pharmaceutical compositions comprise a phenolic opioid prodrug that provides enzymatically-controlled release of a phenolic opioid, and an enzyme inhibitor that interacts with the enzyme(s) that mediates the enzymatically-controlled release of the phenolic opioid from the prodrug so as to... Agent:

20110281887 - Compounds and method for treatment of cancer: a

20110281888 - Fused bicyclic kinase inhibitors:

20110281889 - 5-ht1a receptor subtype agonist:

20110281890 - Piperidine and piperazine derivatives:

20110281891 - N-hydroxyamide derivatives and use thereof: The present invention is related to N-hydroxyamide derivatives of Formula (I) and use thereof in particular for the treatment and/or prophylaxis of autoimmune disorders, inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, cancer, respiratory diseases and fibrosis, including multiple sclerosis, arthritis, emphysema, chronic obstructive pulmonary disease, liver and pulmonary fibrosis.... Agent: Merck Serono Sa

20110281892 - Method and formulation for cold treatment in adults and children with increased safety: Methods and dosage formulations for the safe treatment of cold, cough, flu, and sinus symptoms in children and adolescents by age and nature of symptoms, and adults and the elderly by age, nature of symptoms, and concomitant patient medical conditions. The method of the present invention comprises the formulation of... Agent:

20110281893 - Compound, synthesis, composition and uses thereof: The instant application provides the disclosure for a compound of formula I, synthesis of compound of formula I and its pharmaceutical acceptable salts, as well as its polymorphs, solvates, and hydrates thereof. The pharmaceutically acceptable salt may be formulated for oral administration, systemic administration, transdermal administration and injection. The compound... Agent: Krisani Biosciences (p) Ltd

20110281894 - Hemifumarate salt: The present invention relates to a hemifumarate salt of the compound (1S)-1-(2-(difluoromethyl)pyridin-4-yl)-4-fluoro-1-(3-(pyrimidin-5-yl)phenyl)-1H-isoindol-3-amine, Form A thereof and its pharmaceutical compositions. In addition, the present invention relates to therapeutic methods for the treatment and/or prevention of Aβ-related pathologies such as Downs syndrome, β-amyloid angiopathy such as but not limited to cerebral amyloid... Agent: Astrazeneca Ab

20110281895 - Synthesis and novel salt forms of (r)-5-((e)-2-pyrrolidin-3ylvinyl)pyrimidine: The present invention relates to the stereospecific synthesis of (R)-5-((E)-2-pyrrolidin-3-yl)pyrimidine, novel salt forms, and novel polymorphic forms of these salts.... Agent: Targacept, Inc.

20110281896 - Optically pure quinazoline compounds: Optical pure quinazoline compounds, especially compounds of the general formula (I), wherein R1 and Y are defined as the specification, preparation methods of them, pharmaceutical compositions containing them and their uses are provided. Compounds of the general formula (VII), which are intermediates in the synthesis of the compounds of the... Agent: Jiangsu Hansoh Pharmaceutical Co. Ltd

20110281897 - Heterocyclic compounds and their uses: Substituted bicyclic heteroaryls and compositions containing them, for the treatment of general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, including but not restricted to autoimmune diseases such as systemic lupus erythematosis (SLE),... Agent: Amgen Inc.

20110281898 - Phenoxiacetic acid derivatives: The invention relates to substituted phenoxyacetic acids as useful pharmaceutical compounds for treating respiratory disorders, pharmaceutical compositions containing them, and processes for their preparation.... Agent: Astrazeneca Ab

20110281899 - Methods of preventing and treating low bone mass diseases: The present invention provides methods and therapeutic agents for lowering or increasing serum serotonin levels in a patient in order to increase or decrease bone mass, respectively. In preferred embodiments, the patient is known to have, or to be at risk for, a low bone mass disease such as osteoporosis... Agent: The Trustees Of Columbia University In The City Of New York

20110281900 - Crystalline pharmaceutical: New crystalline forms of lopinavir are disclosed.... Agent: Abbott Laboratories

20110281902 - Combinations comprising a protein kinase inhibitor being a pyrimidylaminobenzamide compound and a hsp90 inhibitor such as 17-aag: w

20110281901 - Pharmaceutical compositions and methods of making same: Pharmaceutical compositions that include an amount of an acid addition salt of pazopanib equivalent to about 5 mg/mL pazopanib, about 2.0 to about 13.0% w/w of a modified cyclodextrin suitable for use in an ophthalmic formulation, and pH adjusting agent as well as methods of making the same are described.... Agent: Glaxo Wellcome Manufacturing Pte Ltd.

20110281903 - Bicyclic heterocyclic spiro compounds: There are disclosed bicyclic heterocyclic spiro compounds; pharmaceutical compositions comprising these compounds; and methods for the treatment in a mammal of diseases and conditions which are susceptible to modulation of the M1 muscarinic receptor, including Alzheimer's disease, insulin resistance syndrome and type 2 diabetes. Other embodiments are also disclosed.... Agent:

20110281905 - Enhancement of impaired motor and mental functions, using dextromethorphan and oxidase enzyme inhibitor: During clinical trials on patients suffering from neurological disorders, it has been observed that some patients obtain dramatic improvements in motor control and/or higher mental functioning, when they receive a combination of dextromethorphan and quinidine, at suitable dosages. Improved motor control has been exemplified to date by improved ability to... Agent:

20110281904 - Use of dextromethorphan in treating addictive behavior or bipolar disorder: The present invention provides a method for treating addictive behavior, comprising administering Dextromethorphan (DM) to a subject suffering addictive behavior. The present invention also provides a method for treating bipolar disorder, comprising administering Dextromethorphan (DM) to a subject suffering bipolar disorder.... Agent: National Cheng Kung University

20110281906 - Sustained release formulation for tacrolimus: A sustained release pharmaceutical composition for tacrolimus, comprising a solid dispersion containing tacrolimus or a pharmaceutically acceptable salt thereof, and a carrier for a sustained release pharmaceutical composition, wherein a dissolution rate of tacrolimus after 4 hours from the beginning of a dissolution test is less than 35%, is disclosed.... Agent: Astellas Pharma Inc.

20110281907 - Compositions and methods for inhibition of hepatocyte growth factor receptor c-met signaling: Derivatives and analogs of inhibitors of receptor tyrosine kinase c-Met obtained by virtual screening, pharmaceutical compositions containing derivatives and analogs of c-Met inhibitors are provided. Methods of making derivatives and analogs of c-Met inhibitors and methods of use thereof are provided. Formula (I)... Agent: The Government Of The United States Of America, As Represented By The Secretary, Dept.of Health And.

20110281908 - Aminoquinoline derived heat shock protein 90 inhibitors, methods of preparing same, and methods for their use: Novel classes of molecular chaperone Heat shock protein 90 (Hsp90) inhibitors and methods for making these classes are provided herein. These compounds are useful in treating and preventing cancer and other Hsp90-related diseases, such as inflammation and neurodegenerative disorders. Also provided herein are methods of treating and preventing cancer and... Agent: Emory University

20110281909 - Substituted quinoline derivatives as h1 receptor antagonists: v

20110281910 - Hepatitis c virus inhibitors: This disclosure concerns novel compounds of Formula (I) or as defined in the specification and compositions comprising such novel compounds. These compounds are useful antiviral agents, especially in inhibiting the function of the NS5A protein encoded by Hepatitis C virus (HCV). Thus, the disclosure also concerns a method of treating... Agent: Bristol-myers Squibb Company

20110281911 - Novel forms of eperisone: The invention relates to substantially enantiopure crystalline salt forms of (2RS)-I-(4-Ethylphenyl)-2-methyl-3-piperidin-1-ylpropan-1-one. The preparation and characterization of the substantially enantiopure crystalline salt forms according to various embodiments of the invention is described. The invention also relates to pharmaceutical compositions containing the substantially enantiopure crystalline salt forms, which are useful to treat... Agent: Bionevia Pharmaceuticals, Inc.

20110281912 - Oral dispersible tablet: The present invention relates to an oral dispersible tablet comprising at least one filler selected from sugars and sugar alcohols, and microcrystalline cellulose.... Agent: Ratiopharm Gmbh

20110281913 - Melanocortin receptor antagonist compounds, process for preparing them and use thereof in human medicine and cosmetics: e

20110281914 - Fentanyl composition for nasal administration: The treatment of acute pain with a sufficient dosage by intranasal administration of fentanyl results in a time to onset of action comparable to intravenous administration and a significantly faster onset of action than nasal titration of fentanyl. The nasal administration of a sufficient amount of fentanyl to obtain pain... Agent:

20110281915 - Thienodithiine derivatives: The present invention relates to new thienodithiine derivatives, to processes for preparing them, to their use for controlling unwanted microorganisms, more particularly phytopathogenic fungi, in crop protection, in the household and hygiene sector and in the protection of materials, and also to crop protection compositions comprising these thienodithiine derivatives.... Agent: Bayer Cropscience Ag

20110281916 - Migrastatin analogs and uses thereof: e

20110281917 - Substituted benzimidazoles for the treatment of astrocytomas: The present invention relates to the use of BENZIMIDAZOLE DERIVATIVES for the preparation of a drug for the treatment of astrocytomas.... Agent:

20110281919 - Agent for treating or preventing digestive ulcer: The pharmaceutical composition of the present invention comprising a non-purine xanthine oxidase inhibitor as the active ingredient is useful as an agent for treating or preventing ulcer that forms in digestive tracts by the attack of gastric acid, pepsin, stress, Helicobacter pylori bacteria, NSAID, etc. In particular, it is useful... Agent: Astellas Pharma Inc.

20110281918 - Antifungal composition: A pharmaceutical composition for oral administration which is self-emulsifying on contact with an aqueous phase, in particular gastrointestinal fluids, and which comprises: (a) an antifungally active compound of formula (I) wherein R1, R2 and R3 are independently of one another hydrogen, F or Cl; or a pharmaceutically acceptable acid addition... Agent:

20110281920 - Injectable parasiticidal formulations of levamisole and macrocyclic lactones: The present invention provides levamisole/macrocyclic lactone-containing injectable formulations that are effective against animal pests, including endoparasites. The formulations may be used for combating parasites in or on birds and mammals. The invention also provides for an improved method for eradicating, controlling and preventing parasite infestation of birds and mammals.... Agent:

20110281921 - Novel anti-biofilm agents: Novel agents exhibiting anti-biofilm formation activity while being non-cytotoxic are provided, as well as methods of using the same, either per se or conjugated to a polymer, for preventing and/or reducing the formation of microbial biofilms and/or for disrupting microbial biofilms. The novel agents described herein include thiazolidine-2,4-diones (TZDs), pyrrolidine-2,5-diones... Agent: Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.

20110281922 - Amide thiazole derivative, preparation method and uses thereof: v

20110281923 - Antagonists of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states: This invention provides a class of therapeutic compounds and methods for the treatment of mammals with physiological disorders, such as for example a frequently occurring type of essential hypertension, which are critically associated with the decreased binding of magnesium to the plasma membranes of their cells. These methods consist of... Agent: Magnesium Diagnostics Inc.

20110281925 - Dual-acting antihypertensive agents: wherein: Ar, r, Y, Z, Q, W, X, and R5-7 are as defined in the specification, and pharmaceutically acceptable salts thereof. These compounds have AT1 receptor antagonist activity and neprilysin inhibition activity. The invention is also directed to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process... Agent: Theravance, Inc.

20110281924 - Novel microbiocides: Compounds of formula (I), in which the substituents are as defined in claim 1, are suitable for use as microbiocides.... Agent: Syngenta Crop Protection LLC

20110281926 - Method for dressing seeds: The present invention relates to a method comprising treating plant propagation material with at least sticker selected from specific acrylate co-copolymers, to seed dressing formulations comprising such stickers and to plant propagation material coated with such stickers.... Agent: Basf Se

20110281927 - Deuterium-enriched doripenem: The present application describes deuterium-enriched doripenem, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Protia, LLC

20110281928 - Process for the preparation of zofenopril and its pharmaceutically acceptable salts thereof: The present invention relates to a process for the preparation of zofenopril and its pharmaceutically acceptable salts and a pharmaceutical composition thereof. The present invention also provides structurally novel compounds, which are useful intermediates in the synthesis of zofenopril.... Agent: Glenmark Generics Ltd

20110281929 - Pharmaceutical compositions comprising 2-oxo-1-pyrrolidine derivatives: The present invention relates to an immediate release formulation of pharmaceutical compounds.... Agent: Ucb Pharma, S.a.

20110281930 - Use of 2-aryl-5-heterocyclyl-cyclohexane-1,3-dione compounds as insecticides, acaricides, and/ or fungicides: The present invention relates to the use of compounds of Formula (I) wherein R1, R2, R3, R4, R5, R6, R7, R8, X and G have the meanings given above as insecticides and/or acaricides and/or fungicides.... Agent: Bayer Cropscience Ag

20110281940 - Method of preparation an inclusion-complex comprising hydrophobic physiological activation material including with cyclodextrin and its use: Disclosed herein are a method for preparation of an inclusion-complex including a physiologically active hydrophobic substance in cjclodextrin and a derivative thereof, and use of the inclusion-complex prepared by the same. More particularly, the present invention provides a method for preparing an inclusion-complex, which includes agitating cjclodextrin and a derivative... Agent: Macrocare Tech., Ltd.

20110281941 - Combination of lycopene, polyphenol, and vitamins for the care of keratin materials: The present invention relates to the cosmetic use, by the oral route, of a combination of lycopene, of vitamin C, of vitamin E and of at least one polyphenol compound derived from pine bark as active ingredient intended for maintaining and/or restoring the biomechanical properties of keratinous materials, and notably... Agent: Laboratoires Inneov Snc

20110281942 - Tautomycetin and tautomycetin analog biosynthesis: The present invention relates to tautomycetin (TTN) and analogs thereof. Also provided are methods of using TTN and analogs thereof in the treatment of various diseases relating to SHP2 function.... Agent: Wisconsin Alumni Research Foundation

20110281943 - Topical composition comprising ascorbic acid derivatives: The present invention discloses topical composition comprising ascorbic acid derivatives. The inventive topical composition that the ascorbic acid derivatives is homogeneously incorporated therein can make the ascorbic acid derivatives more widely used as active ingredient in skin topical formulation.... Agent: Corum Inc.

20110281944 - Method of a rhein compound for inhibiting pancreatic islet beta-cell dysfunction and preventing or treating a pancreatic islet beta-cell dysfunction related disorder: This invention provides a method for inhibiting pancreatic islet β-cell dysfunction, comprising administering to a subject in need thereof an inhibitory effective amount of a rhein compound having the general formula (I) or a pharmaceutically acceptable salt thereof,... Agent: Research Institute Of Nephrology Of Nanjing Pla, China

20110281945 - Gastric acid secretion inhibitor, and potassium channel inhibitor: To provide a drug, quasi-drug, food or drink that can act as a gastric acid secretion suppressant or a potassium channel inhibitor by including a composition that can be safely used and can be inexpensively produced. Each of these products contains one or more cooling sensation compositions that are compounds... Agent:

20110281946 - Polymeric -based composition: The present invention concerns polymeric-based compositions that are useful in the delivery and sustained release of hydrophobic therapeutic and/or cosmetic agents substantially at the point of injury, infection or, in the case of purely cosmetic applications, the point of treatment. Also provided are methods of preparing such compositions and methods... Agent: Northern Hydrogels Ltd

20110281947 - Methods of administering diclofenac compositions for treating photodamaged skin: A method of treating at least one dermatological disorder selected from the group consisting of photodamage-induced wrinkles, rosacea, and acne, includes: (a) providing a composition containing 1-3 wt. % diclofenac or a salt thereof, 0.5-1.5 wt. % benzyl alcohol; 10-30 wt. % PEG monomethyl ether, 0.1-3.0 wt. % sodium hyaluronate;... Agent:

20110281948 - Cosmetic and pharmaceutical formulations of calixarene molecules: The invention relates to the use of calixarenes for preventing or limiting the transfer of an actinide in the body from a site of skin contamination.... Agent: Institut De Radioprotection Et De Surete Nucleaire

20110281949 - Methods and compositions for treating neuronal damage and modulating transient receptor potential channels: Use of alkyl phenol and monocyclic monoterpene-derived compounds in the treatment of neuronal damage and in inhibiting activity of TRPC and non-thermo-TRPM channels, and use of bicyclic monoterpene-derived compounds in activating TRPC and non-thermo-TRPM channels.... Agent:

20110281950 - Compositions and methods for reducing proliferation and viability of lymphoblastoid cells: Pharmaceutical compositions including an HDAC inhibitor and a pharmaceutically acceptable carrier wherein the HDAC inhibitor is present in an amount sufficient to achieve a plasma concentration from about 100 nM to about 2 uM and methods of treatment using the same. Pharmaceutical compositions including an HDAC inhibitor and a pharmaceutically... Agent:

20110281951 - Compositions and methods for treating amyloidosis: or a pharmaceutically acceptable salt or ester, such that modulation of amyloid aggregation occurs. R1 and R2 are each independently a hydrogen atom or a substituted or unsubstituted aliphatic or aryl group. Z and Q are each independently a carbonyl (C═O), thiocarbonyl (C═S), sulfonyl (SO2), or sulfoxide (S═O) group. “k”... Agent:

20110281952 - Deuterium-enriched tolterodine: The present application describes deuterium-enriched tolterodine, pharmaceutically acceptable salt forms thereof, and methods of treating using the same.... Agent: Protia, LLC

20110281954 - Methods of synthesizing cinacalcet and salts thereof: Methods of preparing cinacalcet, cinacalcet derivatives, and salts thereof is disclosed herein. Also disclosed herein are polymorphs of cinacalcet, compositions of cinacalcet, and methods of treating a subject by administering cinacalcet, wherein cinacalcet is prepared by the disclosed methods.... Agent: Amgen Inc.

20110281953 - Process for preparing and drying solid rasagiline base: Disclosed is crystalline R(+)-N-propargyl-1-aminoindan containing water at an amount of less than 0.5% by weight and a pharmaceutical composition comprising the same, and the process for the manufacture and the validation thereof. Also disclosed is a process for the preparation of solid rasagiline base.... Agent: Teva Pharmaceutical Industries, Ltd.

20110281955 - Methods of treating obesity using antioxidant inflammation modulators: The present invention relates to methods of treating and/or preventing obesity comprising the administration of antioxidant inflammation modulators described herein, including for example bardoxolone methyl.... Agent: Reata Pharmaceuticals

20110281956 - Use of thymus capitatus extract, satureja hortensis extract, or carvacrol for treating metabolic diseases: Disclosed is an use of Spanish oregano (Thymus capitatus) extract, summer savory (Satureja hortensis) extract or carvacrol for treating metabolic diseases. More specifically, the present disclosure relates to a composition containing Spanish oregano extract or summer savory extract, carvacrol, which is an aromatic oil component frequently found in mint, oregano,... Agent: Industry-academic Cooperation Foundation, Yonsei University

20110281957 - Enhanced bioactive formulations of resveratrol: Methods and formulations for increasing the water solubility and/or bioavailability of resveratrol are disclosed. The formulations may be employed to treat a disease states, including cancer.... Agent: Lipoprotein Technologies, Inc.

  
11/10/2011 > 172 patent applications in 132 patent subcategories. recently filed with US Patent Office

20110275555 - Compositions containing delta-9-thc-amino acid esters and process of preparation: Compositions of the formulae (I), (II) and (III); where R1, R2 and R3 are residues of amino acids such as, but not limited to, valine, sarcosine, leucine, glutamine, tryptophan, tyrosine, alanine and 4(4-aminophenyl)butyric acid or combination thereof, and salts thereof. Methods of preparation of these compositions and methods of treating... Agent:

20110275554 - Compounds: The present invention relates to prodrugs of vascular disrupting agents comprising a vascular disrupting agent (VDA) associated with a MMP proteolytic cleavage site and to the use of such prodrugs in the targeted treatment of cancer.... Agent: The University Of Bradford

20110275556 - Treatment of atherosclerosis: The present invention relates to the use of compounds for producing a medicament for preventing and/or treating atherosclerosis, atherosclerosis risk diseases and atherosclerosis sequelae.... Agent: Affiris Ag

20110275557 - Truncated cry35 proteins: This invention provides truncated Cry 35 proteins that surprisingly and unexpectedly have increased pesticidal activity as compared to full-length Cry 35 proteins. The subject invention also includes polynucleotides that encode these truncated proteins, transgenic plants comprising a truncated gene of the subject invention, and transgenic plants that produce these truncated... Agent: Dow Agrosciences LLC

20110275558 - Lanthionine synthetase component c-like proteins as molecular targets for preventing and treating diseases and disorders: The present invention relates to the field of medical treatments for diseases and disorders. More specifically, the present invention relates to the use of the lanthionine synthetase component C-like (LANCL) proteins as therapeutic targets for novel classes of anti-inflammatory, immune regulatory and antidiabetic drugs. This includes but it is not... Agent: Virginia Tech Intellectual Properties, Inc.

20110275559 - Long-acting y2 and/or y4 receptor agonists: The present invention relates to a PYY or PP peptide derivative or analogue thereof derivatised with one or more serum albumin binding side chains comprising a dis-tal tetrazole or carboxylic acid group. Moreover, the invention relates to compositions hereof and methods of treatment of conditions responsive to Y receptor modulation.... Agent: Novo Nordisk A/s

20110275560 - Synthetic conjugates and uses thereof: The present disclosure provides a cross-linked material comprising conjugates which include two or more separate affinity ligands bound to a non-polymeric framework, wherein the molecular weight of the non-polymeric framework is less than 10,000 Da; and multivalent cross-linking agents that non-covalently bind the affinity ligands of the conjugates and thereby... Agent:

20110275561 - Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral or non-oral antidiabetic drug: The present invention relates to the finding that certain DPP-4 inhibitors are particularly suitable for treating and/or preventing metabolic diseases, particularly diabetes, in patients with insufficient glycemic control despite a therapy with an oral and/or a non-oral antidiabetic drug.... Agent: Boehringer Ingelheim International Gmbh

20110275562 - Inhibition of gliadin peptides: Novel compounds and methods for the inhibition of biological barrier permeability and for the inhibition of peptide translocation across biological barriers are identified. Assays for determining modulators of biological barrier permeability and for peptide translocation across biological barriers are provided. Methods for treating diseases relating to aberrant biological barrier permeability... Agent:

20110275563 - Use of ctgf as a cardioprotectant: The present invention is based upon the surprising discovery that Connective Tissue Growth Factor (CTGF) may act directly on the heart as a cardioprotective factor and provides CTGF for use in the treatment of a subject who has incurred or is incurring damage to the heart, wherein said CTGF is... Agent:

20110275564 - Erythropoietin: This disclosure relates to erythropoietin (EPO) fusion polypeptides; nucleic acid molecules encoding said polypeptides and methods of treatment that use said polypeptides.... Agent: Asterion Limited

20110275565 - Biocompatible polysaccharide-based hydrogels: Modified polysaccharides and crosslinked modified polysaccharide compositions are described. Methods of using the crosslinked modified polysaccharide compositions to deliver proteins, oligonucleotides, or pharmaceutical agents are also disclosed.... Agent: The Johns Hopkins University

20110275566 - Methods of treating necrotizing enterocolitis using heparin binding epidermal growth factor (hb-egf): Methods of treating, abating and reducing the risk for necrotizing enterocolitis (NEC) in an infant are disclosed. Preferred methods include administering an EGF receptor agonist, such as HB-EGF or EGF, within 24 hours following birth or following the onset of at least one symptom of NEC, in an amount effective... Agent: Nationwide Children's Hospital Inc.

20110275567 - Aqueous composition containing follicle-stimulating hormone: A stable aqueous composition containing follicle-stimulating hormone, which comprises follicle-stimulating hormone and histidine as a stabilizing agent.... Agent: Aska Pharmaceutical Co., Ltd.

20110275568 - Methods of enhancing functioning of the large intestine: The invention relates to glucagon-related peptides and their use for the prevention or treatment of disorders involving the large intestine. In particular, it has now been demonstrated that GLP-2 and peptidic agonists of GLP-2 can cause proliferation of the tissue of large intestine. Thus, the invention provides methods of proliferating... Agent: 1149336 Ontario Inc.

20110275569 - Proteases targeting agents: A protein inhibitor from Sulfolobulus Solfataricus and peptides thereof, which both have the ability to inhibit AARE and elastase. Similarly to the eukaryotic counterparts, the recombinant protein is able to inhibit in vitro the bovine alfa-chymotrypsin with a high specificity, and the porcine elastase but not all commercial available trypsins,... Agent: Consiglio Nazionale Delle Ricerche

20110275570 - Process for obtaining a concentrate of von willebrand factor of a complex of factor viii/von willebrand factor and use of the same: A method of treating a patient suffering from Haemophilia A and/or Von Willebrand's disease involves administering the patient a concentrate of Von Willebrand Factor (VWF) or a complex of Factor VIII/VWF prepared by creating a solution of VWF or a complex of Factor VIII/VWF containing VWF at a concentration of... Agent: Grifols, S.a.

20110275571 - Kv1.3 channel blocking substances for the treatment of diseases associated with intimal hyperplasia: The present invention provides a therapeutic tool against intimal hyperplasia consisting of the use of Kv1.3 channel blocking substances, able to selectively stop cell migration and multiplication of VSMCs.... Agent: Hospital Clinic I Provincial De Barcelona

20110275572 - Nanocomposite hyaluronic acid-clay based hydrogels: Hydrogels formed from hyaluronic acid, a nanoclay and gelatin-type A. The hyaluronic acid is preferably dissolved in a cell culture medium containing amino acids, salts, glucose, vitamins and an antibiotic to form a hyaluronic acid solution. The gelatin-type A has a weight/volume of from about 0.02% to 0.08%. The nanoclay... Agent:

20110275573 - Tissue adhesive: Provided is an adhesive for adhering tissues. The adhesive includes a scaffolding and one or more peptides or proteins capable of binding to cells of both the first and second tissues. In a embodiment, the proteins or peptides have an amino acid sequence that is a subsequence of a ficolin... Agent: Metamorefix Ltd.

20110275574 - Method of inhibiting proliferation of hepatic stellate cells: There is presently provided a method of inhibiting proliferation of a hepatic stellate cell comprising directly down-regulating the hepatic stellate cell proliferation activity of connexin-43 in the hepatic stellate cell for the treatment of hepatic fibrosis or related disorder. This method primarily involves down regulating connexin-43 with agents such as... Agent: Agency For Science, Technology And Research

20110275575 - Peptide inhibitors of protein kinase c: PKC V5 isozyme-specific peptides are described. The sequences and compositions comprising the sequences are useful for treating disease states associated with the PKC isozyme from which they are respectively derived. Methods of treatment, pharmaceutical formulations and methods of identifying compounds that mimic the activity of the peptides are also described.... Agent: Board Of Trustees Of The Leland Stanford Junior University

20110275576 - Carbohydrate-cyclopamine conjugates as anticancer agents: Various anticancer compounds are disclosed, including a series of carbohydrate-cyclopamine conjugates. These compounds include pyranose, furanose, and mannitol conjugates, linked through a 1,2,3-triazine ring to the nitrogen of cyclopamine. Methods for preparing these compounds, pharmaceutical compositions containing these compounds, and their use as anticancer agents are also disclosed.... Agent: Utah State University

20110275577 - Methods of treating dermatologic, gynecologic, and genital disorders with caffeic acid analogs: The present invention relates to caffeic acid analog compounds and methods which may be useful for regeneration, cellular programming, and the treatment of dermatologic, gynecologic, and genital diseases such as inflammatory dermatologic conditions, dysplasia, neoplasia, in situ carcinoma, invasive carcinoma, lichen sclerosus, lichen planus, vaginal dysplasia, vaginal carcinoma, vulvar dysplasia,... Agent: Moleculin, LLC

20110275578 - Treatment of nephrolithiasis and urolithiasis using 1,2,3,4,6-penta-o-galloyl-beta-d-glucose (pgg): The treatment of nephrolithiasis or urolithiasis by methods that include administration of 1,2,3,4,6-penta-O-galloyl-beta-D-glucose (PGG) or a salt or derivative thereof, or a pharmaceutically acceptable composition comprising the same are provided herein.... Agent:

20110275579 - Anti-diabetic extract of rooibos: Novel and useful compositions derived from rooibos for treating diabetes are provided. The present invention is particularly concerned with the treatment of Type 2 diabetes. The invention provides a new use for aspalathin and rutin and compositions containing them for use in the prevention and treatment of diabetes. The invention... Agent: Zadec Aps

20110275580 - Bicyclic derivatives of morphine-6-glucuronide, preparation method thereof and use of same in therapeutics: v

20110275581 - Nuclear export inhibitors of topoisomerase ii alpha: A method of treating cancer in a subject comprising the step of administering to the subject in need thereof an effective amount of a combination of a compound that binds a nuclear export signal (NES inhibitor) on topoisomerase IIα and a topoisomerase inhibitor. Twenty small molecule inhibitors (SMI) that bind... Agent: H. Lee Moffitt Cancer Center And Research Institute, Inc.

20110275582 - Topical avermectin formulations and methods for elimination and prophylaxis of susceptible and treatment resistant strains of head lice: An avermectin-based topical formulation is disclosed which is useful for prevention and treatment of head lice (Pediculus humanus capitis). This topical formulation may be formulated as a shampoo-condition which comprises an effective amount of avermectin, solubilizers, suspending agents, preservatives, non-ionic surfactants, humectants, a silicone compound, and water. Also disclosed are... Agent: Topaz Pharmaceuticals LLC

20110275583 - Synergistic active compound combinations: Novel active compound combinations comprising compounds of the formula (I) and compounds of the formula (II) have very good insecticidal and acaricidal properties.... Agent: Bayer Cropscience Ag

20110275584 - Prevention and treatment of inflammation-induced and/or immune-mediated bone loss: The present invention relates to the use of an 11-β-HSD-type 1 and/or type 2 inhibitor for the manufacture of a pharmaceutical agent for the prevention and/or treatment of inflammation-induced and/or immune-mediated loss of bone and/or cartilage.... Agent: Onepharm Research And Development Gmbh

20110275585 - Targeted delivery of drugs, therapeutic nucleic acids and functional nucleic acids to mammalian cells via intact killed bacterial cells: A composition comprising intact killed bacterial cells that contain a therapeutic nucleic acid, a drug or a functional nucleic acid is useful for targeted delivery to mammalian cells. The targeted delivery optionally employs bispecific ligands, comprising a first arm that carries specificity for a killed bacterial cell surface structure and... Agent: Engeneic Gene Therapy Pty Limited

20110275586 - Antibacterial aminoglycoside analogs: c

20110275587 - Topical delivery of viscous medications for the treatment of diseases associated with chronic sinusitis: A medication or combination of medications for the treatment of a disease involving the sinuses is incorporated into a sterile medical gel. The viscosity of the gel or the adhesion of the gel to the patient's sinus cavity allows the gel to be maintained in the cavity for a sufficient... Agent:

20110275588 - Fused diimidazodiazepine compounds and methods of use and manufacture thereof: The invention encompasses novel compounds and pharmaceutically acceptable salts thereof and compositions including therapeutically or prophylactically effective amounts of such compounds or pharmaceutically acceptable salts thereof. The invention also encompasses methods for treating or preventing diseases and disorders associated abnormal cell growth, for example, treating or preventing cancer or tumor... Agent:

20110275698 - \"test and treat\" strategy for treating transforming hpv infection: The invention is concerned with a “test and treat” method of screening and directly treating female subjects having transforming or abnormal human papillomavirus (HPV) infection.... Agent: Norchip A/s

20110275697 - Regulation of cyclin d: The present invention provides methods for modulating the level or activity of cyclin D by inhibiting EGLN2 expression or activity. The methods are particularly useful for treating or preventing a disorder associated with elevated cyclin D levels or activity, such as cancer.... Agent: Dana Farber Cancer Institute, Inc.

20110275699 - Treatment for obesity and diabetes: The present disclosure relates to strategies aimed at treating/preventing obesity and diabetes. In particular, obesity is a major public health problem, associated with detrimental metabolic consequences such as diabetes, cardiovascular disease, stroke, osteoarthritis and even some types of cancer. Thus, application of DNA-PK inhibitors, that has been connected to the... Agent: University Of California

20110275701 - Anti-thrombin aptamer formulations and methods for use: The invention relates to the formulation, dosing, administration and use of an aptamer antagonist therapeutic that binds to thrombin.... Agent: Archemix Corp.

20110275700 - Biodegradable polyketal polymers and methods for their formation and use: e

20110275702 - Novel dna nanostructures that promote cell-cell interaction and use thereof: The present invention provides a ligand-nucleic acid nanostructure that promotes cell-cell interaction. Specially, the invention provides a ligand-nucleic acid nanostructure for treating tumor in a mammal. The methods of using and making the composition comprising a ligand-nucleic acid nanostructure are also provided.... Agent: Arizona Board Of Regents, A Body Corporate Acting

20110275589 - 3,5-disubstituted and 3,5,7-trisubstituted-3h-oxazolo and 3h-thiazolo[4,5-d]pyrimidin-2-one compounds and prodrugs thereof: The invention is directed to 3,5-disubstituted and 3,5,7-trisubstituted-3H-oxazolo and 3H-thiazolo[4,5-d]pyrimidin-2-one compounds and prodrugs thereof that have immunomodulatory activity. The invention is also directed to the therapeutic or prophylactic use of such compounds and pharmaceutical compositions containing them, and to methods of treating diseases and disorders described herein, by administering effective... Agent: Anadys Pharmaceuticals, Inc.

20110275590 - Conjugates for cancer therapy and diagnosis: The present invention relates to conjugates of a drug and an amino acid or an amino acid derivative or analog, pharmaceutical compositions that include the conjugates and methods of use thereof. In particular, the present invention relates to conjugates of anti-proliferative drugs and asparagine and glutamine and analogs thereof as... Agent: Biosight Ltd.,

20110275591 - Cocktail for modulation of alzheimer's disease: Formulations for the prevention and treatment of neurological diseases and cognitive deficiencies, i.e., Alzheimer's Disease (AD), Parkinson's Disease, amyotrophic lateral sclerosis, mild cognitive impairment and other types of dementia, comprise therapeutically effective amounts of curcumin, piperine, epigallocatechin-3-gallate (EGCG) and one or more of N-acetylcysteine, benfotiamine and alpha-lipoic acid. The combination... Agent: Concourse Health Sciences LLC

20110275592 - Emulsion composition and food and cosmetic products containing the emulsion composition: The invention provides an emulsion composition obtained by mixing an oil phase containing a carotenoid having a melting point of 100° C. or more as detected when it is contained in an oil; and an aqueous phase containing a polyglycerol fatty acid ester and a nonionic emulsifier different from the... Agent: Fujifilm Corporation

20110275593 - Stabilized ophthalmic galactomannan formulations: The present invention relates to viscosity stabilized ophthalmic formulations and ophthalmic formulations suitable for drug delivery. The formulations comprise galactomannans such as guar or hydroxypropyl guar and a borate source such as boric acid. The formulations further comprise a diol alcohol such as sorbitol and, optionally, a pharmaceutically acceptable divalent... Agent: Alcon Research, Ltd.

20110275594 - Oral dosage form: A pharmaceutical or nutraceutical tablet for oral administration comprising at least two fatty acids or derivatives thereof and cyclodextrin.... Agent: Omegatri As

20110275595 - Urea derivatives of substituted nortropanes, medicaments containing such compounds and their use: The present invention relates to compounds defined by formula I wherein the groups R1, Y1 to Y4, V, W, and X are defined as in claim 1, possessing valuable pharmacological activity. Particularly the compounds are inhibitors of 11 β-hydroxysteroid dehydrogenase (HSD) 1 and thus are suitable for treatment and prevention... Agent: Boehringer Ingelheim International Gmbh

20110275596 - Methods for treating neoplasia and for identifying compositions useful in such therapy: Various methods for treating a patient with neoplasia are disclosed, in particular, methods using topoisomerase Ila-preferential poisons, methods using a combination of a topoisomerase Illi-preferential inhibitor and a topoisomerase II poison, and methods using a combination of a topoisomerase II poison and a proteasome inhibitor are disclosed. Novel topoisomerase Ila-preferential... Agent: University Of Medicine And Dentistry Of New Jersey

20110275597 - Pharmaceutical composition: The present invention relates to a parenteral pharmaceutical composition comprising therapeutically effective amounts of N-(2-pyrazine)carbonyl-L-phenylalanine-L-leucine boronic acid or its salts or its derivatives and tromethamine wherein the composition is stable.... Agent: Sun Pharma Advanced Research Company Limited

20110275598 - Cosmetic use of proanthocyanidin a2: The use of proanthocyanidin A2 and of its complexes with phospholipids for the reshaping treatment of the breast and the anti-age treatment of the neck and the décolleté is described.... Agent: Dermogyn Srl

20110275599 - Use of cold-stabilized methylated vegetable oils as an agricultural chemical coformulant: The invention describes the use of a methylated vegetable oil having less than 10 percent by weight of saturated fatty acid methyl esters and less than 10 percent by weight of fatty acid methyl esters of carbon chain length less than C10 as a low-cloud point coformulant in pesticidal compositions.... Agent: Dow Agrosciences LLC

20110275600 - Methods for increasing endogenous plasmalogen levels: The invention provides methods for increasing endogenous plasmalogen levels in an animal by administering to the animal an endogenous plasmalogen level increasing amount of one or more long chain polyunsaturated fatty acids (LCPUFAs).... Agent:

20110275601 - Very low-dosed solid oral dosage forms for hrt: The present invention relates to a very low-dosed dosage form for hormone replacement therapy (HRT). More particularly, the present invention concerns a solid oral dosage form comprising about 0.5 mg estradiol and about 0.25 mg drospirenone, and at least one pharmaceutically acceptable excipient. Despite the very low E2 and DRSP... Agent: Bayer Schering Pharma Aktiengesellschaft

20110275603 - Novel immunomodulator and anti-inflammatory compounds: The present invention provides dihydroorotate dehydrogenase inhibitors, methods of preparing them, pharmaceutical compositions containing them and methods of treatment, prevention and/or amelioration of diseases or disorders wherein the inhibition of Dihydroorotate dehydrogenase is known to show beneficial effect.... Agent: Incozen Therapeutics Pvt. Ltd.

20110275602 - Pharmaceutical association, compositions for topical use, forms of dosage and method of treatment of acute or chronic otitis in pet animals: The present invention refers to a new pharmaceutical association comprising antibiotic from the class of quinolones, azole antifungus, corticoid anti-inflammatory and local anesthesic from the class of amines. The pharmaceutical association of the present invention is particularly appropriate for the treatment of acute or chronic otitis in pet animals, caused... Agent:

20110275604 - Aminoalkylsterol compounds with antitumoral and neuroprotective activity: Sterol derivatives of formula (I) and a method for the production of the compounds, a medicament using one of the compounds and a pharmaceutical composition comprising the medicament.... Agent: Institut National De La Sante Et De La Recherche Medicale (inserm)

20110275605 - Postprandial hyperglycemia-improving agent: A postprandial hyperglycemia-improving agent, the agent is highly safe and exhibits excellent effects of inhibiting the postprandial increase of blood glucose. The postprandial hyperglycemia-improving agent comprises a cycloartenol or a derivative thereof as an active ingredient.... Agent: Kao Corporation

20110275606 - Substituted porphyrins: Discloses are compounds according to Formula I. Further provided are methods of reducing oxidative stress in a cell, methods of treating a disease including cancer, and methods of treating a subject with a disorder associated with oxidative stress, the methods including administering a compound according to the invention. Also disclosed... Agent: Duke University

20110275609 - Bicyclic pyrazolo-heterocycles: The structures of rings A and B and substituents Ra, Rb and Rc are described in the specification. Also provided are pharmaceutically acceptable salts, acid salts, hydrates, solvates and stereoisomers of the compounds of formula I. The compounds are useful as modulators of cannabinoid receptors and for the prophylaxis, treatment... Agent: Cara Therapeutics, Inc.

20110275610 - Substituted pyrazole compounds: Also disclosed are methods of using such compounds as selective agonists for G protein-coupled receptor S1P1, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing the progression of diseases or disorders in a variety of therapeutic areas, such as autoimmune diseases and vascular disease.... Agent:

20110275607 - Nuclear transport modulators and uses thereof: The invention generally relates to the field of nuclear transport modulators, e.g., CRM1 inhibitors, and more particularly to new substituted-heterocyclic azole compounds, the synthesis and use of these compounds and their pharmaceutical compositions, e.g., in the treatment, modulation and/or prevention of physiological conditions associated with CRM1 activity such as in... Agent: Karyopharm Therapeutics, Inc.

20110275608 - Piperidine-containing compounds and use thereof: wherein all symbols have the same meanings as defined in the specification; a salt thereof, an N-oxide thereof, a solvate thereof, or a prodrug thereof has an anti-diabetic effect and a neuroprotective effect. Accordingly, the compound of the formula (I) and the compound of the formula (I-1) are useful in... Agent: Array Biopharma Inc.

20110275611 - Chemical compounds: The invention is directed to 6-(4-pyrimidinyl)-1H-indazole derivatives. Specifically, the invention is directed to compounds according to Formula (I) wherein R1-R4 are defined herein. The compounds of the invention axe inhibitors of PDK1 and can be useful in the treatment of immune and metabolic diseases and disorders characterized by constitutively activated... Agent:

20110275612 - Alpha-substituted n-sulfonyl gylcine amides antagonists of ccr10, compositions containing the same and methods for using them: Disclosed is a compound of formula (I). Wherein R1, R2Ar and Cy are as defined herein, or a pharmaceutically acceptable salt thereof. Also disclosed are pharmaceutical compositions of the compound of formula (I), methods of making the compounds of formula I, and methods of using the compounds of formula (I)... Agent: Boehringer Ingelheim International Gmbh

20110275613 - Organic compounds: The invention relates to organic compounds which have interesting pharmaceutical properties. In particular, the compounds are useful in the treatment and/or prevention of infections such as those caused by Plasmodium falciparum, Plasmodium vivax, Plasmodium malariae, Plasmodium ovale, Trypanosoma cruzi and parasites of the Leishmania genus such as, for example. Leishmania... Agent: Novartis Ag

20110275614 - Methods for the preparation of ivabradine sulfate and form i crystal thereof: Methods for the preparation of Ivabradine sulfate and form I crystal thereof. In particular, the Ivabradine sulfate and the preparation methods thereof, and the stable form I crystal of Ivabradine sulfate and the preparation methods thereof.... Agent:

20110275615 - Novel substituted amides, their preparation and use: t

20110275616 - Combination analgesic employing opioid and neutral antagonist: Methods of utilizing an opioid agonist in a mammalian subject in a manner that inhibits peripheral effects of the opioid agonist are described. The methods comprise administering the opioid agonist in an amount sufficient to confer analgesia the subject and co-administering a neutral opioid antagonist or pharmaceutically acceptable isomorph or... Agent: Aiko Biotechnology

20110275618 - Novel low concentration meloxicam tablets: The invention relates to a solid tablet that is directly-compressed of powder, comprising meloxicam and one or more excipients which are homogenously dispersed within the tablet that can be broken into two, three or four units with each unit containing equal amounts of the active ingredient, meloxicam.... Agent: Boehringer Ingelheim Vetmedica Gmbh

20110275617 - Ophthalmic composition: The present invention provides an ophthalmic composition comprising a hyperbranched polymer. The ophthalmic compositions may also comprise carbonic anhydrase inhibitors, wherein the hyperbranched polymer increases the aqueous solubility of the carbonic anhydrase inhibitor, and increases corneal permeation of the active agent. The ophthalmic compositions may also comprise non-ionic surfactants, such... Agent:

20110275619 - Inhibitors of bace1 and methods for treating alzheimer's disease: Inhibitors of BACE1 and compositions containing them are described. Use of the inhibitors and compositions containing them to treat Alzheimer's disease are described.... Agent: Purdue Research Foundation

20110275620 - Method for preventing or treating a disease related to the glucocorticoid receptor: A method for preventing or treating a disease related to the glucocorticoid receptor involving administering a pharmacologically effective amount of a 1,2-hydroquinoline compound.... Agent: Santen Pharmaceutical Co., Ltd.

20110275621 - Hiv integrase inhibitors: wherein bond a, ring A, R1, R2 and R3 are defined herein. The compounds are useful for the prophylaxis or treatment of infection by HIV and the prophylaxis, treatment, or delay in the onset of AIDS. The compounds are employed against HIV infection and AIDS as compounds per se or... Agent:

20110275623 - Bi-functional pyrazolopyridine compounds: wherein R1 and R2 together with the phenyl to which they are bound may form a bicyclic, fused heterocyclic ring and all other variables are as defined herein, their use in pulmonary inflammation or bronchoconstriction therapy and compositions comprising and processes for preparing the same are provided.... Agent: Gilead Sciences, Inc.

20110275622 - Bi-functional quinoline analogs: R1 and R2 together with the phenyl to which they are bound may form a bicyclic, fused heterocyclic ring, and all other variables are as defined herein, as well as their use in treating pulmonary inflammation or bronchoconstriction and compositions comprising and processes for preparing the same.... Agent: Gilead Sciences, Inc.

20110275624 - Indole and benzomorpholine derivatives as modulators of metabotropic glutamate receptors: The present invention relates to novel compounds, in particular novel indole and benzomorpholine derivatives according to Formula (I) wherein all radicals are as defined in the application and claims. The compounds according to the invention are positive allosteric modulators of metabotropic receptors-subtype 2 (“mGluR2”) which are useful for the treatment... Agent: Ortho-mcneil-janssen Pharmaceuticals, Inc.

20110275626 - Formulation for oral transmucosal administration of analgesic and/or antispasmodic molecules: A formulation for oral transmucosal administration of at least one active principle with antispasmodic and/or analgesic effect, including the active principle in base form and/or in salt form, an aqueous alcohol solution titrating at least 35° alcohol by weight, the active principle being present in a state of stable and... Agent:

20110275625 - Heteroaryl diamide compounds useful as mmp-13 inhibitors: Disclosed are compounds and compositions of the formula (I) as described herein which are inhibitors of MMP-13. Also disclosed are methods of using and making compounds of the formula (I).... Agent: Boehringer Ingelheim International Gmbh

20110275627 - Indolizine inhibitors of leukotriene production: and pharmaceutically acceptable salt thereof, wherein X1 to X4, R1 to R4, A, B, D and m are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and... Agent: Boehringer Ingelheim International Gmbh

20110275628 - Novel pyrazole-3-carboxamide derivative having 5-ht2b receptor antagonist activity: Disclosed is a compound represented by general formula (I) or a pharmaceutically acceptable salt thereof, which is useful as a selective antagonist of a 5-HT2B receptor. The compound and salt are useful for treatment or prevention of various diseases and conditions associated with a 5-HT2B receptor.... Agent:

20110275629 - Pyridazino-pyridinone compounds and methods of use: wherein A, R1, R2, R3, R4, R5, R6, X and n are defined herein. The invention also comprises pharmaceutical compositions including one or more compounds of Formula I, uses of such compounds and compositions for treatment of p38 map kinase mediated diseases including rheumatoid arthritis, psoriasis, chronic obstructive pulmonary disease,... Agent: Amgen Inc.

20110275631 - Heteroaryl substituted indole compounds useful as mmp-13 inhibitors: Disclosed are compounds and compositions of the formula I as described herein which are inhibitors of MMP-13. Also disclosed are methods of using and making compounds of the formula I.... Agent: Boehringer Ingelheim International Gmbh

20110275630 - Isoindolinone kinase inhibitors: s

20110275632 - Method for preventing or treating a disease related to the glucocorticoid receptor: A method for preventing or treating a disease related to the glucocorticoid receptor involving administering a pharmacologically effective amount of a 1,2-dihydroquinoline compound.... Agent: Santen Pharmaceutical Co., Ltd.

20110275633 - 2,4-diaminopyrimidine derivates as ptk2- inhibitors for the treatment of abnormal cell growth: The present invention encompasses compounds of general formula (1) wherein R1-R3 and n are defined as in claim 1, which are suitable for the treatment of diseases characterised by excessive or abnormal cell proliferation, and their use for preparing a medicament having the above-mentioned properties.... Agent: Boehringer Ingelheim International Gmbh

20110275634 - Dual-acting pyrazole antihypertensive agents: wherein: Ar, Z, R3, R4 and R5 are as defined in the specification, or a pharmaceutically acceptable salt thereof These compounds have AT1 receptor antagonist activity and neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and... Agent: Theravance, Inc.

20110275635 - Small molecule inhibitors of nads, namnat, and nmnat: Small molecule inhibitors of bacterial nicotinamide adenine dinucleotide synthetase (NADs), bacterial nicotinic acid mononucleotide adenylyltransferase (NaMNAT), and human nicotinamide mononucleotide adenylyltransferase (NMNAT) are provided, as well as methods of making and using the inhibitors.... Agent: The Uab Research Foundation

20110275636 - Desazadesferrothiocin and desazadesferrothiocin polyether analogues as metal chelation agents: Disclosed herein are new compounds of desazadesferrothiocin polyether (DADFT-PE) analogues, as well as pharmaceutical compositions comprising them and their application as metal chelation agents for the treatment of disease. Methods of chelation of iron and other metals in a human or animal subject are also provided for the treatment of... Agent: Ferrokin Biosciences, Inc.

20110275639 - C5ar antagonists: Compounds are provided that are modulators of the C5a receptor. The compounds are substituted piperidines and are useful in pharmaceutical compositions, methods for the treatment of diseases and disorders involving the pathologic activation of C5a receptors.... Agent: Chemocentryx, Inc.

20110275637 - Piperazine derivatives and their use as leptin receptor modulators: The present invention relates to new compounds of formula (I), to pharmaceutical compositions comprising these compounds and to the use of these compounds as leptin receptor modulator mimetics in the preparation of medicaments against conditions associated with weight gain, type 2 diabetes and dyslipidemias.... Agent:

20110275638 - Piperazine derivatives and their use as leptin receptor modulators: The present invention relates to new compounds of formula (I), to pharmaceutical compositions comprising these compounds and to the use of these compounds as leptin receptor modulator mimetics in the preparation of medicaments against conditions associated with weight gain, type 2 diabetes and dyslipidemias.... Agent:

20110275640 - Preventives or remedies for alzheimer's disease, or amyloid protein fibril-formation inhibitors, which include a nitrogen-containing heteroaryl compound: e

20110275641 - Preventives or remedies for alzheimer's disease, or amyloid protein fibril-formation inhibitors, which include a nitrogen-containing heteroaryl compound:

20110275642 - New method for obtaining 5-amino 2,3-dihydrophthalazine-1,4-dione alkali metal salts and their use in medicine: The invention is related to a method for preparing 5-amino-2,3-dihydrophthalazine-1,4-dione salt with alkali metals of the formula II wherein 5-nitro-2,3-dihydrophthalazine-1,4-dione is solved in water solution of MOH1 where M has the below mentioned meaning, with formation of solution of 5-nitro-2,3-dihydrophthalazine-1,4-dione alkali metal salt, which is catalytically transformed into 5-amino-2,3-dihydrophthalazine-1,4-dione salt... Agent: Abidopharma Pl Sp. Z.o.o.

20110275643 - Aroylquinoline compounds: A serious of nitro heterocyclic derivatives including a structure of formula (I) are provided. In formula (I), P, Q and R1 to R8 are defined in the specification. The derivatives disclosed in the present invention are characterized in inhibiting tubulin polymerization, and treating cancers and other tubulin polymerization-related disorders with... Agent: Taipei Medical University

20110275644 - Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors: The present invention provides diagnostic methods for predicting the effectiveness of treatment of a cancer patient with an IGF-1R kinase inhibitor that inhibits both IGF-1R and IR kinases. Methods are provided for identifying patients with cancer who are likely to benefit from treatment with an IGF-1R kinase inhibitor that inhibits... Agent:

20110275646 - Novel compounds for treatment of cancer and disorders associated with angiogenesis function: Novel compounds for treatment of cancer and disorders associated with angiogenesis function. Also disclosed are a method of preparing the compounds, pharmaceutical compositions and packaged products containing the compounds, a method of using these molecules to treat cancer (e.g., leukemia, non-small cell lung cancer, colon cancer, CNS cancer, melanoma, ovarian... Agent: University Of Southern California

20110275645 - Small molecules for inhibition of protein kinases: The invention provides compounds that inhibit protein kinases, prodrugs of the compounds, intermediates and methods of synthesizing the compounds and/or prodrugs, pharmaceutical compositions including the compounds and/or prodrugs and methods of using the compounds and/or prodrugs in a variety of contexts, including, for example, in the treatment and/or prevention of... Agent:

20110275647 - Pyrimidin-4-(3h)-one derivatives: The present invention relates to a compound represented by a formula (I): or a pharmaceutically acceptable salt thereof, wherein R1 represents lower alkyl or the like; R2 represents phenyl or the like; R represents a halogen atom or the like; X represents an oxygen atom or the like; Y1, Y2,... Agent: Msd K.k.

20110275648 - Flurbiprofen analogs and methods of use in treating cancer: Flurbiprofen analog compounds having an amino acid derivatized at the flurbiprofen alkanoic acid carboxyl group and terminating at an ester or amide group are effective in inhibiting cancer cells in vitro and inhibiting the growth of cancers in viva. The compounds and pharmaceutical compositions containing them are particularly useful for... Agent: The Regents Of The University Of Colorado, A Body Corporate

20110275649 - Combination therapy for the prevention of statin induced diabetes: Novel combinations comprising HMG CoA reductase inhibitors, or statins, with partial fatty acid oxidation inhibitors (pFOXi), and methods for their use, are disclosed. These combinations are useful in preventing or reducing the risk of developing diabetes which results from therapy with a statin.... Agent: Palmetto Pharmaceuticals LLC

20110275650 - Methods and compositions related to targeting monoacylglycerol lipase: This invention provides compounds that selectively inhibit monoacylglycerol lipase (MAGL). The invention also provides methods of using the MAGL selective inhibitors to stimulate 2-Arachidonoylglycerol (2-AG) mediated endocannabinoid signaling in vivo, and to treat conditions that are associated with or linked to endocannabinoid signaling. The invention additionally provides methods of treating... Agent: The Scripps Research Institute

20110275651 - Fused ring heteroaryl kinase inhibitors: Provided herein are fused ring heteroaryl compounds useful in a variety of methods, including reducing the activity of certain kinases and treating certain disease states.... Agent: The Regents Of The University Of California

20110275652 - 2,2-bis-(hydroxymethyl)cyclopropylidenemethyl-purines and -pyrimidines as antiviral agents: wherein B is a purine or pyrimidine heterocyclic ring or base. In a preferred embodiment, the purine include 6-aminopurine (adenine), 6-hydroxypurine (hypoxanthine), 2-amino-6-hydroxypurine (guanine), 2,6-diamino-purine, 2-amino-6-azidopurine, 2-amino-6-halo substituted purines such as 2-amino-6-chloropurine, 2-amino-6-fluoropurine, 2-amino-6-alkoxypurines such as 2-amino-6-methoxypurine, 2-amino-6-cyclopropylaminopurine, 2-amino-6-alkylamino or 2-amino-6-dialkylamino substituted purines, 2-amino-6-thiopurine, 2-amino-6-alkylthio substituted purines, 3-deazapurines, 7-deazapurines and... Agent:

20110275653 - Heterocyclic compounds and their uses: Substituted bicyclic heteroaryls and compositions containing them, for the treatment of general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, including but not restricted to autoimmune diseases such as systemic lupus erythematosis (SLE),... Agent: Amgen Inc.

20110275654 - Long term treatment of hiv-infection with tmc278: This invention relates to the use of a parenteral formulation comprising an anti-virally effective amount of TMC278 or a pharmaceutically acceptable acid-addition salt thereof, and a carrier, for the manufacture of a medicament for the treatment of a subject being infected with HIV, wherein the formulation is to be administered... Agent: Tibotec Pharmaceuticals Ltd. A Corporation

20110275655 - Pyrimidinecarboxamide derivatives as inhibitors of syk kinase: i

20110275656 - 3h-imidazo [4, 5-c] pyridine- 6 -carboxamides as anti-inflammatory agents: There are provided compounds of formula (I), wherein R1, R6, R8, Q2, Q3, Q3a, Q4, L and A have meanings given in the description, and pharmaceutically-acceptable salts thereof, which compounds are useful in the treatment of diseases in which inhibition of the activity of a member of the MAPEG family... Agent: Boehringer Ingelheim International Gmbh

20110275657 - Melanocortin receptor modulators, process for preparing them and use there in human medicine and cosmetics: e

20110275658 - Opioid-containing oral pharmaceutical compositions and methods: The present invention provides sustained-release oral pharmaceutical compositions and methods of use. The sustained-release oral pharmaceutical compositions include an opioid (including salts thereof) and a salt of a non-steroidal anti-inflammatory drug (NSAID).... Agent: Upsher-smith Laboratories, Inc.

20110275659 - Tacrolimus for improved treatment of transplant patients: An extended release oral dosage form comprising as active substance tacrolimus or a pharmaceutically active analogue thereof for a once daily immunosuppressive treatment of a patient in need thereof, preferable a kidney or liver transplant patient. The dosage form releases the active substance over an extended period of time. It... Agent: Lifecycle Pharma A/s

20110275660 - Beta carboline sulphonylurea derivatives as ep4 receptor antagonists: The invention is directed to β-carboline sulphonylurea derivatives as EP4 receptor antagonists useful for the treatment of EP4 mediated diseases or conditions, such as acute and chronic pain, inflammation, osteoarthritis, and rheumatoid arthritis. Pharmaceutical compositions and methods of use are also included.... Agent:

20110275661 - Tricyclic nitrogen compounds used as antibacterials: e

20110275662 - Methods of improving skin quality: Methods of improving skin quality are disclosed. Generally, the methods include topically administering an IRM compound to a treatment area of skin for a period of time and in an amount effective for improving the quality of the skin. Suitable IRM compound compounds include agonists of one or more TLRs.... Agent: 3m Innovative Properties Company

20110275665 - Glucokinase activators: t

20110275664 - Method for treating drug and behavioral addictions: The present invention is directed to the use of ibudilast for treating addictions, including drug and behavioral addictions. In particular, ibudilast is used to diminish the dopamine-mediated reward associated with addictions and to treat withdrawal syndromes after discontinuance of addictive drug use or behavior. In addition, methods are provided for... Agent: Medicnova, Inc.

20110275663 - N-acylthiourea and n-acylurea inhibitors of the hedgehog protein signalling pathway: The present invention relates to the use of acylthiourea or acylurea derivatives for the treatment of pathologies involving a tissue dysfunction associated with a deregulation of the Hedgehog protein signalling pathway, and also to novel acylthiourea or acylurea derivatives as such, to their use as a medicinal product, and to... Agent:

20110275666 - Activated blood coagulation factor x (fxa) inhibitor: or a pharmacologically acceptable salt thereof, or a hydrate thereof, as an active ingredient, wherein (A) a factor involved in the risk of bleeding caused by the anticoagulant agent is selected as a dose determinant; (B) a reference value of the dose determinant is set; (C) the dose determinant of... Agent: Daiichi Sankyo Company, Limited

20110275667 - Compositions useful for treating gastroesophageal reflux disease: The present invention relates to a method of treating GERD in a human subject in need of treatment. The method comprises orally administering to said subject an effective amount of a thieno[3,2-b]pyridine compound of Structural Formula I or a pharmaceutically acceptable salt or N-oxide derivative thereof, wherein the effective amount... Agent: Edusa Pharmaceuticals, Inc.

20110275668 - Compound with antimalarial activity and antimalarial drug containing the same as active ingredient: Compounds with high antimalarial activity; and antimalarial drugs containing the same as an active ingredient. There are provided compounds with antimalarial activity represented by the chemical formula: (wherein R1 is H, Cl or OCH3; R2 is H or CH3; R3 is CH, CH2, C(CH3), CH(CH3) or C(CH3)2; Ar is imidazole,... Agent: Nagoya City University

20110275669 - Novel pyrroles having hypolipidemic hypocholesteremic activities, process for their preparation and pharmaceutical compositions containing them and their use in medicine: m

20110275670 - New compounds vii: The present invention relates to new compounds of formula (I), to pharmaceutical compositions comprising these compounds and to the use of these compounds as leptin receptor modulator mimetics in the preparation of medicaments against conditions associated with weight gain, type 2 diabetes and dyslipidemias.... Agent:

20110275671 - Dihydroindolinone derivatives: Disclosed are dihydroindolone compounds which can modulate the activity of protein tyrosine kinases, a method for preparing the same, and pharmaceutical compositions comprising the same. Also disclosed are use of such compounds and pharmaceutical compositions thereof in the treatment and/or prophylaxis of protein tyrosine kinase associated diseases in an organism,... Agent: Shanghai Institute Of Pharmaceutical Indusrty

20110275672 - Methods for treating cancers using polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione: Methods of treating, preventing and/or managing cancer as well as and diseases and disorders associated with, or characterized by, undesired angiogenesis are disclosed. Specific methods encompass the administration of an immunomodulatory compound alone or in combination with a second active ingredient. The invention further relates to methods of reducing or... Agent: Celgene Corporation

20110275673 - Inhibitors of sphingosine kinase 1: The invention relates to compounds of Formula (I). Compounds of the present invention are inhibitors of sphingosine kinase 3, and are useful in the treatment of various disorders and conditions, such as inflammatory disorders.... Agent:

20110275675 - Antimicrobial dental materials: in which R1=H, C1 to C3 alkylene residue; R2=a linear or branched C4 to C20 alkylene residue; R3=a C6 to C20 alkylene residue; and A−=Cl−, Br−, I−, F−, OH−, alkyl and aryl alcoholate, thiolate, NO3−, BO33−, PO43−, HPO42−, H2PO4−, alkyl and aryl phosphate, alkyl and aryl phosphonate, PF6−, TiF62−, BF4−,... Agent: Ivoclar Vivadent Ag

20110275674 - Small molecules modulator of epigenetic regulation and their therapeutic applications: Disclosed are methods and compositions for modulating the function of transcription factors, especially transcription factors that recruit epigenetic regulators (histone modifying enzymes) to specific DNA promoters. The targeted transcription factors include but are not limited to the myocyte enhancing factor (MEF2), the forkhead/winged helix transcription factor FOXP3 and the transcription... Agent: University Of Southern California

20110275676 - Triazole-substituted anthranilamides as pesticides: s

20110275677 - Indole compounds bearing aryl or heteroaryl groups having sphingosine-1-phosphate (s1p) receptor biological activity: The invention provides well-defined aryl and/or heteroaryl substituted indoles that are useful as sphingosine-1-phosphate agonists or antagonists. As such, the compounds described herein are useful in treating a wide variety of disorders associated with modulation of sphingosine-1-phosphate receptors.... Agent: Allergan, Inc.

20110275678 - New pyridine derivatives as leptin receptor modulator mimetics: The present invention relates to new compounds of formula (I), to pharmaceutical compositions comprising these compounds and to the use of these compounds as leptin receptor modulator mimetics in the preparation of medicaments against conditions associated with weight gain, type 2 diabetes and dyslipidemias.... Agent:

20110275679 - Flupirtine hydrochloride maleic acid cocrystal: The invention relates to crystalline forms of flupirtine, particularly to 1:1 flupirtine hydrochloride maleic acid cocrystal. The preparation and characterization of 1:1 flupirtine hydrochloride maleic acid cocrystal is described. The invention also relates to the therapeutic use of the flupirtine hydrochloride maleic acid cocrystal to treat nervous system disorders, pain... Agent: Bionevia Pharmaceuticals, Inc.

20110275680 - Noxel oxime derivatives of 3, 5-seco-4-nor-cholestane, pharmaceutical compositions containing same, and method for preparing same: The invention relates to novel chemical compounds, in particular oxime derivatives of 3,5-seco-4-nor-cholestane, to the application thereof as drugs, in particular cytoprotective drugs, and more particularly as neuroprotective, cardioprotective and/or hepatoprotective drugs.... Agent: Trophos

20110275682 - Novel choline cocrystal of epalrestat: The invention relates to a novel choline cocrystal of 5-[(1Z,2E)-2-methyl-3-phenylpropenylidene]-4-oxo-2-thioxo-3-thiazolidineacetic acid. The preparation and characterization of the novel choline cocrystal according to various embodiments of the invention is described. The invention also relates to pharmaceutical compositions containing the novel choline cocrystal and the therapeutic use of the novel choline cocrystal... Agent: Bionevia Pharmaceuticals, Inc.

20110275681 - Novel solid forms of epalrestat: The invention relates to novel crystalline salts of 5-[(1Z,2E)-2-methyl-3-phenylpropenylidene]-4-oxo-2-thioxo-3-thiazolidineacetic acid and a novel betaine cocrystal of 5-[(1Z,2E)-2-methyl-3-phenylpropenylidene]-4-oxo-2-thioxo-3-thiazolidineacetic acid. The preparation and characterization of the novel crystalline salts and cocrystal according to various embodiments of the invention is described. The invention also relates to pharmaceutical compositions containing the novel crystalline salts... Agent:

20110275683 - Selenophene and selenazole carboxylic acid derivatives: Derivatives of selenophene and selenazole heterocycles are disclosed. The compounds are useful as inhibitors of D-amino acid oxidase (DAO) and in the treatment of neurodegenerative and psychiatric diseases and disorders.... Agent: Ironwood Pharmaceuticals, Inc

20110275684 - Novel benzotriazole derivatives useful for the treatment of cns disorders: The present invention relates to novel benzotriazole derivatives, efficacious in animal models of CNS disorders and, as such, valuable candidates for the prevention or treatment of CNS (Central Nervous System) diseases or disorders. In other aspects the invention relates to pharmaceutical compositions comprising the benzotriazole derivatives of the invention and... Agent: Neurosearch A/s

20110275685 - Salt and polymorphs of a kinesin inhibitor compound: The present invention relates to salts, polymorphs and hydrates of the kinesin inhibitor compound N-((S)-3-amino-4-fluorobutyl)-N-((R)-1-(1-benzlyl-4-(2,5-difluorophenyl)-1H-imidazol-2-yl)-2,2-dimethylpropyl)-2-hydroxyacetamide, processes to prepare such salts, polymorphs and hydrates and a liquid formulation comprising at least one of these salts, polymorphs and hydrates.... Agent:

20110275686 - Nanoparticle carrier systems based on poly(dl-lactic-co-glycolic acid) (plga) for photodynamic therapy (pdt): Compositions, which are stable in storage, and a method of production of pharmaceutical based nanoparticulate formulations for clinical use in photodynamic therapy comprising a hydrophobic photosensitizer, poly(lactic-co-glycolic) acid and stabilizing agents are provided. These nanoparticulate pharmaceutical formulations provide therapeutically effective amounts of photosensitizer for parenteral administration. In particular, tetrapyrrole derivatives... Agent: Biolitec, Inc.

20110275687 - Saxagliptin intermediates, saxagliptin polymorphs, and processes for preparation thereof: The invention provides Saxagliptin Schiff bases, polymorphs of Saxagliptin and (1S,3S,5S)-2-[(2S)-2-propan-2-ylideneamino-2-(3-hydroxy-1-adamantyl)acetyl]-2-azabicyclo[3.1.0]hexane-3-carbonitrile, processes for preparing Saxagliptin hydrates, and pharmaceutical compositions thereof.... Agent: Teva Pharmaceutical Industries Ltd.

20110275688 - Ketorolac compositions for corneal wound healing: The present invention is directed to an aqueous ophthalmic solution comprising an effective amount of ketorolac which comprises carboxymethyl cellulose which promotes epithelial wound healing in a patient's cornea.... Agent: Allergan, Inc.

20110275690 - New crystal form of sunitinib malate: A process for the preparation of a new crystal form of sunitinib malate, along with pharmaceuticals comprising the same are described.... Agent: Lek Pharmaceuticals D.d.

20110275689 - Preparation of 3-pyrrole substituted 2-indolinone derivatives: The present invention relates to novel intermediates and further to the use of said intermediates in processes for the preparation of indolinone derivatives, in particular 3-pyrrole substituted 2-indolinones having amide moieties on the pyrrole ring. Such compounds are useful in die treatment of abnormal cell growth, such as cancer, in... Agent: Generics [uk] Limited

20110275691 - Methods of treating headaches using 5-ht agonists in combination with long-acting nsaids: The invention is directed to methods and compositions that can be used in the treatment of headaches. In particular, methods and compositions are described involving the combination of a long-acting NSAID and a 5-HT1B/1D agonist.... Agent: Pozen, Inc.

20110275692 - Substituted gamma lactams as therapeutic agents: e

20110275693 - Pharmaceutical compositions comprising 2-oxo-1-pyrrolidine derivatives: The present invention relates to an immediate release formulation of pharmaceutical compounds.... Agent: Ucb Pharma, S.a.

20110275694 - 3-(phenoxyphenylmethyl)pyrrolidine compounds: where a and R1-6 are as defined in the specification, or a pharmaceutically acceptable salt thereof. The compounds of formula I are serotonin and norepinephrine reuptake inhibitors. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and process and intermediates for preparing... Agent: Theravance, Inc.

20110275695 - Crystalline forms of zotepine hydrochloride: The invention relates to crystalline forms of zotepine hydrochloride, including the crystalline hydrochloride salt of zotepine and two cocrystals of zotepine hydrochloride with benzoic acid. The preparation and characterization of these crystalline forms of zotepine hydrochloride is described. The invention also relates to the therapeutic use of the crystalline forms... Agent: Bionevia Pharmaceuticals, Inc.

20110275696 - Thioxanthone-based autophagy inhibitor therapies to treat cancer: The present specification provides compositions comprising a thioxanthone-based autophagy inhibitor and/or a cancer therapeutic autophagy inducing compound, pharmaceutical kits comprising these compositions, and methods of treating cancer using such compounds, compositions and kits. Additionally, the present specification provides methods of treating cancer using a thioxanthone-based autophagy inhibitor and a radiotherapy.... Agent:

20110275703 - Substituted spiroketal derivatives and use thereof as therapeutic drug for diabetes: provided that Ar is a group represented by Formula (a) when R1 is a fluorine atom, methyl group or an ethynyl group, and that R2 is methoxy group, an ethoxy group, an isopropyl group, a propyl group, a trifluoromethyl group, a trifluoromethoxy group, 2-fluoroethyl group or 1-propynyl group when R1... Agent: Chugai Seiyaku Kabushiki Kaisha

20110275706 - Pharmaceutical compositions containing lipase inhibitors: A pharmaceutical composition comprises at least one inhibitor of lipases, preferably an inhibitor of gastrointestinal and pancreatic lipases, such as orlistat, at least one surfactant, and at least one dispersant.... Agent:

20110275704 - Stable formulations for lyophilizing therapeutic particles: The present disclosure generally relates to lyophilized pharmaceutical compositions comprising polymeric nanoparticles which, upon reconstitution, have low levels of greater than 10 micron size particles. Other aspects of the invention include methods of making such nanoparticles.... Agent:

20110275705 - Stable injectable oil-in-water docetaxel nanoemulsion: The present invention describes Stable injectable oil-in-water Docetaxel nanoemulsion composition having Docetaxel concentrations as high as 20 mg/ml, devoid of hypersensitivity reaction and fluid retention. It employs Synthetic triglycerides, and DSPE PEG-2000, Natural phosphatides, Polyhydric alcohol and Water for injection. In another embodiment lyophilised products with added Cryoprotectants have been... Agent: Bharat Serums And Vaccines Ltd.

20110275707 - Substituted afpo (6-aryl-4h-furo[3,2-c]pyran-4-one) derivatives as anti-cancer agents: Compounds of Formulas I are described, along with methods of using such compounds for the treatment of cancer and pharmaceutical formulations thereof.... Agent:

20110275708 - Polycyclic compounds and methods related thereto: The invention relates to a novel compound of formula I or pharmaceutically acceptable salts thereof as well as pharmaceutical, nutraceutical, and botanical drug compositions and therapeutic methods related thereto. In certain embodiments, the compounds are used for the treatment of abnormal cell growth, hyperproliferative disorders, and inflammatory diseases in mammals.... Agent: Cornell University

20110275709 - Tellurium-containing compounds for affecting male's fertility following chemotherapy and/or radiotherapy: Use of tellurium-containing compounds for maintaining and/or augmenting fertility in a male subject following chemotherapy and/or radiotherapy is disclosed. The tellurium-containing compound is utilized in combination with a chemotherapeutic agent and/or radiation, such that the male subject treated by the chemotherapeutic agent and/or radiation and by the tellurium-containing compound is... Agent: Biomas Ltd.

20110275710 - Agricultural pesticide formulations and process for making the same: The present invention provides an agricultural pesticide formulation of reduced toxicity and high dispersibility, and a process for making the same.... Agent: United Phosphorus Inc.

20110275711 - Method for treating macular edema: Provided is a method for treating macular edema in a mammalian subject, comprising administering an effective amount of a fatty acid derivative to the subject in need thereof. The method of the present invention can effectively treat macular edema in a non-invasive manner. In one embodiment of the present invention,... Agent: R-tech Ueno, Ltd.

20110275712 - Oil in water emulsion cosmetic composition for skin: An oil in water emulsion cosmetic composition for skin, in which vitamin A and its derivatives are stably incorporated and which has superior feeling in use (skin familiarity or feeling of skin absorption, feeling of efficacy after application) and base composition stability (emulsion stability) with the passage of time. The... Agent: Shiseido Company, Ltd.

20110275713 - Acetylated amino acids as anti-platelet agents, nutritional and vitamin supplements: This invention relates to pharmaceutical compounds and nutritional supplements that are acetylated derivatives of naturally occurring amino acids and acetylated derivatives of peptides derived from naturally occurring amino acids containing hydroxyl groups. They are as useful as anti-platelet drugs, and as nutritional supplements.... Agent: Signature R&d Holdings, LLC

20110275714 - Use of cationic surfactants as acaricidal agents: This invention relates to a use of a composition for protecting against mites and ticks containing cationic surfactants such as ethyl-Nα-lauroyl-L-arginate HCl (LAE). It has been found that cationic surfactants such as ethyl-Nα-lauroyl-L-arginate HCl (LAE) and its salts are effective acaricidal agents.... Agent: Laboratorios Miret, S. A.

20110275715 - Method for treating retinal disease: The present application provides a method for treating a retinal disease in a patient in need thereof, which comprises administering at least three drops of an ophthalmic composition comprising a fatty acid derivative as an active ingredient in an eye of the patient per day.... Agent: R-tech Ueno, Ltd.

20110275716 - Composition and method for treatment of diabetes: The present invention relates to a method of treating an incretin related disease such as diabetes, obesity and the like by delivery of butyric acid, bile acid, long chain fatty acid, or glutamine to the colon by bypassing the upper digestive tract.... Agent:

20110275717 - Pharmaceutical formulation comprising diclofenac: The present invention relates to a pharmaceutical formulation comprising a pharmaceutically acceptable salt of diclofenac, at least one polyoxyalkylene ester of a hydroxy fatty acid, water, and, optionally, a co-solvent.... Agent: Advance Holdings Limited

20110275718 - Pharmaceutical composition of ibuprofen and paracetamol and methods of using the same: A combination pharmaceutical composition for the treatment of pain comprising between about 125 mg and about 150 mg ibuprofen and between about 475 mg and about 500 mg paracetamol, and a method for alleviating pain in a patient comprising administering to the patient a pharmaceutical composition comprising between about 125... Agent:

20110275719 - Novel trifluoromethylsulfonamide gamma secretase inhibitor: The present invention is directed to a novel trifluoromethylsulfonamide derivative which inhibits the processing of APP by the putative γ-secretase and thus is useful in the treatment or prevention of Alzheimer's disease. This compound possesses favorable pharmacokinetic properties in higher species (rhesus) and thus can be dosed on an intermittent... Agent:

20110275720 - Methods for concomitant administration of colchicine and a second active agent: Methods for concomitant administration of colchicine together with one or more second active agents, e.g., ketoconazole and ritonavir, are disclosed. Such methods reduce the dangers commonly associated with such concomitant administration and provide additional benefits. Methods of notifying health care practitioners and patients regarding appropriate dosing for concomitant administration of... Agent:

20110275721 - Method for the purification of substituted cyclopent-2-en-1-one congeners and substituted 1,3-cyclopentadione congeners from a complex mixture using countercurrent separation: Methods of purifying individual congeners of substituted cyclohexa-2,4-dienones, substituted cyclohexane-1,3,5-triones, substituted cyclopent-2-en-1-ones, and substituted 1,3-cyclopentadiones and compositions using the same are disclosed. The purification method includes the steps of: (a) selecting a congener to be isolated; (b) dissolving the mixture of congeners in a bi-phasic solvent system specific to the... Agent: Metaproteomics, LLC

20110275722 - Propofol based anesthetic with preservative: The invention is a sterile pharmaceutical composition for parenteral administration comprised of an oil-in-water emulsion, in which Propofol is dissolved in a water-immiscible lipophilic agents, and surface stabilizing amphiphilic agent, and tonicity modifying water-soluble hydroxy group and preservative preferably, lipophilic organic compound (butylated hydroxytoluene, butylated hydroxyanisole) or its pharmaceutically acceptable... Agent:

20110275724 - Azeotrope-like compositions of pentafluoropropene and water: Provided are azeotropic and azeotrope-like compositions of 1,2,3,3,3-pentafluoropropene (HFO-1225ye) and water. Such azeotropic and azeotrope-like compositions are useful in isolating 1,2,3,3,3-pentafluoropropene from impurities during production. Azeotropes of the instant invention are similarly useful in final compositions or manufacturing final compositions, such as blowing agent, propellants, refrigerants, diluents for gaseous sterilization... Agent: Honeywell International Inc.

20110275723 - Azeotrope-like compositions of tetrafluoropropene and water: Provided are azeotropic and azeotrope-like compositions of trans-1,3,3,3-tetrafluoropropene (HFO-1234ze(E)) and water. Such azeotropic and azeotrope-like compositions are useful in isolating trans-1,3,3,3-tetrafluoropropene from impurities during production. Azeotropes of the instant invention are similarly useful in final compositions or for the manufacture of final compositions, such as blowing agent, propellants, refrigerants, diluents... Agent: Honeywell International Inc.

20110275725 - Glycerol ester active agent delivery systems and methods: Embodiments of the invention include glycerol esters and use of the same for active agent delivery systems and methods. In an embodiment, the invention includes an active agent eluting device including a glycerol ester, an active agent dispersed within the glycerol ester, the active agent eluting device configured to elute... Agent:

  
11/03/2011 > 188 patent applications in 146 patent subcategories. recently filed with US Patent Office

20110269665 - Compound and method for treating myotonic dystrophy: Provided are 9-base morpholino antisense compounds targeted to polyCUG repeats in the 3′UTR region of dystrophia myotonica protein kinase (DMPK) mRNA, and related methods for treating myotonic dystrophy DM1.... Agent: Avi Biopharma, Inc.

20110269666 - Method and drug composition for treating septic shock hypotension: A method for treating septic hypotension, including administering at least one alpha-2 agonist or other sympatholytic, and at least one vasopressor. The alpha-2 agonist may be clonidine or dexmedetomidine, and the sympaholytic may be rilmelidine, monoxidine, alpha-methyldopa and alpha-methylparatyrosine. The vasopressor may be noradrenaline, adrenaline, vasopressin, angiotensin and phenylephrine. The... Agent:

20110269667 - Methods of generating and using procollagen: A method of promoting wound healing, treating fibrosis and/or promoting angiogenesis is provided. The method comprises administering to a subject in need thereof a therapeutically effective amount of a procollagen, thereby promoting wound healing, treating fibrosis and/or promoting angiogenesis in the subject.... Agent:

20110269668 - Fused heteroaryl diamide compounds useful as mmp-13 inhibitors: Disclosed are compounds and compositions of the formula I as described herein which are inhibitors of MMP-13. Also disclosed are methods of using and making compounds of the formula I.... Agent: Boehringer Ingelheim International Gmbh

20110269669 - Self-decontaminating coatings containing antimicrobial peptides: Disclosed herein is a composition having: a polymeric material and an antimicrobial peptide derived from Chrysophrys major. Also disclosed herein is a method of: combining the polymeric material and antimicrobial peptide to form a coating material, and applying the coating material to a surface.... Agent: The Government Of The United States Of America, As Represented By The Secretary Of The Navy

20110269670 - Carbohydrate binding molecules: The present invention provides compounds, compositions, medicaments and methods comprising or using carbohydrate binding molecules. More specifically, the invention provides a means of treating diseases and/or conditions caused or contributed to by pathogens, particularly microbial pathogens and methods of screening, identifying, detecting tagging and/or labelling carbohydrates.... Agent:

20110269671 - Nisin derivatives and the use thereof: The present invention relates to a nisin derivative comprising amino acid substitutions in the peptide sequence encoding the hinge region of the protein, wherein the derivative exhibits an increased anti-microbial activity.... Agent: University College Cork - National University Of Ireland, Cork

20110269672 - Antifungal paints and coatings: Antifungal and antibacterial peptides, polypeptides and proteins as antifungal additives for paint and other coatings are disclosed, along with antifungal compositions, and coated surfaces with antifungal properties. Methods of using the coatings for treating and/or inhibiting growth of mold, mildew and other fungi and bacteria on objects such as building... Agent: Reactive Surfaces, Ltd. LLP

20110269673 - Antimicrobial peptides: wherein l, m and n are integers from 0 to 10; X and Y, which may be the same or different, are an amino acid selected from the group consisting of hydrophobic amino acids and/or cationic amino acids, together with methods for the use of the peptides in the treatment... Agent: Novabiotics Limited

20110269675 - Strontium-containing compounds for use in the prevention or treatment of necrotic bone conditions: A method for the treatment and/or prophylaxis of an osteonecrotic bone disease in a mammal in need thereof, such as, e.g., idiopathic or secondary osteonecrosis, avascular bone necrosis, glucocorticoid induced bone ischemia/osteonecrosis, Legg-Calve-Perthes disease and femoral head necrosis, the method comprising administering an effective dose of a strontium-containing compound (a)... Agent: Osteologix A/s

20110269674 - Synthetic or natural peptides binding protein phosphatase 2a, identification method and uses: The present invention relates to novel synthetic or natural peptides for use in treating viral or parasitic infections or in the treatment of tumors. The peptides of the present invention are less than 30 amino acids in size, preferably less than 20 amino acids, in particular 15 to 20 amino... Agent: Universite Paris 6 Pierre Et Marie Curie

20110269676 - Bifunctional molecules for inactivating hiv and blocking hiv entry: Disclosed herein are bifunctional molecules which inactivate human immunodeficiency virus (HIV) even before the virus attacks the target cell and inhibits HIV entry into the target cell. Also disclosed are novel anti-HIV therapeutics for treatment of patients infected by HIV. Further disclosed are methods for prophylaxis against HIV and treatment... Agent: New York Blood Center

20110269677 - Oligomer-protease inhibitor conjugates: The invention provides protease inhibitors that are chemically modified by covalent attachment of a water-soluble oligomer. A conjugate of the invention, when administered by any of a number of administration routes, exhibits characteristics that are different from the protease inhibitors not attached to the water-soluble oligomer.... Agent: Nektar Therapeutics

20110269678 - Nutritional method: A method of improving nutrition and/or treating low grade inflammation in an elderly human subject comprises administering to said subject a cysteine source so as to provide metabolically available cysteine in the diet of said subject in a proportion relative to all available amino acids which is greater that the... Agent: Nestec S.a.

20110269679 - Inhibitors of amyloid fibril formation and uses thereof: The present invention provides new antifibrillogenic agents and peptides, compositions and cells containing same, compositions that bind to same, effective therapeutics for preventing or delaying the progression of, e.g., Alzheimer's disease and diabetes, methods for optimizing antifibrillogenic agents, and methods of using the antifibrillogenic agents, peptides, compositions, and cells of... Agent:

20110269680 - Glp-1 analogs and uses thereof: The present invention relates to a peptide selected from a group comprising GLP-1 analogs, its truncated forms, or pharmaceutically acceptable salts and derivatives thereof. The present invention further relates to a peptide selected from a group comprising GLP-1 analogs, its truncated forms, or pharmaceutically acceptable salts and derivatives thereof, wherein... Agent: Panacea Biotec Limited

20110269681 - Prolactin induced increase in neural stem cell numbers: The present invention provides a method of increasing neural stem cell numbers or neurogenesis by using prolactin. The method can be practiced in vivo to obtain more neural stem cells in situ, which can in turn produce more neurons or glial cells to compensate for lost or dysfunctional neural cells.... Agent: Stem Cell Therapeutics Inc.

20110269682 - Compositions and methods for treatment during non-acute periods following cns neurological injury: This invention relates to treatment of neuroinjury in a post-acute window or in a chronic period following neuroinjury.... Agent: Acorda Therapeutics, Inc.

20110269683 - Receptor(sstr2)-selective somatostatin antagonists: SRIF peptide antagonists, which are selective for SSTR2 in contrast to the other cloned SRIF receptors and which bind with high affinity to the cloned human receptor SSTR2 but do not activate the receptor, have many useful functions. Because they do not bind with significant affinity to SSTR1, SSTR3, SSTR4... Agent: Salk Institute For Biological Studies, The Universitat Bern

20110269684 - Natriuretic polypeptides for reducing or preventing restenosis: Materials and Methods related to using natriuretic polypeptides to reduce proliferation of smooth muscle cells, and to reduce or prevent restenosis.... Agent:

20110269685 - Protease resistant mutants of stromal cell derived factor-1 in the repair of tissue damage: The present invention is directed stromal cell derived factor-1 peptides that have been mutated to make them resistant to digestion by the proteases dipeptidyl peptidase IV (DPPIV) and matrix metalloproteinase-2 (MMP-2) but which maintain the ability of native SDF-1 to attract T cells. The mutants may be attached to membranes... Agent: The Brigham And Women's Hospital, Inc.

20110269686 - Cxcr4 antagonist and use thereof: The present invention provides preventive and/or therapeutic drugs for cancer and chronic rheumatoid arthritis which contain a peptide having a CXCR4 antagonism, its amide, its ester or its salt. Also, the present invention provides a novel peptide having a CXCR4 antagonism, its amide, its ester and its salt.... Agent: Biokine Therapeutics Ltd.

20110269687 - Ifbm's to promote the specific attachment of target analytes to the surface of orthopedic implants: The present invention provides an improved coating for surfaces of medical implants. The coating comprises at least one interfacial biomaterial (IFBM) which is comprised of at least one binding module that binds to the surface of an implant or implant-related material (“implant module”) and at least one binding module that... Agent:

20110269688 - Genetic alterations associated with schizophrenia and methods of use thereof for the diagnosis and treatment of the same: Compositions and methods for the detection and treatment of schizophrenia are provided.... Agent:

20110269689 - High penetration compositions and their applications: High penetration compositions (HPC) of a parent compound, which are capable of crossing biological barriers with high penetration efficiency. The HPCs are capable of being converted to parent drugs or parent drug-related compounds such as metabolites after crossing one or more biological barriers and thus can render treatments for the... Agent:

20110269690 - Water-mediated control of depolymerization step of glatiramer acetate synthesis: Methods of making copolymers are described.... Agent: Momenta Pharmaceuticals, Inc.

20110269692 - Alpha-fetoprotein peptides and uses thereof: Therapeutic compounds which are cell proliferation modulators, preferably inhibitors. These modulators contain amino acid structures that are arranged as a hydrophilic analog of an alpha-fetoprotein. The modulator may be a peptide itself, e.g., an octapeptide like that of SEQ ID NO: 5; a peptidomimetic; or may be in the form... Agent:

20110269691 - Compositions and methods for treating pigmentary conditions and melanoma: A method of treating a hypopigmentary condition in a subject comprising administering to the subject an amount of SOX9 sufficient to treat melanoma is disclosed. The hypopigmentary condition can be a result of surgery, trauma or vitiligo. A method of treating a hyperpigmentary condition in a subject comprising administering to... Agent:

20110269693 - Apparatus for treatment of dermatological conditions: This invention relates to ultrasound delivery apparatus comprising flexible arrays of transducers and to methods and topical compositions for the treatment of skin, in particular for the treatment of cosmetic skin conditions and to improve the appearance of sun damaged and/or aged skin; the invention further relates to the use... Agent: Dermaglaia Ltd.

20110269694 - Novel anti-aging peptides and cosmetic and/or pharmaceutical composition containing same: i

20110269695 - Novel anti-aging peptides and cosmetic and/or pharmaceutical composition containing same: Peptide compounds of general formula (I) R1-(AA)n-X1-Ser-Thr-Pro-X2-(AA)p-R2 were developed that restore the circadian rhythm and resynchronize the biological clock of skin cells. Cosmetic or pharmaceutical compositions that include at least one peptide of general formula (I) in a cosmetically or dermatologically acceptable medium, and a cosmetic treatment method for restoring... Agent: Isp Investments

20110269696 - Inhibitors of iaps: The invention provides novel compounds that are inhibitors of IAPs having the general formula: wherein X1, X2, X3, Y, A, R1, R2, R3, R4, R4′, R5, R5′, R6 and R6′ are as described herein. The compouds of the invention may be used to induce apoptosis in cells (or sensitise cells... Agent: Genentech Inc.

20110269697 - Organoarsenic compounds and methods for the treatment of cancer: A method for treating a lymphoma selected from non-Hodgkin's and Hodgkin's lymphoma comprising administering an organoarsenic compound having a structure of the formula (I) wherein X is S or Se and R1 and R2 are independently C1-30alkyl(R3, R3′, R4, R5, W and “n” are as defined in claim 1) in... Agent:

20110269699 - Cancer therapy: The invention provides therapy for treating cancers, such as Bcl-2+ cancers, and Bcl-XL− cancers, and other neoplasms, using romidepsin. The invention provides, inter alia, methods of treating lymphomas, e.g., lymphomas characterized by one or more of Bcl-2 expression, lack of overexpression of Bcl-XL, lack of overexpression of P-glycoprotein, with romidepsin.... Agent:

20110269698 - Novel cyclic pentadepsipeptide derivative and fusarium strain producing the same: Disclosed is a Fusarium strain producing novel cyclic pentadepsipeptides which are of excellent multidrug resistance-reversing activity and inhibitory activity against cancer cells. Also, novel cyclic pentadepsipeptides are provided as active ingredients of the compositions useful in the treatment of cancer and diseases associated with multidrug resistance.... Agent: Chung-ang University Industry-academy Cooperation Foundation

20110269701 - 7,2''-dehydrate puerarin and its salts, preparation method and use thereof: A 7,2″-dehydrate puerarin represented by formula (I) and salt derivatives thereof. The compounds are prepared from puerarin by intramolecular mitsunobu reaction. They are capable of shortening arrhythmia duration and prolonging coagulation time. They can be prepared into oral formulations or injections for treatment of cardiovascular and cerebrovascular diseases including arrhythmia,... Agent: Shangdong University

20110269700 - Glucoside derivatives and uses thereof: 7

20110269702 - Polyacetylenic compounds for protecting against pancreatic islet atrophy:

20110269703 - Method for treating or preventing thrombosis using dabigatran etexilate or a salt thereof with improved safety profile over conventional warfarin therapy: A method for preventing stroke in a patient suffering from atrial fibrillation, wherein the patient has at least one risk factor for major bleeding events, the method comprising administering to the patient 110 mg b.i.d. of dabigatran etexilate, optionally in the form of a pharmaceutically acceptable salt thereof.... Agent: Boehringer Ingelheim International Gmbh

20110269704 - Method for developing a liquid composition to be applied to the skin as a foam and a composition that can be applied topically: A liquid pharmaceutical composition to be applied to the skin as a foam and that has at least one solvent, at least one active pharmaceutical ingredient, and at least one foaming agent. The foam volume and the foam stability are determined according to a standardized SITA measuring method. The foaming... Agent:

20110269706 - Hydroxamic acid derivatives: The disclosure includes hydroxamic compounds of Formula I: (I) wherein P, Z, and m are defined herein. Also disclosed is a method for treating a neoplastic disease or an immune disease with these compounds.... Agent: Northlake Biosciences LLC

20110269705 - Quinolone compound and pharmaceutical composition: e

20110269814 - 2'-f modified rna interference agents: This invention relates to a method of modulating the expression of a target gene in an organism comprising administering an iRNA agent, wherein the iRNA comprises at least one 2′-deoxy-2′-fluoro (2′-F) nucleotide in the antisense strand and at least one modified nucleotide in the sense strand. The invention also relates... Agent: Alnylam Pharamaceuticals, Inc.

20110269821 - 5' and 2' bis-substituted nucleosides and oligomeric compounds prepared therefrom: The present invention provides modified nucleosides and oligomeric compounds prepared therefrom. More particularyl, the present invention provides modified nucleosides having at least one 5′-substituent and a 2′-O-substituent, oligomeric compounds comprising at least one of these modified nucleosides and methods of using the oligomeric compounds. In some embodiments, the oligomeric compounds... Agent: Isis Pharmaceuticals, Inc.

20110269823 - Compositions and methods for inhibiting expression of the hamp gene: The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the HAMP gene (HAMP gene), comprising an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part... Agent:

20110269817 - Compositions and methods related to sirt1 function: The invention relates to modulation of circadian rhythm and underlying biological processes.... Agent: The Regents Of The University Of California

20110269813 - Gene silencing by single-stranded polynucleotides: The present invention relates to compositions and methods for concurrently activating antisense and double-stranded RNase (dsRNase) mechanisms for inhibiting expression of a targeted gene, by delivering a single stranded bifunctional chimeric DNA/RNA oligonucleotide optimized for siRNA activity as well as antisense activity, into the nucleus of a target cell.... Agent: Genesegues, Inc.

20110269816 - Inhibition of viral gene expression using small interfering rna: The invention provides methods, compositions, and kits comprising small interfering RNA (shRNA or siRNA) that are useful for inhibition of viral-mediated gene expression. Small interfering RNAs as described herein can be used in methods of treatment of HCV infection. ShRNA and siRNA constructs targetING the internal ribosome entry site (IRES)... Agent:

20110269819 - Methods and compositions for targeting skip: Provided herein are methods and compositions for modulating apoptosis by targeting SKIP (Ski-interacting protein) activity. Methods of increasing DNA damage-induced cell death in cancer cells, and reducing DNA damage-induced cell death in normal cells are provided.... Agent: Salk Institute For Biological Studies

20110269815 - Methods of reducing cellular proliferation by inhibiting acsvl3: The present invention is directed to methods of reducing cancer cell proliferation and/or treating cancer by administering a therapeutically effective amount of a compound that inhibits the activity of ACSVL3.... Agent: The Johns Hopkins University

20110269818 - Modulation of prion expression: Disclosed herein are compounds and methods for decreasing PrP and preventing, ameliorating, or treating a prion disease or conformational neurodegenerative disorder, in an individual in need thereof. Examples of disease conditions that can be ameliorated with the administration of antisense compounds targeted to PrP include Creutzfeldt-Jakob disease (CJD); variant Creutzfeldt-Jakob... Agent: Isis Pharmaceuticals, Inc

20110269822 - Rnai-mediated inhibition of histamine receptor h1-related conditions: RNA interference is provided for inhibition of histamine receptor H1 mRNA expression, in particular, for treating patients having an HRH1-related condition or at risk of developing an HRH1-related condition such as allergic conjunctivitis, ocular inflammation, dermatitis, rhinitis, asthma, or allergy.... Agent: Alcon Research, Ltd.

20110269820 - Spinal muscular atrophy treatment via targeting smn2 catalytic core: The present invention is directed to methods and compositions for blocking the effect of the intronic inhibitory splicing region of intron 7 of the SMN2 gene. The compositions and methods of the instant invention include short oligonucleotide reagents (e.g., oligoribonucleotides) that effectively target sites in the SMN2 pre-mRNA, thereby modulating... Agent: Iowa State University Research Foundation, Inc.

20110269824 - Cancer cell death inducing agent having effects of potentiating anticancer drug against anticancer-drug-resistant cancer: The present invention provides a drug capable of causing cancer cells to restore anticancer drug sensitivity in cases in which cancer has acquired resistance to an anticancer drug and inducing cell death in cancer cells. The present invention specifically provides a cancer cell death inducing agent comprising REIC/Dkk-3 DNA as... Agent: Momotaro-gene Inc.

20110269826 - Method: The present invention provides methods for: (i) treating and/or preventing Parkinson's disease in a subject without causing cognitive impairment by using dopamine replacement gene therapy to maintain or restore constant physiological dopaminergic tone in both the dorsal and ventral striatum of the subject; (ii) normalising neuronal electrical activity in basal... Agent: Oxford Biomedica (uk) Limited

20110269825 - Modified thromboxane a2 receptor promoter sequence: The invention provides nucleic acid sequences useful in regulating the transcription of a gene. In particular, the invention relates to a promoter sequence, and variants thereof, that can be used to differentially regulate the transcription of a gene. The present invention, accordingly, provides methods for regulating transcription of a gene,... Agent:

20110269707 - Modified nucleosides for the treatment of viral infections and abnormal cellullar proliferation: e

20110269708 - P2x7 antagonists to treat affective disorders: The present invention provides methods to treat mood disorders and anxiety disorders using antagonists of the P2X7 receptor and pharmaceutical compositions thereof, or combinations.... Agent: Abbott Laboratories

20110269709 - Prodrugs containing novel bio-cleavable linkers: The invention provides the compounds of formula (I) or pharmaceutically acceptable salts thereof. The invention also provides pharmaceutical compositions comprising one or more compounds of formula I or intermediates thereof and one more of pharmaceutically acceptable carriers, vehicles or diluents. The invention further provides methods of preparation and methods of... Agent: Apparao Satyam

20110269710 - Pharmaceutical composition of complex carbohydrates and essential oils and methods of using the same: The invention discloses the discovery that a pharmaceutical composition containing complex carbohydrates with or without natural or synthetic essential oils can work effectively as a topical, oral or mucosal pharmaceutical composition. Such pharmaceutical compositions reduce inflammation, assist in wound healing, protect against bruising, relieve itching, relieve pain and swelling and... Agent:

20110269711 - Methods and compositions for inducing satiety: The present invention provides a medicament or food supplement, that when ingested by an individual, forms a gel mass in the individual's stomach, said gel mass consisting essentially of methylcellulose and water, as well as methods for inducing satiety, reversibly reducing stomach void volume, and reducing caloric intake in an... Agent:

20110269713 - Bryostatin analogues and methods of making and using thereof: Described herein are tricyclic macrolactones. The macrolactones have a high binding affinity for PKC. The compounds described herein can be used in a number of therapeutic applications including cancer and Alzheimer's prevention and treatment. The compounds described herein can also treat memory loss. Also described herein are methods for producing... Agent: University Of Utah Research Foundation

20110269712 - Fungicidal carboxamides: This invention is directed to compounds of Formula (1) including all geometric and stereoisomers, N oxides, and agriculturally suitable salts thereof, agricultural compositions containing them and their use as fungicides, (1) provided that the compound of Formula 1 is other than 2-[1-[(2-chlorophenyl)acetyl]-4-piperidinyl]-N-methyl-N-[(1R)-1-phenylethyl]-4-thiazolecarboxamide and R1 is other than 4-fluorophenyl; wherein R1,... Agent:

20110269714 - Polycyclic tetracycline compounds: i

20110269715 - Abnormal cannabidiols as agents for lowering intraocular pressure:

20110269716 - Antioxidant compounds and methods of their use: The invention relates to antioxidant substituted isoindoline nitroxide compounds and their use in methods of treating or preventing diseases or disorders related to oxidative stress, methods of reducing oxidative stress and methods of protecting a subject from oxidative stress upon exposure to ionising radiation. Pharmaceutical compositions comprising the antioxidant compounds... Agent: Queensland University Of Technology

20110269717 - Neurogenesis by modulating angiotensin: The instant invention describes methods for treating diseases and conditions of the central and peripheral nervous system by stimulating or increasing neurogenesis. The invention includes compositions and methods based on modulating angiotensin activity to stimulate or activate the formation of new nerve cells.... Agent: Braincells Inc.

20110269718 - Pharmaceutical composition containing malathion and volatile cyclic silicone: The invention described comprises using volatile silicone oils in stabilising malathion. The invention also comprises pediculicidal and/or nit-killing compositions comprising malathion and volatile silicone oils and also excipients for topical use.... Agent: Pierre Fabre Dermo-cosmetique Corporation

20110269719 - Pharmaceutical compositions with phosphonium antimicrobial agents: The present invention is related to pharmaceutical compositions that include a phosphonium antimicrobial agent. In a preferred embodiment, the present invention relates to an otic, nasal or ophthalmic composition (e.g., an aqueous ophthalmic solution) that includes a phosphonium salt compound as an antimicrobial agent. The compositions typically possess sufficient antimicrobial... Agent:

20110269720 - Minocycline and rifampin microparticles: Methods and kits for treating infection associated with implantation of a medical device use of minocycline and rifampin microparticles. The microparticles, in a suitable medium, can be injected in a patient in proximity to the device. The drugs may be configured to be released from the polymer matrix in a... Agent: Medtronic, Inc.

20110269721 - Methods of treating thalassemia: Provided herein are method of treating, ameliorating, or delaying at least one symptom of a genetic blood disorder, e.g. sickle cell disorder or thalassemia, in a patient in need thereof, comprising administering a therapeutically effective amount of a Jak2 inhibitor. Also provided in part is a method of reducing an... Agent: Targegen, Inc.

20110269722 - Prodrugs containing novel bio-cleavable linkers: The invention provides the compounds of formula (I) or pharmaceutically acceptable salts thereof. The invention also provides pharmaceutical compositions comprising one or more compounds of formula I or intermediates thereof and one more of pharmaceutically acceptable carriers, vehicles or diluents. The invention further provides methods of preparation and methods of... Agent: Apparao Satyam

20110269723 - Spill resistant formulations containing clays: The invention relates to novel spill resistant formulations comprising either a weak base or a weak acid as the pharmaceutical ingredient, a liquid base, a clay and a water soluble cellulose ether. The clay and cellulose ether allow for a broader pH range into which the pharmaceutically active agent may... Agent: Taro Pharmaceuticals U.s.a., Inc.

20110269724 - Combination therapy with non-selective cox inhibitors to prevent cox-related gastric injuries: The present invention is directed to nicotinamide, nicotinamide derivatives and prostaglandin mimetics, alone or in combination with an NSAID, and their use in treating pain, inflammation, and/or gastrointestinal toxicty,... Agent: Cortria Corporation

20110269725 - Novel estrogenic compounds: wherein the bond represented by the wavy line may be a single or double bond such that when the wavy line is a single bond, R1 is selected from the group consisting of hydrogen, sulfate and glucoronate or other esters, and when the wavy line is a double bond, R1... Agent:

20110269727 - Composition to reduce allodynic back pain and related method of use: The invention relates to a pharmaceutical composition to reduce back pain comprising two compounds: an opioid antagonist and a direct-acting alpha 2 adrenegic agonist. The Opioid antagonist is selected from the group consisting of alvimopan, nalmefene, naloxone, naltrexone, methylnaltrexone, nalorphine, and pharmaceutically acceptable salt. The direct-acting alpha 2 adrenegic agonist... Agent:

20110269726 - Method of and system for treatment of inflammatory skin conditions: For treating inflammatory skin conditions a treatment cream including hydrocortisone is applied on a skin; and the applying the treatment cream is combined with treatment of the skin with moisturizer with a moisturizer.... Agent:

20110269728 - Methods and compositions related to glucocorticoid receptor antagonists and breast cancer: Embodiments of the invention are directed to methods of determining the prognosis of a breast cancer patient by evaluating the activity of the glucocorticoid receptor in tumor cells. Other embodiment include methods of treating breast cancer cells, particularly, chemo-resistant cells, with a glucocorticoid receptor antagonist and an anticancer agent or... Agent:

20110269729 - Testosterone gel and method of use: The present invention relates to an improved transdermal hydroalcoholic testosterone gen formulation that provides, among other things, a desirable pharmacokinetic hormone profile, and methods of use.... Agent:

20110269730 - Metal complexes of thiourea and derivatives as metal delivering anti-cancer and anti-inflammatory agents: The present invention relates to metal thiourea complexes comprising N-substituted thiourea ligands and sulfur-coordinated metal ions, and methods for using the metal thiourea complexes for delivering otherwise unstable or impermeable metal ions to mammalian cells, for inhibiting cancer cell growth and inflammation, and for inhibiting the activities of associated drug... Agent:

20110269731 - Nanoparticles of beta-lactam derivatives: The present invention relates to a complex made up of at least one beta-lactam molecule covalently bonded to at least one hydrocarbon radical including at least 18 carbon atoms and containing at least one unit of 2-methyl-buta-2-ene, to nanoparticles of said complexes, and to a method for preparing same, said... Agent:

20110269735 - Genetic polymorphisms associated with statin response and cardiovascular diseases, methods of detection and uses thereof: The present invention provides compositions and methods based on genetic polymorphisms that are associated with response to statin treatment, particularly for reducing the risk of cardiovascular disease, especially coronary heart disease (such as myocardial infarction) and stroke. For example, the present invention relates to nucleic acid molecules containing the polymorphisms,... Agent: Celera Corporation

20110269736 - 1,1'-diadamantyl carboxylic acids, medicaments containing such compounds and their use: The present invention relates to compounds defined by formula (I) wherein the group R is defined as in claim 1, possessing valuable pharmacological activity. Particularly the compounds are inhibitors of 11 β-hydroxysteroid dehydrogenase (HSD) 1 and thus are suitable for treatment and prevention of diseases which can be influenced by... Agent: Boehringer Ingelheim International Gmbh

20110269737 - 7-(piperazine-1-ymethyl)-1h-indole-2-carboxylic acid (phenyl)-amide derivatives and allied compounds as p38 map kinase inhibitors for the treatment of respiratory diseases: e

20110269738 - Compounds: The present invention relates to novel compounds having pharmacological activity, processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of various disorders.... Agent: Glaxo Group Limited

20110269732 - Drug discovery methods: The present invention relates to drug discovery methods, particularly methods for assaying compounds for activity as Aurora kinase inhibitors. This invention also relates to a pharmacophore describing compounds that are able to promote a conformational change in the protein AuroraB and whose binding constant for the two-step process is given... Agent: Vertex Pharmaceuticals Incorporated

20110269734 - Piperidinyl gpcr agonists: Compounds of formula (I):or pharmaceutically acceptable salts thereof, are GPCR agonists and are useful as for the treatment of diabetes and obesity.... Agent: Prosidion Limited

20110269733 - Silent desensitizers of neuronal nachr and methods of use thereof: One aspect of the present invention relates to heterocyclic compounds that are ligands for nicotinic acetylcholine receptors. A second aspect of the invention relates to the use of a compound of the invention for modulation of a mammalian nicotinic acetylcholine receptor.... Agent: Georgetown University

20110269740 - Jak kinase modulating compounds and methods of use thereof: Provided herein are pyrrolotriazine compounds for treatment of JAK kinase, including JAK2 kinase mediated diseases. Also provided are pharmaceutical compositions comprising the compounds and methods of using the compounds and compositions.... Agent: Ambit Biosciences Corporation

20110269739 - Kinase inhibitors: The present invention provides a new group of protein kinase inhibitors, pyrido[4,3,-d]pyrimidin-5-one derivatives, and pharmaceutically acceptable salts thereof that are useful for intreating cell proliferative disease and disorder such as cancer, autoimmune diseases, infection, cardiovascular disease and neurodegenerative disease and disorder. The present invention provides methods for synthesizing and administering... Agent: Genosco

20110269741 - Novel compositions and methods of use: Described herein are novel enzyme inhibitors. In some embodiments the enzyme inhibitors are integrase inhibitors, particularly HIV integrase inhibitors. Also described herein are compositions containing them and methods of using them. Thus, the compounds and compositions described herein are useful for the in vitro and in vivo inhibition of HIV... Agent: Ardea Biosciences, Inc.

20110269742 - Serotonin 5-ht2b receptor inhibitors: Disclosed are Serotonin 5-HT2B receptor inhibitors of the formula I. Also disclosed are methods of making and methods of using these compounds.... Agent: Boehringer Ingelheim International Gmbh

20110269743 - Phenylthiophenyldihydrobenzothiazepine inhibitors of store operated calcium release: Described herein are compounds and pharmaceutical compositions containing such compounds, which modulate the activity of store-operated calcium (SOC) channels. Also described herein are methods of using such SOC channel modulators, alone and in combination with other compounds, for treating diseases, disorders or conditions that would benefit from inhibition of SOC... Agent: Calcimedica, Inc

20110269744 - Benzazepine compound: [Means for Solution] The present inventors have investigated compounds having a 5-HT2C receptor agonist activity, which is promising as an active ingredient of a pharmaceutical composition for treating or preventing incontinence such as stress urinary incontinence, urge urinary incontinence, mixed urinary incontinence, and the like, sexual dysfunction such as erectile... Agent: Astellas Pharma Inc.

20110269745 - 6-arylalkylamino-2,3,4,5-tetrahydro-1h-benzo[d]azepines as 5-ht2c receptor agonists: The present invention provides 6-substituted 2,3,4,5-tetrahydro-1H-benzo[d]azepines of Formula (I) as selective 5-HT2c receptor agonists for the treatment of 5-HT2c associated disorders including obesity, obsessive/compulsive disorder, depression, and anxiety, where, R6 is —NR10R11, where R10 is substituted phenylalkyl or substituted pyridylalkyl and other substituents are as defined in the specification.... Agent: Eli Lilly And Company

20110269746 - Cyclic compound having hetero atom: e

20110269747 - Polyarylcarboxamides useful as lipid lowering agents:

20110269748 - 2-aniline-4-aryl substituted thiazole derivatives: Ar represents phenyl optionally substituted with halo, C1-6alkyl, C1-6alkyl-O— or polyhaloC1-6alkyl; for the manufacture of a medicament for the prevention or the treatment or prophylaxis of psychotic disorders, intellectual impairment disorders or diseases or conditions in which modulation of the α7 nicotinic receptor is beneficial.... Agent:

20110269749 - Tricyclic carbamate jak inhibitors: The present disclosure relates to 2,4-pyrimidinediamines substituted with tricyclic carbamates and the compositions and methods using these compounds in the treatment of conditions in which modulation of the JAK pathway or inhibition of JAK kinases, such as JAK2 or JAK3, is therapeutically useful.... Agent: Rigel Pharmaceuticals, Inc.

20110269750 - Roflumilast for the treatment of diabetes mellitus: The application relates to specific combinations of Roflumilast and/or Roflumilast N-Oxide and a PPAR-agonist, as well as their use in the treatment of diabetes mellitus type 2.... Agent: Nycomed Gmbh

20110269751 - Heterocyclic nitrogenous or oxygenous compounds with insecticidal activity formed from dialdehydes and their preparation and uses thereof: The heterocyclic nitrogenous or oxygenous compounds of formula (A), (B), (C) or (D) formed from dialdehydes, their optical isomers, cis- and trans- isomers, or agrochemically acceptable salts, their preparation methods, agrochemical compositions comprising the compounds and the uses thereof are provided. The compounds and their derivatives have high insecticidal activities... Agent: East China University Of Science And Technology

20110269752 - Imidazo[1,2-b]pyridazine derivatives and their use as pde10 inhibitors: The present invention relates to novel imidazo[1,2-b]pyridazine derivatives which are inhibitors of the phosphodiesterase 10 enzyme (PDE10) and which are useful for the treatment or prevention of neurological, psychiatric and metabolic disorders in which the PDE10 enzyme is involved. The invention is also directed to pharmaceutical compositions comprising such compounds,... Agent:

20110269753 - Heterocyclic compounds as phosphodiesterase inhibitors: Compounds of the formula (I), their derivatives, analogs, tautomeric forms, regioisomers, stereoisomers, polymorphs, solvates, intermediates, pharmaceutically acceptable salts, pharmaceutical compositions, N-oxides, metabolites and prodrugs thereof. These compounds are phosphodiesterase type 4 (PDE4) inhibitors. They are useful in the treatment of a variety of allergic or inflammatory diseases including asthma, COPD,... Agent: Orchid Research Laboratories Ltd.

20110269754 - Compounds and compositions for reducing lipid levels: Compositions comprising extracts or isolated or purified compounds from plants of the genus Corydalis provide prevention and treatment of hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, hepatic steatosis, and metabolic syndrome. Corydalis compounds and their derivatives of natural and synthetic origins lower total cholesterol, LDL-cholesterol, and triglycerides and increase hepatic LDL receptor expression and... Agent:

20110269755 - Compositions and methods for treating vascular, autoimmune, and inflammatory diseases: The disclosure provides compositions and methods for the treatment of vascular, autoimmune, and inflammatory diseases using a combination of an inosine monophosphate dehydrogenase (IMPDH) inhibitor and a HMG CoA reductase inhibitor.... Agent: Aspreva International Ltd.

20110269756 - Benzothiazolone derivatives: Compounds of the formula I, in which R1, R2, R3, R3′, R4, R4′, E, E′, E″ and E′″ have the meanings indicated in Claim 1, are inhibitors of tyrosine kinases, in particular Met kinase, and can be employed, inter alia, for the treatment of tumours.... Agent: Merck Patent Gesellschaft Mit Beschrankter Haftung

20110269757 - Pyrazolo pyridine derivatives as nadph oxidase inhibitors: The present invention is related to pyrazolo pyridine derivatives of Formula (I), pharmaceutical composition thereof and to their use for the treatment and/or prophylaxis of disorders or conditions related to Nicotinamide adenine dinucleotide phosphate oxidase (NADPH Oxidase).... Agent: Genkyotex Sa

20110269758 - Naphthyridinones as protein kinase inhibitors: Naphthyridinone derivative compounds that inhibit Aurora kinase enzymes are disclosed along with pharmaceutical compositions comprising these compounds and methods for synthesizing the same. Such compounds have utility in the treatment of proliferative diseases resulting from unregulated and/or disturbed Aurora kinases such as cancers, psoriasis, viral and bacterial infections, inflammatory and... Agent: Merck Patent Gmbh

20110269759 - Pyrimidine compounds as delta opioid receptor modulators: p

20110269760 - Tubulin inhibitors: Compounds of general formula (I), (II), (III) and (V) are described for use in modulating microtubule polymerisation and in the treatment of associated disease states. Use of compounds (I), (III) and (V) in the treatment of kinase-associated disease states is also described. Further described are novel compounds of formula (II),... Agent: Cytopia Research Pty Ltd

20110269761 - Arylsulphonylglycine derivatives, the preparation thereof and their use as medicaments: The invention relates to substituted aryl-sulphonylglycine derivatives of general formula (I) wherein the groups Ra to Rf, A and Z are defined as in the specification and claims, which are suitable for preparing a pharmaceutical composition for the treatment of metabolic disorders, particularly type 1 or type 2 diabetes mellitus.... Agent: Boehringer Ingelheim International Gmbh

20110269762 - Methods for treating atrial fibrillation and reducing stroke rate in atrial fibrillation patients: The subject invention provides methods for reducing stroke rate, methods for preventing atrial remodeling, and methods for reversing atrial remodeling by administering budiodarone to reduce atrial fibrillation (AF) episode duration and an anticoagulant (AC). According to some methods of the invention, the average AF episode duration can be reduced to... Agent:

20110269763 - Crth2 receptor ligands for medicinal uses: wherein A represents a carboxyl group —COOH, or a carboxyl bioisostere; A1 is hydrogen or methyl; ring Ar1 is an optionally substituted phenyl ring or 5- or 6-membered monocyclic heteroaryl ring, in which AA1CHO— and L2 are linked to adjacent ring atoms; rings Ar2, Ar3 each independently represent a phenyl... Agent: 7tm Pharma A/s

20110269764 - Therapeutic approaches for treating alzheimer disease and related disorders through a modulation of synapse function: The present invention relates to compositions and methods for the treatment of Alzheimer's disease and related disorders. More particularly, the invention relates to combined therapies that modulate synapse function for treating said disease.... Agent: Pharnext

20110269766 - Benzimidazole-4-carboxamide derivatives, their preparation methods, pharmaceutical compositions and their uses: The present invention relates to the benzimidazole-4-carboxamide derivatives, their preparation methods, pharmaceutical compositions and their uses; wherein X represents monosubstituted or bissubstituted or polysubstitued C1-C14 alkoxy, monosubstituted or bisubstituted or polysubstitued C1-C14 alkyl, monosubstituted or bisubstituted or polysubstitued C2-C14 alkenyl, monosubstituted or bisubstituted or polysubstitued C6-C14 aryl, or monosubstituted or... Agent:

20110269767 - Novel polymorphic forms of 3-(1--6-oxo-1,6-dihydro-pyridazin-3-yl)-benzonitrile hydrochloride salt and processes of manufacturing thereof: The present invention relates to 3-(1-{3-[5-(1-methyl-piperidin-4-ylmethoxy)-pyrimidin-2-yl]-benzyl}-6-oxo-1,6-dihydro-pyridazin-3-yl)-benzonitrile hydrochloride solvates and crystalline modifications thereof. The present invention further relates to processes of manufacturing these crystalline modifications as well as their use in the treatment and/or prophylaxis of physiological and/or pathophysiological conditions, which are caused, mediated and/or propagated by the inhibition, regulation and/or... Agent: Merck Patent Gesellschaft Mit Beschrankter Haftung

20110269765 - Pyridazinone derivatives: Compounds of the formula (I) in which D, R1, R2, R3, R4 have the meanings indicated in Claim 1, are inhibitors of tyrosine kinases, in particular of Met kinase, and can be employed, inter alia, for the treatment of tumours.... Agent: Merck Patent Gmbh

20110269768 - Urotensin ii receptor antagonists: m

20110269769 - Imidazole derivatives useful as inhibitors of faah: The present invention is directed to certain imidazole derivatives which are useful as inhibitors of Fatty Acid Amide Hydrolase (FAAH). The invention is also concerned with pharmaceutical formulations comprising these compounds as active ingredients and the use of the compounds and their formulations in the treatment of certain disorders, including... Agent:

20110269770 - Pyrazole compounds for controlling invertebrate pests: The present invention further relates to a method for controlling invertebrate pests, to a method for protecting plant propagation material and/or the plants which grow therefrom, to plant propagation material, comprising at least one compound according to the present invention, to a method for treating or protecting an animal from... Agent: Basf Se

20110269771 - Pyridazinone derivatives: Compounds of the formula (I), in which D, R1, R2, R3, R4 have the meanings indicated in claim 1, are inhibitors of tyrosine kinases, in particular of Met kinase, and can be employed, inter alia, for the treatment of tumours.... Agent:

20110269772 - Axl kinase inhibitors: Axl kinase inhibitory compounds are disclosed, as well as compositions and methods of using the same in the treatment of cancer and other conditions mediated by and/or associated with Axl kinase.... Agent: Supergen, Inc.

20110269773 - Dihydrofuro pyrimidines as akt protein kinase inhibitors: The present invention provides compounds, including resolved enantiomers, diastereomers, solvates and pharmaceutically acceptable salts thereof, comprising the Formula (I): Also provided are methods of using the compounds of this invention as AKT protein kinase inhibitors and for the treatment of hyperproliferative diseases such as cancer.... Agent:

20110269774 - Pyrazolylaminopyridines as inhibitors of fak: e

20110269775 - Piperazine derivatives:

20110269776 - Treatment of oxidative stress disorders including contrast nephropathy, radiation damage and disruptions in the function of red cells: Methods of treating or suppressing oxidative stress diseases and symptoms related to oxidative stress affecting normal electron flow in the cells or caused by reactive oxygen species with redox-active therapeutics. Use of redox-active therapeutics for the reduction, suppression or treatment of oxidative stress induced by chemical agents such as contrast... Agent: Edison Pharmaceuticals, Inc.

20110269777 - Methods and compositions for treating schizophrenia using antipsychotic combination therapy: The present invention relates to combination therapies and methods for treating, preventing and/or delaying the onset and/or development of schizophrenia, wherein the combination therapies comprise a hydrogenated pyrido[4,3-b]indole or a pharmaceutically acceptable salt thereof, such as dimebon, and an antipsychotic.... Agent: Medivation Neurology, Inc.

20110269778 - Novel diphenyl purine derivatives useful as modulators of nicotinic acetylcholine receptors: This invention relates to novel (6-phenyl-5-amino/nitro-pyrimidin-4-yl)-phenyl-amines, which are found to be modulators of the nicotinic acetylcholine receptors. Due to their pharmacological profile the compounds of the invention may be useful for the treatment of diseases or disorders as diverse as those related to the cholinergic system of the central nervous... Agent: Neurosearch A/s

20110269779 - Methods and compositions for treatment of ophthalmic conditions: The present invention provides chemical entities or compounds and pharmaceutical compositions thereof that are capable of modulating signal transduction by certain protein kinases such as mTor, tyrosine kinases, and/or lipid kinases such as PB kinase in an ocular tissue. Also provided in the present invention are methods of using these... Agent: Intellikine, Inc.

20110269780 - Aza-benzimidazolone chymase inhibitors: Disclosed are small molecule inhibitors of the formula (I): and the pharmaceutical compositions thereof and processes of making the same. The compounds are useful in treating various diseases and conditions involving chymase.... Agent: Boehringer Ingelheim International Gmbh

20110269781 - Compounds: The present invention includes novel compounds useful in the treatment of various disorders in particular infectious diseases, cancer, and allergic diseases and other inflammatory conditions for example allergic rhinitis and asthma, and as vaccine adjuvants.... Agent: Glaxosmithkline LLC

20110269782 - Use of nmda activity enhancers to treat hypersomnia, reduced wakefulness or reduced vigilance: The present invention discloses the use of an enhancer of NMDA activity that acts via the glycine modulatory site to treat hypersomnia, reduced wakefulness or reduced vigilance as well as methods for preparing such compounds.... Agent:

20110269783 - Novel 2,3-diamino-quinazolinone derivatives and their medical use: The present invention relates to novel 2,3-diamino-quinazolinone derivatives having medical utility, to use of the derivatives for the manufacture of a medicament, to pharmaceutical compositions comprising the derivatives, and to methods of treating a disorder, disease or a condition responsive to activation of Kv7 channels.... Agent: Neurosearch A/s

20110269784 - Use of tetrahydropyrimidines: e

20110269785 - Substituted 2-aminoacetamides and the use thereof: and to pharmaceutically acceptable salts and prodrugs thereof, wherein the substituents are defined herein. The invention is also directed to the use of substituted 2-aminoacetamides in methods for the treatment of neuronal damage following global and focal ischemia, and for the treatment, prevention or amelioration of pain, anxiety, or manic... Agent: Purdue Neuroscience Company

20110269786 - Treatment of major adverse cardiac events and acute coronary syndrome in diabetic patients using secretory phospholipase a2 (spla2) inhibitor or spla2 inhibitor combination therapies: Administration of sPLA2 inhibitors in combination with statins has been found to reduce the occurrence of major adverse cardiac events (MACEs), specifically unstable angina (UA) requiring urgent hospitalization, in diabetic subjects who have recently experienced an index ACS event to a significantly greater degree than statins alone. These results were... Agent:

20110269787 - Azabicyclic compounds as alpha-7 nicotinic acetylcholine receptor ligands: The disclosure provides compounds of formula I, including their salts, as well as compositions and methods of using the compounds. The compounds are ligands for the nicotinic α7 receptor and may be useful for the treatment of various disorders of the central nervous system, especially affective and neurodegenerative disorders.... Agent: Bristol-myers Squibb Company

20110269788 - Spiro-oxindole-derivatives as sodium channel blockers: This invention is directed to spiro-oxindole compounds of formulas (I), (II), (III), as stereoisomers, enantiomers, tautomers thereof or mixtures thereof; or pharmaceutically acceptable salts, solvates or prodrugs thereof, for the treatment and/or prevention of sodium channel-mediated diseases or conditions, such as pain.... Agent: Xenon Pharmaceuticals Inc.

20110269789 - Compositions and methods for achieving sustained therapeutic drug concentrations in a subject: Provided herein are compounds and methods for achieving a sustained therapeutic effect of small molecule anti-cancer agents when administered in vivo.... Agent: Nektar Therapeutics

20110269790 - Novel thienopyridines as pharmacologically active agents: The present invention provides compounds and pharmaceutically acceptable salts thereof methods for synthesizing thienopyridines and methods for inhibiting TNF-α activity for the treatment of cancer, asthma, arthritis, diabetes and inflammation. Provided are compounds of formula (I).... Agent:

20110269791 - Alicyclic carboxylic acid derivatives of benzomorphans and related scaffolds, medicaments containing such compounds and their use: The present invention relates to compounds defined by Formula (I), wherein the groups A, B, X, m, n and o are defined as in claim 1, possessing valuable pharmacological activity. Particularly the compounds are inhibitors of 11β-hydroxysteroid dehydrogenase (HSD) 1 and thus are suitable for treatment and prevention of diseases... Agent: Boehringer Ingelheim International Gmbh

20110269792 - Compositions useful for treating irritable bowel syndrome: The present invention relates to a method of treating irritable bowel syndrome with constipation (IBS-c) or irritable bowel syndrome with alternating constipation and diarrhea (IBS-a) in a subject in need of treatment. The method comprises administering to said subject a therapeutically effective amount of a thieno[3,2-b]pyridine compound of Structural Formula... Agent: Edusa Pharmaceuticals, Inc.

20110269793 - Method for preventing tau protein aggregation and treating alzheimer's disease with a quinoline derivative compound: e

20110269794 - External preparation for athlete's foot treatment: External preparations for athlete's foot treatment capable of enhancing patient's compliance and capable of reducing the symptom of rubefaction, comprising an anti-trichophyton drug mixed with at least one compound selected from among 1-menthol, menthol analogue compounds and bactericidal compounds.... Agent: Hisamitsu Pharmaceutical Co., Inc.

20110269795 - Use of glucosidase inhibitors for therapy of mucovisidosis: A method provides for the use of glycosidase inhibitors selected from compounds of general formula (1), wherein R1 represents a CH3 group, or CH2OH, R2 represents H or an alkyl group having 1-5 carbon atoms, or R1 and R2 together form a group having formula (II), with carbon in position... Agent: Centre National De La Recherche Scientifique (cnrs)

20110269797 - Anln protein as an endocrine treatment predictive factor: The present invention provides methods, uses and means for breast cancer prognostics and treatment prediction. Provided methods comprises the steps of: providing a sample earlier obtained from a breast cancer subject; evaluating the amount of ANLN protein present in at least part of said sample, and determining a sample value... Agent: Atlas Antibodies Ab

20110269796 - Use of levocabastine for modulating generation of pro-inflammatory cytokines: A composition for modulating generation of pro-inflammatory cytokines comprises levocabastine or a pharmaceutically acceptable salt or ester thereof. Such composition is useful for treating or controlling diseases having an inflammatory component, such as ocular diseases that are caused by inflammation or have inflammatory sequelae.... Agent:

20110269799 - Method for treating or preventing thrombosis using dabigatran etexilate or a salt thereof with improved efficacy over conventional warfarin therapy: A method for preventing stroke in a patient suffering from atrial fibrillation, wherein the patient has no risk factors for major bleeding events, the method comprising administering to the patient 150 mg b.i.d. of dabigatran etexilate, optionally in the form of a pharmaceutically acceptable salt thereof.... Agent: Boehringer Ingelheim International Gmbh

20110269798 - Precursor phase and use thereof for preparing the magnesium tetrahydrate salt of an omeprazole enantiomer: A precursor phase of the magnesium tetrahydrate salt of an omeprazole enantiomer, and also processes for preparing it and its use for the preparation of the magnesium tetrahydrate salt are described. Crystals of the magnesium tetrahydrate salt thus obtained, and their uses, especially in the synthesis of the dihydrate form... Agent: Produits Chimiques Auxiliaires Et De Synthese

20110269800 - P38 map kinase inhibitors: There is provided a compound of formula (I) or a pharmaceutically acceptable salt or solvate thereof, including all tautomers thereof, compositions comprising the same, use of said compound and compositions for treatment, in particular for the treatment of asthma and COPD, and processes for the preparation of said compound.... Agent:

20110269801 - Use of 1-hydroxy-2-pyridones for the treatment of seborrheic dermatitis: Compounds of the formula (I) are disclosed and are suitable for the treatment of seborrheic dermatitis.... Agent:

20110269802 - Method of delivery of perishable liquid mixtures using mixing cap and container system: Methods for preparing and delivering perishable liquid mixtures comprising at least one active ingredient. The methods use systems comprising vessels having novel barriers for segregating solvent liquids from active ingredients prior to preparation. Novel liquid mixtures having therapeutic properties are also disclosed.... Agent:

20110269803 - Azole compounds used as tuberculostatic and leishmanicide agents: while radical Rn can be located in any one or in more than one of the carbon atoms of the aromatic ring, and these radicals can be equal or different, represented by hydrogen, alkylic groups with 1 or more carbon atoms in a linear or branched chain alkenes or alkynes,... Agent: Fundacao Oswaldo Cruz - Fiocruz

20110269804 - Insecticidal compounds: i

20110269805 - Method of treating sensorimotor disorders with 4-(1-(2,3-dimethylphenyl)ethyl)-1h-imidazole-2(3h)-thione: Disclosed herein is a method of treating sensorimotor disorders comprising administering to a subject in need of such treatment 4-(1-(2,3-dimethylphenyl)ethyl)-1H-imidazole-2(3H)-thione.... Agent:

20110269806 - 2-(2-hydroxybiphenyl-3-yl)-1h-benzoimidazole-5-carboxamidine derivatives as factor viia inhibitors: The present invention relates to novel inhibitors of Factors VIIa, IXa, Xa, XIa, in particular Factor VIIa, pharmaceutical compositions comprising these inhibitors, and methods for using these inhibitors for treating or preventing thromboembolic disorders, cancer or rheumatoid arthritis. Processes for preparing these inhibitors are also disclosed.... Agent: Pharmacyclics, Inc.

20110269808 - Compositions comprising (s)-2-amino-1-(4-chlorophenyl)-1-[4-(1h-pyrazol-4-yl)-phenyl]-ethanol as modulator of protein kinases: The invention provides a composition comprising (S) 2-amino-1-(4-chloro-phenyl)-1-[4-(1H-pyrazol-4-yl)-phenyl]-ethanol, wherein the composition is either substantially free of (R) 2-amino-1-(4-chloro-phenyl)-1-[4-(1H-pyrazol-4-yl)-phenyl]-ethanol or the composition contains a mixture of the (S) and (R) enantiomers in which the (S) enantiomer predominates. Also provided are processes for the preparation of the (S) 2-amino-1-(4-chloro-phenyl)-1-[4-(1H-pyrazol-4-yl)-phenyl]-ethanok novel process intermediates... Agent: The Institute Of Cancer Research: Royal Cancer Hospital

20110269807 - Novel treatment for age related macular degeneration and ocular ischemic disease associated with complement activation by targeting 5-lipoxygenase: The invention relates to compounds, compositions, drug delivery systems, and methods for treating age-related macular degeneration (AMD) and ocular ischemic disease in an individual in need.... Agent: Allergan, Inc.

20110269809 - Spiroindolinone pyrrolidines: e

20110269810 - Selective inhibitors of c-jun n-terminal kinase: Compositions and methods for treating, preventing, or ameliorating one or more symptoms, disorders, or conditions associated with particular c-Jun N-terminal kinase(s) (JNKs) activity are provided. Compositions contain small molecules such as pyrazoloanthrones.... Agent: Mayo Foundation For Medical Education And Research

20110269811 - Inhibitors of semicarbazide-sensitive amine oxidase (ssao) and vap-1 mediated adhesion useful for treatment and prevention of diseases: Compositions and methods of using compositions for treatment of inflammatory diseases and immune disorders are provided. Allylamino compounds are disclosed which are inhibitors of semicarbazide-sensitive amine oxidase (SSAO) and/or vascular adhesion protein 1 (VAP-1). The compounds have therapeutic utility in suppressing inflammation and inflammatory responses, and in treatment of several... Agent:

20110269812 - Novel benzylidene-indolinone and their medical and diagnostic uses: The present invention relates generally to organic chemistry, biochemistry, pharmacology and medicine. More particularly, it relates to 3-benzylidene-indolin-2-one derivatives and their physiologically acceptable salts and prodrugs which modulate the activity of protein kinases (“PKs”), especially protein tyrosine kinase, and, therefore, are expected to exhibit a salutary effect against disorders related... Agent: National University Of Singapore

20110269828 - Compositions and methods for treating and preventing weight-related disorders in companion animals: The invention encompasses compositions and methods for treating or preventing disorders in companion animals, wherein the compositions and methods include feeding the companion animal a composition including lipoic acid or a salt thereof.... Agent: Hill's Pet Nutrition, Inc.

20110269827 - Use of lipoic acid for treating or preventing degenerative joint conditions, osteoarthritis, cartilage damage, and related disorders in companion animals: The invention encompasses pet food compositions and uses thereof for the treatment and/or prevention of diseases or disorders in companion animals, for example, for the treatment or prevention of degenerative joint conditions, osteoarthritis, cartilage damage, and maintaining or increasing bone mineral density, wherein the compositions and uses include feeding a... Agent: Hill's Pet Nutrition, Inc.

20110269829 - Non-aqueous taxane pro-emulsion formulations and methods of making and using the same: Non-aqueous taxane pro-emulsion formulations are provided. Pro-emulsion formulations of embodiments of the invention include a taxane, an oil component, a surfactant component and, optionally, a non-aqueous solvent component. Also provided are methods of making and using the pro-emulsion formulations, as well as kits that include the pro-emulsion formulations.... Agent:

20110269830 - Statin nanoparticles: The present invention relates to a complex made up of at least one molecule of statin or a derivative thereof, covalently bonded to at least one hydrocarbon radical including at least 18 carbon atoms and containing at least one 2-methyl-buta-2-ene unit, to nanoparticles of such a complex, and to a... Agent:

20110269831 - Reducing nephropathy with inhibitors of soluble epoxide hydrolase and epoxyeicosanoids: The invention provides uses and methods for reducing nephropathy in persons with diabetes mellitus (particularly Type 2 diabetes), in persons with metabolic syndrome, in persons with triglyceride levels over 215 mg/dL, and in persons with a cholesterol level over 200 mg/dL, by administering an inhibitor of soluble epoxide hydrolase (“sEH”).... Agent: The Regents Of The University Of California

20110269832 - Use of propineb as bird repellent: The present invention relates to the novel use of Propineb as bird repellent.... Agent: Bayer Cropscience Ag

20110269833 - Continuous administration of dopa decarboxylase inhibitors and compositions for same: Disclosed herein are compositions that include for example the arginine salt of carbidopa, and methods for treating neurological or movement diseases or disorders such as restless leg syndrome, Parkinson's disease, secondary parkinsonism, Huntington's disease, Parkinson's like syndrome, PSP, MSA, ALS, Shy-Drager syndrome and conditions resulting from brain injury including carbon... Agent:

20110269834 - Compounds and methods for treating respiratory diseases: Described herein are compounds and compositions, and methods for using the compounds and compositions, for treating respiratory diseases and illness, such as severe acute respiratory syndrome (SARS).... Agent: Purdue Research Foundation

20110269835 - Female sex pheromone of the dogwood borer (dwb), synanthedon scitula, and attraction inhibitor (antagonist): A method for inhibiting (antagonizing) male Synanthedon scitula attraction to female Synanthedon scitula, involving exposing a Synanthedon scitula population to a composition containing E,Z-3,13-octadecadienyl acetate in a quantity sufficient to inhibit (antagonize) male Synanthedon scitula attraction to female Synanthedon scitula, and optionally a carrier material or carrier.... Agent:

20110269836 - Intrathecal baclofen pharmaceutical dosage forms and related delivery system: According to the subject invention, there is disclosed, a dosage and packaging configuration which includes the use of color-coded pre-filled syringes and vials to fill and refill infusion systems with existing and new dosage forms of intrathecal baclofen.... Agent: Cns Therapeutics, Inc.

20110269837 - Phosphorus binder composition for treatment of hyperphosphatemia: The present invention relates to oral pharmaceutical products which are useful for binding phosphorus in ingesta, and inhibiting absorption of phosphorus from the gastrointestinal tract of subjects. A method for binding phosphorus in ingesta and inhibiting its absorption from the gastrointestinal tract is also provided. The pharmaceutical products and methods... Agent: Biolink Life Sciences, Inc.

20110269838 - Novel processes and pure polymorphs: The present invention relates to crystalline forms of the active pharmaceutical ingredient vorinostat, processes for their preparation and their use in pharmaceutical compositions.... Agent:

20110269839 - Anti-snoring composition containing a termogelling polymer: The invention relates to a composition for treating and/or preventing snoring, comprising at least one thermogelling polymer that includes water-soluble units as well as units having a lower critical demixing temperature in water. Said composition has the specific feature of being liquid in the packaging thereof and becoming a gel... Agent: Polymerexpert Sa

20110269840 - Treating renal cancer using a 4-[bis[2-[(methylsulfonyl)oxy]ethyl]amino]-2-methyl-benzaldehyde: The present invention features methods of treating a mammalian subject having renal cancer by administration of certain dimethylsulfonate compounds, such as a 4-[bis[2-[(methylsulfonyl)oxy]ethyl]amino]-benzaldehyde. The present invention further features administration protocols and dosing schedules for methods of treating patients having renal cancer and pharmaceutical compositions suitable for use in the treatment... Agent: Government Of The United States Of America, As Represented By The Secretary, Department Of

20110269841 - Thin film with methadone active ingredient: An orally dissolvable thin film strip for the administration of the pharmaceutical active Methadone is formed by mixing a wet slurry of a water-soluble polymer, a polar solvent, Methadone HCl, and optional additives. The slurry is then cast onto a substrate by slot die or knife-over-roll and is dried in... Agent: Innoteq, Inc.

20110269842 - Compositions comprising cb receptor agonists, uses thereof and methods for their preparation: Provided are compositions including (3R, 4R, 6R)-stereoisomers of phenyl substituted pinenes having CB receptor agonist properties, methods of treating diseases or disorders with the pharmaceutical compositions, and processes for their preparation are also provided.... Agent: Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd.

20110269843 - Methods for delivering volatile anesthetics for regional anesthesia and/or pain relief: The present invention provides methods for reducing pain in a subject in need of such pain reduction by delivering, e.g., intrathecally or epidurally, a volatile anesthetic such as a halogenated ether compound in an amount effective to reduce pain. Chronic or acute pain may be treated, or the anesthetic may... Agent: The Board Of Regents Of The University Of Texas System

20110269844 - Thin film with propofol active ingredient: An orally dissolvable thin film strip for the administration of the pharmaceutical active Propofol is formed by mixing a wet slurry of a water-soluble polymer, a polar solvent, the active Propofol, and optional additives. The slurry is then cast onto a substrate by slot die or knife-over-roll and is dried... Agent: Innoteq, Inc.

20110269845 - Interference pigments on the basis of perlite flakes: The present invention relates to pigments, comprising a plate-like substrate of perlite which does not contain 3D twin structure particles contained in milled expanded perlite in an amount of greater than 5% by weight, and (a) a dielectric material, especially a metal oxide, having a high index of refraction; and/or... Agent: Basf Se

20110269846 - Formulations with high percentage cis-p-menthan-7-ol and preparation thereof: Perfumed compositions or articles, and particularly perfumes, soaps, cosmetics, aftershaves, eye creams, insecticides and antiseptics formulations, containing p-menthane-7-ol wherein the cis portion of the p-menthane-7-ol exceeds 90% by weight, preferably comprises 93% or more, and more preferably comprises 95% or more, provide greatly improved fragrance characteristics wherein the odor produced... Agent: Bedoukian Research, Inc.

20110269847 - Storage-stable compositions of glycerol monoalkyl ethers: r

20110269848 - N-substituted monomers and polymers: Biocompatible, bioresorbable polymers comprising a plurality of monomeric repeating units containing an amide group, wherein said amide groups are N-substituted and the N-substituent and degree of N-substitution are effective to lower the melt viscosity, the solution viscosity, or both, compared to the same polymer without N-substitution.... Agent: Rutgers, The State University Of New Jersey

20110269849 - Emulsions and methods for the preparation thereof, and methods for improving oxidative stability of lipids: An emulsion includes a lipid, an emulsifier, and ε-polylysine. A method for improving oxidative stability of a lipid includes forming an emulsion that includes the lipid, an emulsifier, and ε-polylysine, such that the emulsion further includes a complex layer at an oil-water interface configured to provide a physical and/or electrostatic... Agent:

20110269850 - Shellac enteric coatings: The field of the invention generally relates to a shellac-based enteric coating with a reliable and consistent dissolution profile in both acid and neutral environments based on the selective choice of coating excipients used with the shellac. The enteric coating formulation includes a shellac, a maltrin, sodium alginate, one or... Agent:

20110269851 - Reducing astringency in compositions containing phenolic compounds: The present invention in general relates to the field of taste. In particular it relates to the reduction of astringency. One embodiment of the present invention relates to the use of at least one phospholipid for the preparation of a phenol containing composition to reduce the astringency of the composition.... Agent: Nestec S.a.

20110269852 - Methods and mechanisms involving hyperpigmentation particularly for african american skin: Sets of genes are identified that show modulated activity in hyperpigmented sun-exposed (HE) and non-hyperpigmented sun-exposed (NHE) skin, when compared to non-hyperpigmented non-exposed (NHNE) skin. The modulated sets of genes reveal important information about the genetic changes that take place in skin as a result of environmental exposure and damage.... Agent: Hampton University

Previous industry: Perfume compositions
Next industry: Colloid systems and wetting agents; subcombinations thereof; processes of


######

RSS FEED for 20140918: xml
Integrate FreshPatents.com into your RSS reader/aggregator or website to track weekly updates.
For more info, read this article.

######

Thank you for viewing Drug, bio-affecting and body treating compositions patents on the FreshPatents.com website. These are patent applications which have been filed in the United States. There are a variety ways to browse Drug, bio-affecting and body treating compositions patent applications on our website including browsing by date, agent, inventor, and industry. If you are interested in receiving occasional emails regarding Drug, bio-affecting and body treating compositions patents we recommend signing up for free keyword monitoring by email.



Results in 3.16903 seconds

PATENT INFO